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Summary
3-beta hydroxysteroid dehydrogenase A5/A4 isomerase (3B-HSD) catalyses the oxidative 
conversion of A5-36-hydroxysteroids to their corresponding A4-3-ketosteroid 
configuration, and is essential for the biosynthesis of all classes of steroid hormone; 
mineralocorticoids, glucocorticoids, progestins, androgens and oestrogens. In humans 
two homologous linked, genes, HSD3B1 an HSD3B2, encoding 3B-HSD type I and type 
II enzymes, have been isolated and mapped to the human chromosomal region lpl3.1. 
RNase protection assays have localised 3B-HSD type I transcripts principally in placenta 
and skin, while 3B-HSD type II transcripts are almost exclusively found in the adrenals 
and gonads. The two forms are 93.5 % identical in primary structure and antibodies 
raised against purified human placental protein react immunocytochemically with 3B- 
HSD in all four tissues. Such tissue specificity is shown by monoclonal antibody FDO 
161G which reacts with 3B-HSD, and was originally raised against human 
syncytiotrophoblast cells from the placenta. However, a further mouse monoclonal 
antibody, FDO 26G, raised against purified 3B-HSD from placental villous tissue showed 
more restrictive tissue reactivity. Immunocytochemically, FDO 26G reacted with 3B- 
HSD in villous syncytiotrophoblast and adrenals, but reacted weakly with extravillous 
trophoblast and Leydig cells of the testis. These experimental observations provide 
evidence for the expression of a further isoform of 3B-HSD exists in extravillous 
trophoblast and adult Leydig cells; either a post-translational modification within the 
region of monoclonal antibody binding (the epitope) or the expression of as yet 
unidentified 3B-HSD gene that encodes a different amino acid sequence over the FDO 
26G epitope.
Using a combination of lac Z  fusion polypeptides and synthetic peptides, the FDO 26G 
epitope was located to residues 354-366 at the carboxy terminal end of 3B-HSD type I, an 
amino sequence that is identical in the type I and type II forms of the enzyme. This 
epitope contains a consensus for caesin kinase II phosphorylation , with serine 359 as the 
candidate target of phosphorylation. This suggested that the lack of reactivity of FDO 
26G in certain trophoblast cells of the placenta might be due to phosphorylation of serine 
359. Peptide 354-366 was synthesised with phosphoserine at residue 359. FDO 26G 
reactivity to the phosphopeptide and unphosphorylated peptide was compared. FDO 26G 
bound the phospho-peptide at least as strongly as the unphosphorylated peptide. It was 
concluded that phosphorylation of serine 359 was not responsible for lack of FDO 26G 
reactivity in placental trophoblast populations.
A number of 3B-HSD cDNAs and genes have been cloned from a variety of vertebrate 
species. In mouse six homologous 3B-HSD cDNAs have been isolated and shown to be
expressed tissue- and sex- specifically. This gene family clustered on mouse 
chromosome 3 includes two functionally distinct groups of proteins; enzymes that 
catalyse the oxidative conversion of A5-3B-hydroxysteroids (characterised by an aspartic 
acid at residue 36) and enzymes that exclusively act as 3-ketosteroid reductases 
(characterised by a tyrosine (rat) or phenylalanine (mouse) at residue 36).
Several bands of hybridisation are detected when Southern blots of human genomic DNA 
were probed with HSD3B1 exon specific probes suggesting that 3B-HSD-like sequences 
other than HSD3B1 and HSD3B2 exist in the human genome. In addition when 
screening amplified segments of patient DNA for mutations in 3B-HSD types I and n, it 
is relatively common to amplify novel but closely related 3B-HSD sequences.
To estimate the size of the 3B-HSD gene family two human genomic Xgem 11 libraries 
were screened with 3B-HSD type I cDNA under non-stringent conditions. From a total of 
1.4xl06 clones, fifty-seven positive clones hybridised reproducibly through to the second 
stage of screening. These clones were tested as templates for PCR using primers that 
were known to amplify homologous members of the gene family (from mutation 
screening ). PCR products were classified into groups depending on their mobility on 
denaturing gradient electrophoresis gels. Representatives of each group were sequenced. 
The remaining PCR-amplified products were directly sequenced. A total of seven 
distinct 3B-HSD gene family members, including HSD3B1 and HSD3B2, were identified 
and mapped to the human chromosomal region lpl3. All of the newly identified genes 
contained 3B-HSD-like exon and intron sequences indicating that these clones were not 
processed pseudogenes. Novel 3B-HSD sequences were subcloned and sequenced from 
each of the new members of the family. The presence of frameshift and in some cases, 
missense mutations associated with 3B-HSD type II deficiency suggests that these genes 
are not expressed as functional 36-HSD enzymes. There was no evidence of a human 3B- 
HSD ketosteroid reductase enzyme.
Based on alignments of the predicted cDNAs, from each of the novel genes, human 3B- 
HSD type I and n, macaque, bovine and the rodent 36-HSD gene families, a phylogenetic 
relationship was generated using the maximum parsimony method. The analysis suggests 
that several gene duplication and events have occurred independently, in the evolution of 
the 36-HSD gene family in different species. Since primates and rodents diverged, an 
ancestral 3B-HSD gene(s) has duplicated a number of times in the primate lineage and 
several gene duplications events have taken place in the rodent lineage. Interestingly, the 
amplification of the 3B-HSD gene family in rodents leads to many 3B-HSD genes 
expressed tissue- and sex- specifically, whereas in humans, there appear to be only two 
genes expressed in a tissue specific manner.
Chapter 1
General Introduction 
1.1 Principles of hormone action.
Regulation of metabolic processes and many other aspects of multicellular organism 
function are controlled by hormones (chemical mediators) of the endocrine, paracrine, 
autocrine, intracrine and neurotransmitter systems. Hormones maintain the internal 
environment in a state of homeostasis, and enable it to react to changes in the external 
enviroment. Even unicellular organisms produce molecules that are very similar to the 
hormonal peptides of vertebrates, suggesting that the biochemistry of co-ordinate cell to 
cell communication may have its origins in simple unicellular organisms (LeRoith et al 
1980; Roth et al 1982).
Endocrinology is the broad discipline of the study of the action of hormones and the 
organs in which they are synthesised and secreted. Hormones can be classified in many 
ways, including by the cells they target (Figure 1.1).
Endocrine
-------------
Paracrine Autocrine Intracrine
Figure 1.1. Schematic diagram o f endocrine, paracrine, autocrine, and intracrine action. Classically, 
endocrine hormones are synthesised and secreted in specialised glands for release into the general circulation  
and transport to distant target cells. In addition, hormones released from one cell can influence neighbouring 
cells (paracrine activity) or can exert a positive or negative effect on the secretory cell itself (autocrine 
activity). Intracrine activity describes the local formation o f  active hormones which influence the cells in 
which they are synthesised without release into the extracellular compartment.
Classically hormones were divided into four groups; peptides, steroids, idiothyronines and 
catecholamines. However, new classes of ligands have been added to the list including 
prostaglandins, amino acids and lipids. In each case, these molecules interact with target 
cells by binding with receptor proteins which recognise the hormone selectively
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conferring specificity of response. Despite the multiple chemical classes of hormones, 
hormone receptors fall into two general classes. Charged molecules such as peptide 
hormones and neurotransmitters interact with cell surface plasma membrane receptors and 
act through stimulation of second messenger pathways (Dohlman etal 1987). Uncharged 
(lipophillic) molecules such as steroid and thyroid hormones diffuse into the cell and bind 
intracellular receptor proteins with high affinity (Evans et al 1988), which may be found 
within the cytoplasmic or nuclear compartments. The hormone- receptor complex binds 
to specific DNA sequences, the hormone response element that is positioned upstream of 
the transcription initiation site. As a result, mRNA and subsequent protein synthesis are 
affected.
1.2 Steroid hormones
Steroid hormones control many metabolic and biosynthetic pathways, in almost all organs 
and tissues. All steroid hormones are derivatives of cholesterol and are structurally 
similar, containing the cyclopentanoperhydrophenanthine nucleus (Figure 1.2).
HO
Figure 1.2. Ring and carbon numbering system in the steroid cholesterol.
Various side chains and degrees of saturation confer specificity to the different hormone 
molecules by their action on one or more specific hormone receptors. As regulators of 
physiological processes, they are categorised in five main groups; mineralocorticoids, 
glucocorticoids, progestins, androgens and oestrogens.
Mineralocorticoids
Aldosterone is the principal mineralocorticoid and is normally produced exclusively in the 
zona glomerulosa of the adrenal cortex (Figure 1.3). Other steroids in the aldosterone 
biosynthetic pathway also have mineralocorticoid activity, and act by binding the Type I 
(mineralocorticoid) receptor (Arriza et al 1987). Mineralocorticoids regulate Na+ and K+
2
transport in epithelial cells such as the proximal and distal tubules of the kidney, salivary 
and sweat glands and the gastrointestinal tract. These cells respond in a similar manner to 
mineralocorticoids, by increasing salt (Na+) absorption from various tubules or ducts back 
into the body while excreting K+ ions (Morris et al 1981). Patients with 
mineralocorticoid deficiency develop weight loss, hyperkalemia and are hypotensive, 
whereas patients with mineralocorticoid excess develop hypernatremia and are 
hypertensive.
Glucocorticoids
Glucocorticoids, mainly cortisol in humans, influence a wide variety of metabolic 
processes in many organs and tissues of the body (Schulster, D. 1976). They have 
important effects on carbohydrate metabolism, raising the concentration of glucose in the 
blood by increasing the synthesis of a number of enzymes in gluconeogenesis (Cidlowski 
et al 1982). The glucocorticoids also alter protein metabolism causing breakdown of 
muscle tissue, mobilising an alternative energy source to glucose. Other effects of 
glucocorticoids include suppression of DNA synthesis and inhibition of the inflammatory 
response to infection or injury. Increased secretion of cortisol also occurs as a response to 
stress.
Androgens
The tissues and organs that are regulated by androgens are diverse. Androgens stimulate 
male sexual differentiation, and maturation of the reproductive organs in utero. They also 
promote development of male secondary sexual characteristics and behaviour. The two 
most important androgens are testosterone and 5a-dihydrotestosterone (Figure 1.3 and 
sections 1.5-1.7).
Oestrogens and progestins
In both male and female, oestrogens are derived from either the adrenal gland or the 
gonad. The enzyme P450arom (aromatase) converts androgens to oestrogens and is 
present in many tissues of the body (Figure 1.3). Progesterone is derived from the 
conversion of pregnenolone by 36-hydroxysteroid dehydrogenase (Figure 1.3 and sections 
1.5-1.7). Oestrogens and progesterone interact to control the growth, development and 
physiology of the female reproductive tract, to regulate the menstrual cycle and induce
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development of female secondary sexual characteristics such as mammary glands. They 
are also key hormones for fertility and maintenance of pregnancy (Siiteri et al 1967).
1.3 Steroid hormone biosynthetic pathways
Steroid biosynthesis occurs in a variety of organs, including adrenal cortex, testes and 
ovaries, and during pregnancy the placenta develops as an additional source of steroid 
hormones. The principal pathways of steroid hormone biosynthesis were established over 
twenty years ago through advances in steroid radioisotopic and chromatographic 
techniques (Schulster D 1976). Cholesterol is essential for steroid hormone and bile acid 
biosynthesis and is available from three sources, de novo synthesis from acetate, from 
plasma low density plasma lipoprotein or through storage as lipid inclusions (Gwynne & 
Strauss 1982). Steroid hormone biosynthesis in all endocrine organs is similar. It is 
catalysed by six forms of cytochrome P450 (Nebert & Gonzalez 1987), and two forms of 
hydroxysteroid dehydrogenase, many of which utilise multiple steroid substrates and have 
more than one enzyme activity (Figure 1.3). Tissue-specific expression of these distinct 
enzymes determines the steroid hormones that are synthesised. These enzymes are present 
within the mitochondria and the endoplasmic reticulum; therefore intermediates in 
steroidogenesis must 'shuffle' between distinct organelles, a process that is not well 
understood. Different electron transport chains are utilised depending whether enzymatic 
reactions takes place in the endoplasmic reticulum or mitochondria (Miller 1988).
Steroid hormones are not stored to any great extent within endocrine cells. There are large 
stores of cholesterol and pituitary trophic hormones (e.g ACTH and gonadotropins) 
stimulate cholesterol transfer from the outer to inner mitochondrial membrane by 
activating the steroid acute response protein (StAR) increasing the availability of substrate 
cholesterol for steroidogenesis (Sugawara et al 1995). This function is in addition to and 
reinforces the induction effects these hormones have on specific pathways and hence 
contribute to feedback loops between the anterior pituitary and the end organ.
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Cholesterol
17-hydroxy pregnenolonePregnenolone Dehydroepiandrosterone (DHEA)
OestroneProgesterone 17-hydroxyprogesterone Androstenedione
Deoxycorticosterone 11-deoxycortisol Testosterone - Oestradiol
5 a-dihydrotestosteroneCorticosterone Cortisol
18-hydroxycorticosterone
o
P450scc
P450cl 1B2
P450cl 1B2
P450cl1B2 5a-reductaseP450cllBl
17B-hydroxysteroid dehydrogenaseP450c21
P450 cl7
313-hydroxysteroid dehydrogenase A /^ isomerase (3B-HSD)
Aldosterone
[  Mineralocorticoids ^  [  Glucocorticoids -1 |-Androgens-| |-Oestrogens-|
Figure 1.3. Principal pathways of steroidogenesis in the adrenal cortex and gonadal tissues. 3B-HSD utilises 
multiple substrates and is required for the synthesis of all classes of steroid hormone. The major steroid 
products are highlighted in bold as is the category of steroid hormone to which they belong, except for 
progesterone which is a progestin . The enzymes P450scc, P450cl 1B1 and P450cl 1B2 are located in the 
inner mitochondrial membrane. P450cl7, P450c21, P450arom are localised to the endoplasmic reticulum. 
3B-HSD activity localises to both compartments. The 17B-hydroxysteroid dehydrogenase (17B-HSD) 
reaction is catalysed by multiple isozymes that favour the reduction reaction in testis and ovary and the 
oxidation reaction in extragonadal tissues.
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1.4 3B-hydroxysteroid dehydrogenase A5/ A4 isomerase (3B-HSD)
The enzyme 36-hydroxysteroid dehydrogenase A5/ A4 isomerase (3B-HSD) catalyses 
essential early steps in the biosynthesis of all classes of biologically active steroid 
hormone; mineralocorticoids, glucocorticoids, progestins, androgens and oestrogens 
(Figure 1.3). It catalyses the oxidation of multiple 3B-hydroxy-A5-steroid substrates to 
their corresponding A4-3-oxo configuration utilising NAD+ as cofactor (Figures 1.3 and 
1.4).
CH, CH-
I
C = c =
T°
NADH
HO NAD+
CH,
C =  O
5-pregnenolone 5-pregnene-3,20-dione 4-progesterone
Figure 1.4. Schematic representation of the 3B-HSD two step catalytic reaction using pregnenolone as 
substrate. The first step is the dehydrogenase reaction using NAD+ as cofactor. End product NADH acts as 
an allosteric activator of the A5/ A4 isomerase activity (Thomas et al 1995).
In the following sections steroidogenesis in various human tissues will be described, 
emphasising the central role of 38-HSD activity in the biosynthesis of steroid hormones, 
followed by a brief description of genetic disease caused by deficiencies in certain 
steroidogenic enzymes. As a large proportion of my work is concerned with the human 
3B-HSD gene family, emphasis will be placed on genes encoding steroidogenic enzymes 
present in multiple copies in the human genome.
1.5 Steroidogenesis in fetal tissues
The biosynthesis of steroids in the placenta differs in several important aspects from the 
biosynthetic route in other endocrine tissues such as the adrenal cortex. The placenta is 
deficient in several important enzymes, such as P450cl7 and enzymes necessary for de 
novo synthesis of cholesterol, although it has considerable capacity to aromatise 
androgens to oestrogens. This led to the concept of the fetal placental unit (Diczfalusy
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1969) in which the fetus and placenta complement each other in their ability to synthesise 
the many different steroids produced during human pregnancy (Figure 1.5).
During human pregnancy the placenta is the major site of 36-HSD expression in fetal 
compartments. Large amounts of progesterone are produced by the placenta and released 
into the maternal circulation (Milewich et al 1975 ). Placental 36-HSD activity is also 
essential for the conversion of DHEA to oestrogens (Figure 1.5).
The human fetal adrenal (HFA) has two morphologically and steroidogenically distinct 
zones, the neocortex (20%) and fetal (80%) zones . The neocortex zone is the primary site 
for cortisol synthesis and secretion, initially utilising placental progesterone as substrate; 
but eventually expression of 36-HSD in the neocortex zone allows synthesis of cortisol 
from A5 steroid intermediates of fetal adrenal origin. The fetal zone is more 
steroidogenically active than the neocortical zone, using placental pregnenolone to 
synthesise dehydroepiandrosterone-sulphate (DHEA-S) and dehydroepiandrosterone 
(DHEA) which serve as precursors for placental oestrogen formation (Sitteri et al 1973).
Fetal testicular 36-HSD enzyme activity is critical for the biosynthesis of testosterone, the 
major androgenic hormone that controls primary male sexual characteristics (Jost et al 
1973). By the seventh week of uterine life, the fetus contains the primordia of both male 
(Wolffian) and female (Mullerian) genital ducts. Testosterone induces the differentiation 
of the Wolffian ducts into the epididymis, vas deferens, seminal vesicles and ejaculatory 
ducts of the male. Functional fetal testes also secrete anti-Mullerian hormone causing 
involution of the Mullerian ducts. Although testosterone is the principal androgen 
secreted, in many peripheral target tissues testosterone is converted to the more potent 
androgen 5a-dihydrotestosterone (5a-DHT), which is critical for the masculinisation of 
external genitalia. There is a critical period for the action of androgens, after about the 
twelfth week of gestation fusion of the labioscotal folds will not occur, leading to 
incomplete masculinisation of the male fetus and hypospadias (Hiort et al 1994). 
Exposure of the female fetus to androgens during this period can result in virilisation of 
female external genitalia (Kelnar et al 1993).
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Placenta MotherFoetus
Progesterone ProgesteroneProgesterone
Human foetal 
adrenal (HFA) 3B-HSD
Neocortex
zone
(20%)
Pregenenolone Cholesterol
Foetal
zone
(80%)
DHEA
sulphate
-  DHEA
3B-HSD
Androstenedione
Oestrone Oestrone
Human foetal 
liver Oestradiol Oestradiol
-  Oestriol Oestriol16a- DHEA 
sulphate
Pregenenolone
sulphate
Cortisol
synthesis
DHEA
sulphate
Figure 1.5. Biosynthesis of progesterone and oestrogens (oestrone, oestradiol and oestriol) from the fetal- 
placental unit. Placental 36-HSD enzyme activity is required for the maintenance of pregnancy and normal 
development of the fetus.
1.6 Adult adrenal steroidogenesis
The adult adrenal glands are endocrinologically complex organs, situated near the anterior 
poles of each kidney, embedded in perirenal adipose tissue. Each adrenal gland consists 
of two distinct organs, one surrounding the other, with separate function and different 
embryological origins . The inner medulla arises from the neural crests, and secretes the 
catecholamines (e.g adrenaline and noradrenaline). Stress can cause an immediate release 
of adrenaline which prepares the body for extraordinary physical and mental exertion.
The adrenal cortex emanates from the mesoderm at an early stage of development of the 
embryo. The adrenal cortex is divided morphologically and functionally into three distinct 
zones, zona glomerulosa (ZG), zona fasciculata (ZF) and zona reticularis (ZR). Tissue 
specific expression of steroid hormone biosynthetic enzymes determine the steroid 
hormones synthesised in different zones (Figure 1.6). The ultrastructure of adrenocortical 
cells is similar to that of other steroid secreting cells, including the corpus luteum of the 
ovary and Leydig interstitial cells of the testis. They have large amounts of smooth 
endoplasmic reticulum, numerous lipid inclusions (cholesterol stored as esters with fatty 
acids), abundant mitochondria, and a prominent Golgi complex (James 1979; The Adrenal 
Gland, Raven press).
The outer zona glomerulosa (ZG) constitutes about 15% of the cortex, synthesising 
mineralocorticoids, principally aldosterone (Figure 1.6), mainly under the control of the 
renin-angiotensin system (Gibbons et al 1984). The zona fasciculata (ZF) is deep, 
approximately 75% of the cortex, and synthesises glucocorticoids, mainly cortisol.
Cortisol secretion in the ZF is primarily controlled by periodic releases of a single chain 
polypeptide, adrenocorticotrophic hormone (ACTH). ACTH is synthesised in the anterior 
pituitary corticotroph cells, and is released on stimulation of the cell by the hypothalamic 
peptide corticotrophin- releasing factor (CRF). ACTH binds to high affinity plasma 
membrane receptors of adrenocortical cells, activating the adenylate cyclase system 
(cAMP). The principal physiological action of ACTH is to cause a rapid increase in 
adrenocortical steroid hormone synthesis and secretion, but it also increases growth, size 
and blood flow through the gland. The negative feedback loop is completed when 
glucocorticoids 'feedback' to the hypothalamus and the anterior pituitary to limit CRF and 
ACTH synthesis and secretion. Precursor intermediates in the androgen biosynthetic path 
way, dehydroepiandrosterone (DHEA) and dehydroepiandrosterone-sulphate (DHEA- 
sulphate) are the main secretion products of the zona reticularis (ZR) which are released 
into the circulation.
40% of androgens in man (Moghissi et al 1984) and the majority of oestrogens in women 
are synthesised in extra adrenal and extragonadal target tissues from precursor steroids of 
adrenal origin, specifically DHEA-S and DHEA (Labrie 1988). It is therefore not 
surprising that the enzyme activities required for the conversion of DHEA and DHEA-S, 
38-HSD, 178-HSD, P450 aromatase, 5a-reductase and steroid sulphatase are expressed in 
a large number of peripheral tissues (Milewhich et al 1991).
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Figure 1.6. Steroid biosynthetic pathways in the three functionally distinct zones of the adrenal cortex (not 
to scale). Aldosterone and cortisol are the principal mineralocorticoid and glucocorticoid secreted by the 
zona glomerulosa and fasciculata . Precursor sex steroids, DHEA, DHEA-S and androstenedione are 
secreted mainly from the zona reticularis.
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1.7 Testicular and Ovarian steroidogenesis
The testis is the male gonad. Its primary functions are the production of spermatozoa and 
testosterone under complex feedback controls by hypothalamic-pituitary peptides 
including LH and FSH. Testes consist mainly of loops of convoluted seminiferous 
tubules, along which spermatozoa form from primitive germ cells. Between the tubules 
are nests of Leydig interstitial cells which contain the necessary enzyme complement for 
the synthesis of testosterone. An outline of testicular steroidogenesis is given in figure 
1.7.
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Figure 1.7. Leydig cell steroidogenesis. 
Testosterone is the major androgenic steroid 
hormone secreted by Leydig cells. Leydig 
cells do not metabolise 17-OH progesterone 
efficiently. The potent androgenic hormone 
5a-DHT is only secreted in small amounts; 
the major sites of formation and action of 
5a-DHT are in peripheral tissues 
(extraadrenal and extragonadal).
5a-reductase
' OH
H
5a-dihydrotestosterone
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The main female reproductive organs are the ovaries, fallopian tubes, uterus and the 
vagina. Their function is to produce the ova, ensure fertilisation, allow it to grow and 
develop in a suitable environment and delivered at term. The ovaries are situated on either 
side of the uterus. The centre is known as the medulla or stroma which consists mainly of 
connective tissues containing collagen fibres. Surrounding the medulla is the cortex, 
which consists of germinal epithelium, and follicles containing the immature ovum. The 
major steroid producing cells of the ovary, thecal, granulosa and corpus luteum cells 
contain the complete enzyme complement required for the biosynthesis of androgens, 
oestrogens and progestins (Figure 1.8).
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Figure 1.8. Principal pathways of steroid hormone 
biosynthesis in the human ovary. Each cell type of 
the ovary contains the complete enzyme complement 
for the formation of oestradiol from cholesterol; 
however the concentrations of various enzymes 
differ amoung the cell types, and consequently 
hormones are synthesised in thecal and granulosa 
compartments as indicated. As in Leydig cells 
ovarian cell types do not metabolise 17-OH 
progesterone efficiently
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Oestrogens are produced by the ovary during follicular maturation, and stimulate 
glandular proliferation of the endometrium. Oestrogens also stimulate the synthesis of 
progesterone receptors and promote the development of female secondary characteristics 
later in development. Progesterone is a key hormone in fertilisation and maintenance of 
pregnancy. It induces decidulisation of the endometrium, inhibits uterine contractions and 
with oestrogens promotes the glandular development of the breast. In contrast to other 
steroidogenic tissues, ovarian steroidogenesis is episodic, cyclical and is precisely 
coordinated by a number of local factors, some of which are produced within the ovary 
itself. Oestrogen biosynthesis is complicated by the constantly changing population of 
cells as the process of follicular development, ovulation and corpus luteum formation 
occurs with each menstrual cycle. At maturation the Graafian follicle produces less 
oestrogen and more progesterone. These hormones together with gonadotrophin-releasing 
hormone produce a massive release of LH into the bloodstream, causing the follicle to 
rupture and release the ovum. The follicle now becomes the progesterone- secreting 
corpus luteum (yellow body) with maximum secretion around day eight post ovulation. If 
fertilisation does not occur, the corpus luteum secretes less progesterone and becomes the 
corpus albicans (white body). The endometrium collapses due to the lack of blood and the 
lining is lost with the menstrual flow.
The regulation of steroid hormone synthesis by enzyme localisation is complemented by 
substrate availability. Granulosa cells of the follicle are avascular and do not have access 
to low density lipoprotein (LDL) plasma substrate (Carr etal 1981). After ovulation, 
extensive neovasculinization of the follicle takes place, providing increased amounts of 
cholesterol to the luteinized granulosa cells, allowing increased production of 
progesterone during the luteal phase of the menstrual cycle.
1.8 Congenital adrenal hyperplasia (CAH)
A central question I investigate in results chapters 5 and 6 is the number of genes within 
the human 36-HSD gene family and where I attempt to address the effect of multiple 36- 
HSD genes in the generation of 36-HSD deficiencies. To further explore this argument I 
would like to draw parallels between other steroidogenic deficiencies, specifically when 
the steroid genes include multiple members.
Congenital adrenal hyperplasia (CAH) is the most frequent cause of ambiguous genitalia 
and adrenal insufficiency in neonates. It results from an inherited defect in any of the 
enzymatic steps required to synthesise cortisol from cholesterol in the adrenal cortex, 
leading to a compensatory hyper secretion of ACTH by the anterior pituitary with
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consequent hyperplasia of the adrenal gland (New et al 1989). Each enzyme deficiency 
produces abnormal levels of adrenal hormones and precursors. A defect may have clinical 
significance not only because cortisol is not synthesised efficiently, but because precursor 
steroids proximal to the block may accumulate and be shunted into other metabolic 
pathways, particularly that of androgen biosynthesis. Excessive androgen production 
results in virilization of both males and females causing hirsutism in females, penile or 
clitoral enlargement, precocious adrenarche and early epiphyseal closure ultimately 
resulting in short stature. Although any of the five different enzymes involved in cortisol 
biosynthesis in the adrenal cortex could be impaired (Figure 1.6), P450c21 deficiency, due 
to a mutation within the CYP21 gene, accounts for more than 90% of CAH patients 
(White P.C. 1987a and 1987b). The remainder mainly consist of P450cl 1 and 36-HSD 
enzyme deficiencies (Saenger et al 1995; Hermans etal 1996).
Cytochrome P450c21 deficiency
Cytochrome P450c21 deficiency is one of the most common inborn errors of metabolism 
in humans, impairing mineralocorticoid and glucocorticoid steroid formation exclusively 
in the adrenal cortex. Microsomal P450c21 converts progesterone to deoxcorticosterone 
and 17-hydroxyprogesterone to 11-deoxycortisol, deficiency causes accumulation of 
cortisol precursors which may be shunted into the adrenal androgen pathway (Figure 1.6). 
There are a number of recognised clinical phenotypes of P450c21 deficiency; salt wasting 
severe classic CAH, simple virilising, non-classic and cryptic. The severe classic P450c21 
deficiency occurs 1 in 10,000-15,000 live births (Cacciari et al 1983) and is associated 
with genital ambiguity and varying degrees of low aldosterone levels leading to electrolyte 
imbalance. If untreated, low concentrations of sodium will result in death during the 
neonatal period. Approximately 25% of cases of P450c21 deficiency can synthesise 
sufficient amounts of aldosterone to prevent salt loss and are classified as 'simple 
virilizers' (Fiet et al 1989). Nonclassical P450c21 deficiency is common (Azziz et al 
1989) and is caused by allelic variants of CYP21 that have between 20 and 50% wild type 
P450c21 enzyme activity. Patients present some time after birth with evidence of 
androgen excess (Mahesh et al 1968; Speiser et al 1985) or may remain asymtomatic 
(Cryptic).
Cytochrome P450c21 deficiency is inherited as a monogenic recessive disorder linked to 
the class HI region of the HLA complex on chromosome 6p21.3 next to the C4A and C4B 
components of serum complement (White et al 1985a). This region includes the 
functional P450c21 gene, CYP21 and a highly homologous pseudogene, CYP21P, both 
genes contain 10 exons and 9 introns, 98% and 96% homologous respectively (Higashi et 
al 1986; White et al 1986). All mutant alleles identified to date have been generated
14
through intergenic recombination, 20% of which have a 30kb deletion that results in a 
single non-functional chimeric gene, with the 5' end corresponding to CYP21P and the 3' 
end to CYP21 (White et al 1985b). 75% of alleles have apparently been generated by 
gene conversion events, where CYP21 carries one or more deleterious mutations normally 
found in the CYP21P pseudogene. Although the mechanisms by which these mutation 
events are generated is not well understood, it has been suggested that large deletions are 
generated by unequal meiotic crossing over, whereas gene conversion is associated with 
mitotic recombination (Collier et al 1993; Tusie-Luna et al 1995). The very high 
proportion of intergenic crossing over suggests these genes contain one or more hotspots 
for recombination or the HLA region may be subject to relatively high rates of gene 
conversion.
Cytochrome P450cll Deficiency
P450cl 1 deficiency is the second most common cause of congenital adrenal hyperplasia 
with an incidence of 1 in 100,000 live births, approximately 5% of adrenal steroid defects 
(White etal 1987a; White et al 1987b; Zachmann et al 1983). Patients with this defect 
are unable to convert 11-deoxycortisol to cortisol (Figure 1.6). Elevated ACTH cause 
accumulation of steroid precursors that may be utilised in adrenal androgen biosynthesis. 
Patients present with similar symptoms as P450c21 deficiency, and both sexes show signs 
of mild androgen excess, rapid somatic growth with premature epiphyseal closure 
resulting in short adult stature. A parallel defect in the mineralocorticoid pathway leads to 
the accumulation of deoxycorticosterone causing hypertension. This clinical feature 
distinguishes P450cl 1 from P450c21 deficiency.
There are two homologous P450cl 1 enzymes encoded by CYP11B1 and CYP11B2 on 
chromosome 8q21-22 (Momet et al 1989). CYP11B1 is expressed in the zona fasciculata 
under ACTH regulation and is required for cortisol biosynthesis. CYP11B2 has three 
activities required for aldosterone synthesis in the zona glomerulosa and is mainly 
regulated by the renin-angiotensin system. P4501cl 1 deficiency may be inherited as an 
autosomal recessive disease, however there is a from of hypertension that is inherited in an 
autosomal dominant disorder. It can be distinguished from primary aldosterism by 
suppression of aldosterone hypersecretion with dexamethasone. This suggests that 
CYP11B2 may be under in appropriate control by ACTH. Unequal intergenic 
recombination between CYP1 IB 1 and CYP11B2 results in a hybrid gene with the 5' 
terminal region of CYP1 IB 1 fused to the coding region of CYP11B2 (Lifton et al 1992).
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3fi-HSD deficiency
313-HSD converts 3B-hydroxy-A5-steroids to their corresponding A4-3-oxo steroids (Figure
1.3 and 1.6). Deficiency of the enzyme results in a rare form of CAH and is of interest 
because the biosynthesis of all classes of steroid hormones in the adrenal cortex and 
gonads are impaired (Figures 1.6-1.8), characterised by elevated serum ratios of A5-ene to 
A4-ene steroids and increased secretion of A5 metabolites, pregnentriol and 16a- 
pregnentriol in urine. Deficiency in cortisol synthesis causes increased secretion of ACTH 
and hyperplasia of the adrenal gland, and low androgen levels lead to an increase in 
luteinising hormone (LH) and follicle stimulating hormone (FSH) synthesis and secretion. 
As with P450c21 deficiency there are several clinical phenotypes. Neonates affected with 
severe classic CAH exhibit signs of electrolyte imbalance to varying degrees which may 
be fatal if not diagnosed and treated early (Bongiovanni et al 1962). Male infants present 
with incomplete masculinisation of the external genitalia, due to low levels of 
testosterone, while affected females show near normal sexual differentiation or slight 
virilization (Rheaume et al 1992; Chang et al 1993). In contrast non-salt losing 3G-HSD 
deficiency is normally diagnosed sometime after birth, males present with ambiguous 
genitalia or hypospadias and females present with mild androgen excess but (both sexes) 
synthesise sufficient aldosterone to avoid salt wasting crises. By analogy with P450c21 
deficiency it has been suggested that non-classical 313-HSD (NC-3G-HSD) deficiency is an 
allelic variant of classical 313-HSD deficiency (Pang et al 1985) that was initially estimated 
to be more frequent than NC-21 OH (Zerah et al 1991) on the basis of elevated serum 
levels of basal and post ACTH stimulation of A5-ene steroids or by elevated urinary 5-ene 
steroid metabolites. No 3G-HSD mutation has been found in patients diagnosed with NC- 
313-HSD deficiency suggests this disorder does not result from mutations in 313-HSD type 
II enzyme (Mathieson etal 1992; Zerah et al 1994).
3G-HSD deficiency is inherited as an autosomal recessive disorder. As discussed more 
fully in section 1.9, in humans at least two homologous, closely linked genes are 
expressed, HSD3B1 and HSD3B2. These genes encode the 313-HSD type 1 enzyme 
expressed principally in placenta and skin, and the type 2 enzyme in adrenals and gonads 
(The et al 1989, Rheume et al 1991). Consistent with the biochemical profiles, 
mutations have been detected in various HSD3B2 genes from patients, showing that 313- 
HSD type II activity expressed predominantly in adrenals and gonads is affected Table 1.1 
(Rheume etal 1992; Rheaume etal 1994, Simard etal 1993b). The complete nucleotide 
sequence of HSD3B1 has been determined from patients with 3G-HSD deficiency, no 
deleterious mutations have been identified suggesting that 313-HSD type I is functional in 
these patients. The increased levels of serum A4-steroids and their metabolites in patients 
with classic 3G-HSD deficiency are explained by peripheral (extra-adrenal and extra-
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gonadal) 36-HSD activity catalysing elevated levels of A5 substrates resulting from 36- 
HSD type II deficiency in adrenals and gonads. Whether 36-HSD type I is solely 
responsible for peripheral activity has yet to be determined. It has been known for some 
time from Southern blot evidence that a number of homologous 36-HSD gene sequences 
other than HSD3B1 and HSD3B2 exist in the human genome. It is not known whether 
these sequences represent the human 36-HSD ketosteroid reductase activity, peripheral 
36-HSD activity or pseudogenes. Furthermore recombination, whether intergenic or 
apparent gene conversion plays a major role in the generation of mutations in cytochrome 
P450c21 and P450cl 1 deficiency. The extent to which the as yet unidentified 36-HSD 
sequences are involved in the generation of 36-HSD type II mutations is unknown.
Most of the defects in 36-HSD deficiency are due to nucleotide changes that cause single 
amino acid substitutions or premature termination codons within the open reading frame 
encoding 36-HSD type II (Table 1.1). Less frequently frameshift mutations have been 
identified. The majority of these mutations are localised to residues highly conserved 
throughout the vertebrate 36-HSD isozyme family and result in partial or complete 
impairment of 36-HSD type II enzyme activity.
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Table 1.1. Catalogue of 36-HSD type II mutations.
36-HSD type II 
amino acid 
mutation
36-HSD type II 
DNA mutation
Phenotype 
(% activity of mutant enzyme)
G15D 
Rheaume 1995
GGT -> GAT 
(Missense)
Salt wasting male pseudohemaphrodite 
(None detectable)
A82T (Vas) 
Medonca 1994
GCC -> ACC 
(Missense)
Nonsaltwasting male, female pseudo; premature pubarche; cryptic 
(None detectable)
N100S (Sta) 
Mebarki 1995
AAT -> AGT 
(Missense)
Non saltwasting salt wasting male, female pseudo
Splicing
mutation
G -> A (nt 6651) Male pseudo without salt wasting; Premature pubarche
L108W 
Sanchez 1994
TTG -> TGG 
(Missense)
Salt wasting male pseudohemaphrodite
G129R 
Rheaume 1994
GGG -> AGG 
(Missense)
Nonsalt wasting male pseudo; Premature pubarche
E142K 
Simard 1993
GAA -> AAA
(Missense)
Male, female pseudo; varying salt loss 
(None detectable)
W171X 
Rheaume 1992
TGG -> TAG 
(Nonsense)
Male hypospadias and gynecomastia; Female salt wasting 
(None detectable)
L173R (Ran) 
Russell 1994
CTA -> CGA 
(Missense)
Non saltwasting salt wasting male, female pseudo.
P186L 
Sanchez 1994
CCC -> CTC 
(Missense)
Salt wasting male pseudohemaphrodite
186/C/187 
Rheaume 1992
(Frameshift) Male hypospadias and gynecomastia; Female salt wasting
L205P* CTG -> CCG 
(Missense)
S213G AGT -> GGT 
(Missense)
Female pseudo; premature pubarche
K216E AAG -> GAG 
(Missense)
Female pseudo; premature pubarche
A245P 
Simard 1993
GCC -> CCC 
(Missense)
Nonsalt wasting 
(11%)
V248N 
Chang 1993
GTC -> AAC 
(Missense)
Salt wasting male, female pseudohemaphrodite 
(None detectable)
R249X 
Chang 1993
CGA -> TAG 
(Nonsense)
Salt wasting male, female pseudohemaphrodite 
(None detectable)
Y253N 
Simard 1993
TAT -> AAT 
(Missense)
Male, female pseudo; varying salt loss 
(None detectable)
Y254D 
Sanchez 1994
TAC -> GAC 
(Missense)
Non salt wasting female pseudo. (Only one allele isolated) 
(None detectable)
T259M( De 
Porto)
ACG -> ATG 
(Missense)
273AAA 
Simard 1994
(Frameshift) Salt wasting female pseudo
318 AC 
Zhang 1996
(Frameshift) Salt wasting female pseudo
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1.9 Molecular biology of 3fi-hydroxysteroid dehydrogenase A5/ A4 isomerase 
(36-HSD).
Following 36-HSD purification from human placenta (Thomas et al 1988) and 
development of polyclonal and monoclonal antibodies, cDNAs from different vertebrate 
species have been isolated and characterised by a number of groups. Multigene families 
for 36-HSD have been described in myomorph rodents, which encode enzymes with 
distinct functional properties. 36-HSD type I-III in mouse and I, HI and IV in rat have 
dehydrogenase/ isomerase activities and utilise NAD+ as cofactor (Bain etal 1991; Zhao 
et al 1991; DeLaunoit et al 1992; Keeney et al 1993). 36-HSD types IV and V in mouse 
and type HI in rat have an exclusive keto steroid reductase (KSR) activity, which is 
NADP-dependent and is most likely associated with the inactivation of reduced hormone 
derivatives such as 5a-dihydrotestosterone (Clarke et al 1993a; Clarke et al 1993b; 
Simard et al 1993a; Abbaszade et al 1995; see sections 1.10 and 6.1).
In humans two highly homologous 36-HSD cDNAs have been cloned and map to the 
chromosomal region lpl3.1, syntenic with the mouse 36-HSD gene family on 
chromosome 3 (Bain et al 1993). RNase protection assays have been used to estimate 
the abundance and specific location of 36-HSD transcripts within human tissue (Rheaume 
et al 1991). Human 36-HSD type I mRNA is principally expressed in placenta and skin 
and at low levels in liver, breast and testis, while 36-HSD type II mRNA is found almost 
exclusively in the adrenal cortex, testis and ovary (Labrie 1992). The two cDNA 
sequences show 93.5% identity within the coding region. 36-HSD type I cDNA encodes a 
protein of 373 amino acids and 36-HSD type II encodes a protein of 372 amino acids.
Type I and type II cDNAs expressed transiently in non-steroidogenic COS-1 cells convert 
multiple A5-3 6-hydroxy steroids substrate to their corresponding A4-3-ketosteroids proving 
that both the dehydrogenase and isomerase activities reside within a single protein 
(Lorence et al 1990, Rheume et al 1991). Both enzymes have ketosteroid reductase 
activity, and no other ketosteroid reductase enzyme has been described.
Corresponding genes, HSD3B1 and HSD3B2 were subsequently identified from human 
leukocyte genomic libraries using 36-HSD type I cDNA as a probe (Lorence eta l 1991; 
Lachance 1991). As illustrated in figure 1.9, the two human genomic 36-HSD genes are 
similar containing 4 exons and 3 introns , with conserved intron-exon splice junctions.
The first exon contains 53 bp of the 5' non-coding, while exon 2 contains 85 bp of the non­
coding region as well as the nucleotide sequence of the first 48 amino acids of 36-HSD 
type I. Exon 3 is relatively small encoding 55 amino acids. Exon 4 contains nucleotides 
encoding the remaining 270 amino acids as well as approximately 400 bp of the 3'
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untranslated region. HSD3B2 is similar except that the encoded protein utilises a different 
initiator methionine; therefore 36-HSD type II is one amino acid smaller.
HSD3B1 (~ 7.7 kb fragment)
a a
HSD2B2 (~ 7.7 kb fragment)
g S
C 1— 1 IVTATA
rich
Figure 1.9. Intron/ exon structure and partial restriction map of the 3B-HSD genes (not to scale). Exons are 
represented by boxes numbered I, II, III and IV. Open boxes represent 5' and 3' untranslated sequences, 
Introns are labelled A, B and C. Common restriction sites, and the translational initiator and stop codons are 
indicated.
The HSD3B1 gene was assigned by fluorescent in situ hybridisation (FISH) to human 
chromosome region lpl3.1 (Berube etal 1989; Morrison etal 1991), and HSD3B1 and 
HSD3B2 were shown to be in close genetic linkage (Russell et al 1994; Lorence et al 
1991). Several bands of hybridisation were detected when Southern blots of human 
genomic DNA were probed with 36-HSD type I exon specific probes (Lachance et al 
1990; Lachance et al 1991; Russell 1993) suggesting that there are other 36-HSD-like 
sequences in the human genome. Genomic Not I and Sac II restriction digests resolved on 
pulse field gels were hybridised under low stringency conditions with 36-HSD type I and 
II cDNAs. A single band of hybridisation of about 290 kb was detected after digestion 
with Sac II restriction enzyme (Morrisette 1993). This suggests that the human 36-HSD 
gene family is located within this 290 kb Sac II DNA fragment, consistent with the mouse 
chromosomal localisation data (Bain et al 1993).
1.10 Structure-function predictions of 3B-HSD isozymes.
The 36-dehydrogenase and A5/ A4 isomerase reactions are encoded by separate genes in 
Pseudomonas bacteria (Yin et al 1991), however, in vertebrate tissues the two activities 
are catalysed by a single protein (Lorence et al 1990, Rheume et al 1991). The 
evolutionary significance of constraining these activities within a single protein is 
unknown, however mammalian 36-HSD isozymes are highly homologous, showing less
20
variation across species than other steroidogenic gene families show within a single 
species (Krozowski 1992).
A number of 36-HSD cDNAs have been identified from mammalian species. The amino 
acid sequences of mammalian 36-HSD isozymes reveal little significant sequence 
similarity with 116- and 176-hydroxysteroid dehydrogenases (HSD), cytochrome P450 
enzymes or steroid-binding proteins. However, sequence similarity is found between 
mammalian 36-HSD isozymes and barley Al protein, and a bacterial (Norcardia) 
cholesterol dehydrogenase as well as open reading frames in vaccinia virus (Baker & 
Blasco 1992).
Based on alignments of predicted amino acids of mouse, rat, human, macaque and bovine 
36-HSD cDNAs, Abbaszade et al (1995) suggested that several gene duplications have 
occurred during the evolution of the 36-HSD gene family in these species. One such 
event arose during the evolution of primates, an ancestral 36-HSD gene was duplicated 
specifically in the primate lineage to yield the two human 36-HSD genes identified to 
date, HSD3B1 and HSD3B2. Another 36-HSD gene duplication event occurred during 
the evolution of rodents before the divergence of the mouse and rat ancestor and several 
gene duplications took place independently after divergence in these lineages.
Considering the presumed evolutionary constraints necessary for 36-HSD activity, it 
seems likely that amino acids conserved across mammalian species are important for 
enzyme activity.
Examination of the mammalian 36-HSD isozymes shows a typical pap dinucleotide 
binding fold in the amino terminal region (residues 2-36) (Wirenga et al 1986). Affinity 
alkylation of purified bovine adrenal 36-HSD with the cofactor analogue 5'-[p- 
(fluorosulphonyl) benzoyl] [adenosine-814C] confirms the amino terminal region for 
cofactor (NAD+) binding, and that residues 20 and 278 are in close proximity in the 3 
dimensional structure of the protein (Rutherfurd etal 1991a; Rutherfurd etal 1991b). 
Residue 36, aspartic acid (D-36), is the acidic amino acid predicted to hydrogen bond with 
all known NAD-dependent dehydrogenases, and is identified in all vertebrate 36-HSD 
isozymes except mouse IV, V and rat III. Mouse IV, V and rat III enzymes are 
characterised by either a phenylalanine (F) or tyrosine (Y) at residue 36, and do not 
display oxidative activity on the classical substrates pregnenolone and 
dehydroepiandrostenedione (DHEA) (Figure 1.3 and 1.4). Using NADPH as cofactor, the 
preferred substrates are 5a-dihydrotestosterone and other 3-keto saturated steroids. These 
enzymes are classified as ketosteroid reductases (KSR).
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Using site directed mutagenesis a point mutation was introduced in the predicted Pap 
dinucleotide binding region of the rat 36-HSD type IE isoform replacing tyrosine (Y) with 
aspartic acid (D) at amino acid position 36 (Turgeon 1995). Transient expression of rat El 
Y36D in tissue culture cells shows a decrease in activity with NADPH as cofactor, but a 
marked improvement of catalytic activity utilising NADH as cofactor. Rat IE Y36D 
shows a similar affinity for NADH to rat 36-HSD type I, a classic dehydrogenase/ 
isomerase for cofactor. This suggests that residue 36 may be diagnostic of cofactor 
specificity, D-36 characterises the enzyme utilising NADH as cofactor and Y-36 (or F-36 
in mouse) utilising NADPH as cofactor.
Affinity radioalkylation experiments of human 36-HSD type I protein has identified 
peptides and amino acids involved in substrate and cofactor binding. Both substrate 
(pregnenolone Thomas et al 1993) and cofactor (NADH Thomas et al 1994) protect the 
same internal tryptic, residues 251- 274 and 176-186. Protection and radioalkylation of 
residues His 262 and Cys 183 suggest that they are involved in substrate and cofactor 
binding, and are in close proximity in the 3 dimensional structure of the protein, forming a 
bifunctional catalytic site. Based on these results, Thomas 1995 proposed that initially the 
36-HSD enzyme is in the dehydrogenase configuration as it oxidises 36-hydroxy-5-ene 
steroids to their 3-oxo-5-ene steroid intermediates and NAD+ is reduced to NADH. End 
product NADH induces a conformational change that activates isomerase activity to 
produce the 3-oxo-4-ene steroid. Once the reaction is complete, product steroid and 
NADH dissociate, and the enzyme returns to the dehydrogenase conformation (Thomas et 
al 1995).
1.11 Tissue distribution of 36-HSD activity in humans.
The tissue distribution of 36-HSD protein has been investigated using polyclonal and 
monoclonal antibodies raised against purified human placental 36-HSD protein (Mueller 
et al 1987, Thomas et al 1988).These antibodies have been used in immunohistochemical 
studies of a number of species including human, rodent and bovine (Sasano et al 1990; 
Naville etal 1991; Riley et al 1992; Dumont etal 1992).
In humans, high levels of immunoreactivity to 36-HSD was observed in placental tissues, 
specifically syncytiotrophoblst cells, extravillous cytotrophoblasts and cells of the chorion 
laeve of normal term placenta (Riley et al 1992). A description of 36-HSD protein 
localisation in the placenta is also described in section 1.13. Immunoreactive protein is 
observed in fetal testis at an early stage of development (Pelletier et al 1992) consistent
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with its critical role in the biosynthesis of testosterone. In the female fetus ovarian 38- 
HSD immunoreactivity appears around the fourth month during the period of genital and 
urethral separation (Pelletier etal 1992).
Adult interstitial Leydig cells of the human testis contain significant amounts of 
immunoreactive protein. In small developing follicles of the ovary, immunoreactivity was 
observed only in the theca interna, but staining became apparent in granulosa cells as the 
menstrual cycle progressed (Sasano et al 1990). In the adult adrenal cortex all three 
morphological zones, zona glomerulosa, zona fasciculata, zona reticularis exhibited 
immunoreactivity (Sasano etal 1990) as well as a few peripheral tissues such as 
sebaceous glands in skin (Dumont et al 1992).
38-HSD activity is also associated with many other peripheral tissues including kidney, 
lung and brain (Milewhich et al 1991). However, protein was not readily detected by 
immunoblot analysis, and the identity of these 38-HSD isozymes remains to be 
established.
1.12 Subcellular localisation of 38-HSD.
38-HSD enzyme activity localises both to the endoplasmic reticulum, with the active sites 
for substrate and cofactor binding facing the cystol (Alvarez et al 1994), and to the inner 
mitochondrial membrane where the active sites face the matrix space (Sauer et al). 60% 
of total 38-HSD activity localised to microsomes, and 40% to mitochondria. 38-HSD 
does not contain a mitochondrial localisation signal, although other steroidogenic enzymes 
localising to mitochondria e.g. P450scc and P450cl 1 contain an amino-terminal peptide 
leader sequence. Purified 38-HSD enzyme from both microsomal and mitochondrial 
compartments exhibit identical biophysical properties, suggesting that they were the same 
protein localised to different compartments. In addition the amino-terminal amino acid 
sequences determined for enzyme purified from each organelle were identical (Thomas 
1989). Using bovine adrenalcortical cells, Cherradi et al 1993 supported the dual 
localisation of a single 38-HSD protein to the endoplasmic reticulum and mitochondria. 
However, substrate specificities of 38-HSD differed between the two organelles, 
suggesting that 38-HSD activity could be modulated in the bovine adrenal cortex, thereby 
affecting substrate utilisation (Charradi etal 1994).
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1.13 Background and objectives of project.
At the interface between the developing conceptus and the maternal circulation, the fetal 
cells surface membrane may well play a role in providing immunological protection for 
the genetically alien fetus. In the human placenta, cells of the villous syncytiotrophoblast 
and non-villous cytotrophoblast are in immediate contact with maternal blood (Boyd & 
Hamilton 1970). Much interest has been shown in identifying proteins expressed by the 
surface membrane of fetal cells sinced they may provide an understanding of the 
mechanisms which allow the fetus to survive. Mouse monoclonal antibodies were raised 
to human first trimester trophoblast cells, including FDO 161G. which bound to villous 
syncytiotrophoblast and non-villous trophoblast in first trimester and term placentae 
(Mueller et al 1987). However, after examining reactivities with a panel of other cells 
and tissues, it was shown that FDO 161G was not trophoblast specific. A further mouse 
monoclonal antibody, FDO 26G, raised against protein which had been purified from 
placental villous tissue, had more restrictive tissue reactivity. Immunocytochemically, it 
reacted with placental villous trophoblast and cells of the adult adrenal cortex, but reacted 
weakly or not at all with placental extravillous trophoblast and adult testicular Leydig 
interstitial cells (Hawes et al 1994).
In chapter three the main objectives were to identify a cDNA encoding the FDO 161G 
reactive protein and confirm reactivity to FDO 26G. As part of a collaborative effort, a 
cDNA was identified and sequenced and identified as 38-hydroxysteroid dehydrogenase 
A5/ A4 isomerase type I (38-HSD type I). Furthermore, FDO 26G reactivity was 
confirmed to this protein in Chinese hamster ovaries (CHO) cells.
As indicated in sections 1.9, two 38-HSD enzymes have been descibed in humans; 38- 
HSD type I is principally expressed in placenta and skin, while 38HSD type II is 
expressed in adrenals and gonads (Lachance et al 1990, Rheume etal 1991). The two 
forms are 95% similar in primary amino acid sequence and antibodies raised against 
human placental 38-HSD react immunocytochemically with 38-HSD in all four 
steroidogenic tissues. Such tissue specificity has been demonstrated by the monoclonal 
antibody (mAb) FDO 161G (Mueller etal 1987, Nickson et al 1991). However, the 
staining patterns of FDO 26G were unexpected, providing evidence for expression of a 
further 38-HSD isozyme in certain placental tissues and in adult testis. From these 
experimental observations, two hypothesis for the extinction of FDO 26G reactivity in 
placental tissues seem likely; either a post-translational modification within the region of 
monclonal antibody binding (the epitope) or the expression of as yet unidentified 38-HSD 
gene that encodes a different amino acid sequence over the FDO 26G epitope.
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Several bands of hybridisation are detected when Southern blots of human genomic DNA 
are hybridised with 38-HSD type I cDNA. The intensity and pattern of hybridization 
suggest that a number of 38-HSD genes other than HSD3B1 and HSD3B2 are present in 
the human genome (Russell 1993). Furthermore when screening PCR amplified 
fragments of patient DNA for mutations in the genes encoding 38-HSD types I and n, it 
was relatively common to amplify novel but closely related 38-HSD exon sequence 
(Russell 1993). This is consistent with the identification of multigene families for 38- 
HSD in rodents, expressed sex-specifically in peripheral and steroidogenic tissues (Bain 
et al 1991;Zhao HF etal 1991; DeLaunoit etal 1992; Keeney et al 1993; Clarke etal 
1993b; Simard etal 1993a; Abbaszade etal 1995).
Two experimental strategies were devised to address the central questions of the extinction 
of FDO 26G reactivity in certain placental tissue and the number of human 38-HSD genes 
in the family.
Western immunoblot analysis implicated the FDO 26G epitope as the site of modification 
(Hawes et al 1994). In chapter four, the main objective was to map the FDO 26G epitope 
on the 38-HSD type I protein using lacZ gene fusions and synthetic peptides.
Identification of the epitope may suggest a post-translational modification consensus 
sequence, which could be tested using modified peptides.
The size of the human 38-HSD gene family would be investigated by homology probing 
with 38-HSD type I cDNA under nonstringent conditions. In chapter 5, a number of 
positive clones were identified from two genomic libraries. The main objective in this 
chapter was to identify a corresponding genomic clone of a previously amplified novel 
putative exon 3 fragment from a patient genomic library and a normal control genomic 
library, and to investigate whether this novel gene was responsible for idiopathic hirsutism 
in family Phe (Russell 1993). The remaining genomic clones would be investigated in 
chapter 6. These clones were screened for novel members of the gene family by PCR 
amplification followed by denaturing gradient gel electrophoresis (DGGE) analysis. 
Various combinations of PCR primers were utilised, particularly those that previously 
amplified other novel PCR products from genomic DNA (Russell 1993). It was hoped 
that genomic clones could be identified that included these fragments.
DGGE is one of the most powerful and simple methods for detecting mutations in DNA 
without sequencing. The addition of GC clamps to the end of one of the primers 
(Sheffield et al 1989) and the additional refinement of screening for heteroduplex DNA 
molecules provides a detection system close to 100% efficiency (Mendonca et al 1984; 
Lerman &Silverstein 1987). It therefore has adequate power to distinguish between
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different members of a multigene family which can be amplified with same PCR primer 
pair. Fortunately the DGGE conditions had previously been optimised for these sequences 
(Russel 1993). However, with the onset of technology, as sequencing directly from PCR 
products became more simple without the additional requirement for cloning, this method 
would also be fully exploited in identifying novel members.
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Chapter 2 
Materials and Methods
2.1 Random priming of DNA: 20ng of DNA was labelled with [alpha-32P]dCTP 
(3000Ci/mmol; Amersham) by the random primer method, using a Ready-To-Go 
DNA labelling kit (Pharmacia), to a specific activity of 109dpm/ug. The reaction 
mixture (final volume 50ul) consisted of 20ng DNA in 45ul water, 5ul [alpha- 
32P]dCTP (lOuCi/ul), and Reaction Mix (dATP, dGTP, dTTP, FPLC pureR Klenow 
fragment 4-8 units), and random oligodeoxyribonucleotides, primarily 9-mers). DNA 
was heated at 100°C for 2 minutes before adding to the above mix. The reaction was 
incubated at room temperature overnight then the reaction was stopped using 2ul of 
0.5M EDTA. After adjusting the volume to lOOul with TE the labelled DNA was 
separated from the unincorporated [alpha-32P]dCTP by chromatography on a 
Sephadex G-50 column, using a 2cm x 1cm bed ( height x diameter).
2.2 PCR primer sequences: A comprehensive schematic representation of PCR/ 
sequencing primer hybridisation sites is presented in figure 6.1.
38-HSD type I (Numbers represent coordinates for 38-HSD type I genomic sequence)
Exon 1/2
M- 1354- AGTGCATAAAGCTTCAG -1370
L- 1545- TAACCATTTGACATCTC -1561
I- 1585- CCTAGAATCAGATC TGC -1601
Y- 1654- ATGACGGGCTGGAGCTGCCTTGTGAC -1679
K- 1791- TTCCTCTCTCAATTCTGGTCCGAAGGCC -17 6 4
J- 1855- CCACATACATGCAGTGT -1839
Exon 3
A- 5655- CCAATGACCTGACCTGT -5671
P- 5662- CCTGACCTGTGTTCTTG -5679
D- 5682- AACTCCAGAACAAGACC -5698
Q- 5786- AGGCGGTGCGGATGACT -5770
B- 5881- CCACCTTGCTGCATCTC -5865
Exon 4
E- 7955- CGTGGTTGGCACCTCTT -7971 
V- 8031- GAGGCCTGTGTCCAAGC -8047
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G- 8400- CACATTCTGGCCTTGAG -8416 
W- 8158- GGCCATGTGTTTTCCAG -8142 
H- 8466- AGTAGAACTGTCCTCGG -8450 
R- 8930- CTTGTGCCCTTTGTCACT -8903
38-HSD type II (Numbers represent coordinates for 38-HSD type II genomic 
sequence)
Exon 1/2
T- 1219- AGAGCATAAAGCTCCAG -1235 
S- 1855- CCACATACATGCAGTGT -1839
Exon 3
A- 5655- CCAATGACCTGACCTGT -5671 
C- 5714- CCAACTTGTTTTATCTC -5698
Exon 4
F- 7849- TGTGGTTGCAGCTCCTT -7865 
Z- 8270- AGACTGGGTTGACTGAT -8254
Unless otherwise indicated, the non-stringent PCR reactions conditions were as 
follows:
94°C 90 sec
45°C 30sec 35 cycles.
72°C 60sec
2.3 Screening of human placental expression library X gt 11 and PCR reaction 
conditions: A lambda gtl 1 expression library containing 1.5xl06 independent clones 
was screened using a partial cDNA fragment labelled by random priming. 
Hybridisation was caried out overnight at 65°C in 5x SSC, 5x Denhardt's solution, 
0.2% SDS and lOOpg/ml salmon sperm DNA, followed by a single wash at room 
temperature in lx SSC, 0.1% SDS for 15minutes and 2 washes at 65°C in lx SSC, 
0.1% SDS each for 15 minutes. Selected plaques were picked as BBL- agarose plugs 
(Maniatas et al 1982) which were twice freeze thawed in 50j l i 1 to release 
bacteriophage DNA. The supernatant was used as a source of template for PCR 
reactions (94oC 30sec, 45oC 30sec, 72oC 30sec, 35 cycles), which were carried out in 
50pl final volume in Taq buffer (50mM-KCL/ lOOmM Tris-HCL pH8.4/ 15mM- 
MgC12/ 0.1% gelatin), containing 8pl of a dNTP solution (1.25mM dATP/ 1.25mM
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dCTP/ 1.25mM dGTP/ 1.25mM dTTP) and ljj.1 of PCR primers that hybridise to the 
lambda arms on either side of the EcoR I cloning site. 1 unit of Taq was used / 
reaction.
2.4 Agarose gel electrophoresis: Unless otherwise indicated, all agarose gels were 
run in TBE buffer (89mM Tris, 89mM boric acid, 2mM EDTA). Ethidium bromide 
was added to each gel at a concentration of 0.5ug/ml. The sample loading buffer used 
consisted of 0.25% bromophenol blue, 40% (w/v) sucrose in water (6x buffer).
2.5 Mammalian cell culture: The cell lines used in this study were COS-7 and 
Chinese hamster ovary (CHO. A2H) cells. For transfections and general passaging of 
cells Glasgow Modified Eagles Medium (GMEM) was used. It was made from a lOx 
stock and the following supplements were added to 400mls of lx media.
300.0 mis ddH20.
40.0 mis lOx GMEM.
13.4 mis Sodium bicarbonate (7.5% w/v) stored at 4°C.
4.0 mis sodium pyruvate ( lOmM).
4.0 mis non-essential amino acids (lOOx liquid) stored at 4°C (see
below)
4.0 mis Penicillin/ streptomycin (1000units/ 10000jig/ ml)
4.0 mis L-Glutamine (200mM) ( for COS-7 media)
Proline ( for CHO.2AH media)
40.0mls Fetal calf serum (FCS) heat treated for 1 hour at 65°C.
Non-essential amino acids (lOOx liquid)
sa
0.89 
1.50 
1.33 
0.75
1.15
1.05
The media was filter sterilised to remove large protein and lipid precipitates, prior to 
use.
L-alanine
L-Asparagine
L-Glutamic acid
Glycine
L-Proline
L-Serine
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All cells were grown as monlayers in plastic tissue culture flasks (base area 25cm2) 
under 10 mis of GMEM at 37 °C in an atmosphere of 5% carbon dioxide. When 
confluence was reached, cells were passaged as follows. The medium was aspirated 
and the cells washed with lOmls of PBS (5mM Na2HP04,7.5mM KH2P 04, 2.75 
mMKCL, 170mM NaCl) and detached with Trypsin/ EDTA (Life Technologies) for 1 
minute at 37°C. Fresh cultures were initiated with several dilutions (1/10, 1/20 and 
1/50).
2.6 Transfection of mammalian cells using CaP04: This method is described by 
Davis et al 1986. DNA is presented as a calcium phosphate DNA co-precipitate to 
the cell. Cells were plated 24 hours before transfection, at approximately 3xl05 cells 
/ dish. The coprecipitate was formed by mixing plasmid DNA (10|ig), 125mM 
CaCl2, and lx HBS (2x HBS 1.5mM Na2HP04, lOmM KCL, 280mM NaCl, 12mM 
glucose, 50mM HEPES pH7.0) in a final volume of 1ml. The mixture was left at 
room temperature for 30 minutes, to allow precipitate to form. The precipitate was 
mixed by pippeting up and down and slowly added to the cells. After 48 hours the 
cells were trypsinised and either harvested (in the case of transient transfection) or 
placed under G418 selection to obtain stable transfectants.
2.7 Selection of Stable CHO cell lines: The mechanism of selection is based upon 
the cells sensitivity to the aminoglycoside antibiotic G418. The resistance gene is 
located on the pcDNAI/Neo (Clonetech) plasmid. Integration of the plasmid, with the 
desired insert, into the CHO cell genome allows selection with G418. Cells were 
incubated in the presence of G418 (800|ig/ml). After 10 days of selection, clones 
were lifted using cloning rings and trypsin, and plated to multi-well plates where they 
were grown until they reached confluence. They were passed to tissue culture plasks 
and analysed on western blots (see western immunoblot analysis).
2.8 Immunostaininng of transfected cells: Transfected slides were grown in 
slideflasks. After 24 hours they were washed in PBS, dismantled and fixed in PBS/ 
acetone (3:2) for 5 minutes at 4°C, followed by several washes in PBS to remove any 
excess acetone and left to dry at room temperature. Slides were placed in a humid 
slide box and wetted with TBS/ BSA. The appropiate dilution of primary antibody 
(see table 2.1) was added lOOpl/slide, followed by an incubation of 30 min at room 
temperature. Thereafter the slides were washed three times in a circulating bath of 
TBS. The slides were drained and the second antibody conjugated to FITC, 
previously diluted in TBS/ BSA (see table 2.1), were added (1 OOjil/ slide) and 
incubated at room temperature for 15 minutes, washed and dried as described above. 
A cover slip was put over the cells with a 50% glycerol/TBS (v/v), 0.1% propidium
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iodide solution. The propidium iodide was added to visualise the nucleus. Slides 
were analysed with a fluorescent microscope, and photographs taken with a standard 
camera attachment and EKTAR 1000 asa film.
TBS
9.5g NaCl
50mls lMTris-HCLpH7.5 
to 1 litre with dH20
TBS/BSA 
lx TBS 
3mg/ml BSA
Table 2.1 Primary and secondary antibody used in immunostaining tissue culture cells.
Primary antibody Dilution
W6/32 (seralab) Positive control; anti-HLA-A, -B, -C 
(Barnstable etal 1978)
1/50
FDO 161G Mueller et al 1987 1/10
Secondary antibody
Goat FITC 
(seralab)
anti-mouse conjugated polyvalent 1/100
2.9 Fusion proteins : Fusion genes were expressed in DS 941 and protein was 
recovered as inclusion bodies, according to the methods of Ruther & Hill (1983).
2.10 SDS-polyacrylamide gel electrophoresis and western immunoblot analysis:
Inclusion body preperations and tissue culture cells were run on discontiuous SDS- 
lammeli gels. The resolving gel (10%) was made from a 30% stock of acrylamide 
(acrylamide: bis 30:0.8) diluted in 0.575M pH8.8, 0.1%SDS, and polymerised by the 
addition of 0.1% APS and 0.05% of TEMED. A solution of 0.1% SDS was overlaid 
to exclude oxygen (an inhibitor of polymerisation) and ensure a horizontal interface 
between the stacking and resolving gel. The stacking gel was (5%) was prepared by 
diluting the 30% stock (30:0.8) in 0.126M Tris pH6.8/0.1% SDS and polymerised by 
addition of 0.1% ammonium persulphate and 0.5% TEMED, and poured on top of the 
resolving gel. Samples were diluted in final sample buffer (1:2) and heated to 100°C 
for 5 minutes before loading. The gels were run in Tris/ Glycine buffer (25mMTris- 
HCL, 192mM Glycine, 20% (v/v) methanol) at 40mA for between 30-60 minutes. A 
marker of known molecular weight were loaded onto the gel.
31
Tissue culture cell preparations, fusion proteins and peptide conjugates were blotted 
onto Hybond C-super (Amersham International pic) in a blotting buffer or 25mM 
Tris, 192mM glycine, 20% (v/v) methanol, and transferred at 100mA for 15 hours at 
23°C. Transfer membranes were blocked with 6% (w/v) non-fat skimmed milk in 
TBS/ Tween (50 mM Tris-HCL buffer, 150mM NaCl, 0.05% Tween, pH8.0) for 1 
hour. Primary antibody, FDO 26G, was incubated for 1 hour. After washing 2x 
15minutes in TBS/ Tween. An alkaline phosphatase conjugated, anti-mouse, second 
antibody (1/5000) was added for 1 hour and washed 2x 15 minutes TBS/ Tween. 
Reactivity was detected using DAB and BCIP (Promega) as substrate.
2.11 Peptides : These were synthesised by ALta Bioscience (Birmingham 
University, Birmingham, UK). Phosphopeptides were synthesised by Peptide and 
Protein Research (Washington Singer laboratories, Exeter, Devon, UK) and their 
structures were confirmed analytically by mass spectrometry. All peptides were 
synthesised with N-terminal cysteines to permit conjugation to carrier protein.
Pptides based on an internal sequence of 38-HSD were synthesised with a N-terminal 
amide group to minimise charge differences when compared with the native 
polypeptide. For binding experiments, peptides were conjugated to either activated 
keyhole limpet haemocyanin (KLH), or BSA using methods provided by the suppliers 
(Piece, Rockford. IL, USA), with a molar ratio of hapten to carrier of approximately 
1000:1.
2.12 Peptide Competition experiments: Unphosphorylated peptide 354-366 was 
conjugated to BSA, transferred to Hybond C-super using a slot blotter and blocked 
with 50mM tris-HCL, 150mM NaCl, 0.05% tween, pH 8.0. FDO 26G was added at a 
final dilution of 1:100 to aliquots (1ml) of 1-20 000 nM solutions of either 
phosphorylated or unphosphorylated peptide. A strip of Hybond C-super bearing the 
BSA-peptide conjugate was immersed in each aliquot for 1 hour, washed, and stained 
for antibody (see methods for western immunoblot).
2.13 Screening of human genomic libraries in X gem ll and PCR reaction 
conditions: Two human genomic libraries were created in X geml 1 (AMS 
Biotechnology, Witney, Oxon, UK). One was from patient IV-2, the other was from an 
unrelated normal control. The libraries were screened with 32P-labelled cDNA of 38- 
HSD type I clone B/3 (Nickson et al. 1991) under non-stringent conditions (hybridization 
17h in 5x SSC, 5x Denhardt's solution, 0.2% SDS, lOOmg/ml salmon sperm DNA at 
65°C; washed twice in 2x SSC, 0.1% SDS at 65°C). From a total of 1.4 x 106 plaques (7 
genome equivalents), 57 positive plaques hybridised reproducibly through to the 
secondary stage of screening. Plaques were re-purified through a second round of plating
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and hybridisation and then picked into lOOpl H2O with a pasteur pipette and boiled to 
release phage DNA. This DNA was tested as templates for PCR amplification (94oC 
30sec, 45oC 30sec, 72oC 30sec, 35 cycles). Amplification products were either cloned in 
pT7 Blue T-vector (AMS Biotechnology, Witney, Oxon, U K ).
2.14 Polymerase chain reaction (PCR): Segments of the genes for 36-HSD types I 
and II were amplified from lymphocyte DNA by PCR. PCRs were performed in a 
Hybaid "Omnigene" for 35 cycles of: [1] 91°C for 30sec, [2] annealing temperature 
for 30sec, [3] 72°C for 30sec, 35 cycles). The reaction mixture ( final volume 50ul) 
consisted of amplification buffer ( 50mM KC1, lOmM Tris-HCl ( pH9.0), 0.1%
Triton X-100, 15mM M gCl), 0.2mM of each dNTP, luM of each oligonucleotide 
primer, 0.5-1 unit of Taq DNA polymerase (Promega), and 10-50ng of DNA 
template.
2.15 Denaturing gradient gel electrophoresis: The DGGE system including 
materials, reagents, gel preparation, and electrophoresis has been described in detail 
by Myers et al (1987). Segments of the genes for 36-HSD types I and II were 
amplified from bacteriophage DNA by PCR. In each case the sequence of the GC 
clamp at the 5' end of the PCR primer was that defined by Sheffield et al (1989).
DGGE was carried out in 6.5% polyacrylamide gels ( 37.5:1, acrylamide:bis 
acrylamide) in a buffer tank containing 91 of TAE buffer (40mM Tris, 20mM sodium 
acetate, ImM EDTA, pH 7.4) (Figure 2.1). Denaturing gradient gels (16 x 18 x 0.1 
cm) were poured using a Dual Slab Electrophoresis SE 600 gel former (Hoeffer). A 
Grant Immersion Thermostat (TA 0-150) was used to circulate the electrophoresis 
buffer at a constant temperature of 60° C. The power pack used was a Kikusui PAB 
(250-0.25). Appropriate denaturant and acrylamide concentrations were achieved in 
each gel by the mixing of two stock solutions, 0% denaturant stock (6.5% acrylamide 
(37.5:1, acrylamide:bis acrylamide) in TAE), and 100% denaturant stock (6.5% 
acrylamide (37.5:1, acrylamide:bis acrylamide), 7M urea, 40% formamide in TAE).
Stock solutions were filtered twice through Whatman No.l paper and stored in brown 
bottles at 4°C. 1/200 gel volume of 20% ammonium persulphate and 1/2000 gel 
volume of TEMED ( N, N, N', N'- Tetra methyl ethylenediamine ) were used as 
polymerisation catalysts. DGGE analysis
had already been optimised (Russell 1993); Exon 3 DGGE analysis was carried out 
using 50-70% denaturant gels, while Exon 4B DGGE analysis was carried out with 
40-70% denatyurant gels. All DGGE gels were run at 80V, 100mA for 20 hours.
Best resolution was achieved in the centre and lower two thirds of the gel matrix.
DGGE gels were stained by immersion in 280 ug/ul ethidium bromide for 30 minutes.
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Samples which exhibited altered mobility on DGGE were either cloned into pT7 
vector or directly sequenced.
60 C
Upper buffer chamber
Thermostat/Pump
Lower buffer chamber
c n
Denaturing gel
Figure 2.1: Denaturing gradient gel electrophoresis. Schematic diagram to illustrate 
the equipment used in the running of denaturant gradient gels. The direction of buffer 
flow is indicated by arrows.
2.16 Confirmation of putative clones by PCR: Individual white colonies were 
selected and grown up in 2ml LB broth ( lOg bacto-tryptone, 5g bacto-yeast extract, 
lOg NaCl, 950ml H2O ) incubated at 37°C overnight. lOul of culture was added to 
40ul water and heated in a boiling water bath for 5 minutes. lOul of the boiled culture 
was used as template in the appropriate PCR reaction. PCR products were screened 
for artefactual PCR mutations by resolution on the appropriate DGGE gel alongside 
controls ( the original PCR product). Only independent clones which resolved 
indistinguishably from the original genomic template were selected for sequencing. 
Large scale plasmid preparation of DNA for sequencing was performed using Qiagen 
columns. Sequencing was carried out using the sequenase version 2.0 DNA 
sequencing kit (U.S.B.).
2.17 pT7 Blue T-vector cloning of PCR products: 50ng (0.03pmol) of pT7 Blue 
T-vector was ligated with 10-50ng (0.04-0.2pmol) of PCR product. PCR products 
were not band purified before cloning into pT7 Blue T-vector. The reaction mixture 
(final volume lOul) consisted of T4 DNA ligase buffer (30mM Tris-HCl (pH 7.8), 
lOmM MgCb lOmM DTT), lOmM ATP, 50ng pT7 Blue T-vector, 10-50ng PCR 
product, and 2-3 Weiss units T4 DNA ligase (B.R.L.). The reaction mixture was
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incubated at 15°C overnight, lul of ligation reaction was added to 20ul of Nova Blue 
competent cells (Invitrogen) and placed on ice for 30 minutes. The cells were heated 
for 40 seconds in a 42°C water bath and then placed on ice for 2 minutes. 80ul of SOC 
medium ( 20g bacto-tryptone, 5g bacto-yeast extract, 0.5g NaCl, 20ml of 1M glucose, 
950ml H2O) was added and the cells incubated at 37°C for 1 hour. 300ul more SOC 
medium was added and lOOul portions were spread on LB ( Luria-Bertani) agar 
plates ( lOg bacto-tryptone, 5g bacto-yeast extract, lOg NaCl, 15g bacto-agar, 950ml 
H2O ) containing 50ug/ml ampicillin. For blue/white screening of recombinants 35ul 
of 50mg/ml X-gal in dimethylformamide and 20ul lOOmM IPTG in water were spread 
on the plates and allowed to soak in for about 30 minutes prior to plating. Plates were 
incubated at 37°C overnight. Putative clones were identified by blue/white selection.
2.18 Preparation of DNA: Plasmid DNA was prepared using Wizard mini-prep kits 
(Promega).
2.19 Dideoxy DNA sequencing: Double stranded plasmid sequencing was carried 
out with a Sequenase kit, USB version 2. Subclones of inserts were sequenced using 
primers to both pUC18 and T-vector plasmid and to sections of the insert DNA.
2.20 Direct sequencing of PCR products: PCR products were electrophoresed 
through a 1% agarose at 8V/cm gel length for 1-2 hours. Bands were visualised using 
long wavelength ultraviolet light and relevant bands were excised using a scalpel. 
DNA was purified from the gel slice using a Magic Prep column ( Promega). 
Sequencing was carried out using the sequenase version 2.0 DNA sequencing kit ( 
U.S.B.).
2.21 Bacteriophage lambda DNA: DNA was prepared using a Lambda DNA 
purification kit (Promega, A7290).
2.22 Bidirectional Southern blot analysis of lamda DNA: 1 -5 (ig of lambda DNA 
was restricted with 10 units of retsricton enzyme and the Life Technologies system of 
REACT buffers and were carried out at 37oC for 2 hours. DNA gels to be blotted 
were run on lx TBE agarose gels. The gels were depurinated in dilute acid (HCL) to 
increase efficiency of transfer and then washed by rocking, in a tray, 2x 15minutes 
denaturing solution (500mls, 1.5M NaCl, 0.5MNaOH). The gels were then was 
rinsed by rocking, 2x 20 minutes neutralising solution (3.0M NaCl, 0.5 Tris-HLC pH 
8.0). A sandwich arrangement was set up as follows. Flat paper towels, 
approximately 2-3 inches thick were placed on the bench, followed by 3 sheets of 
3MM paper and finally the nylon positively charged membrane(Boerhinger
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Mannheim). The 3MM paper and the nylon membrane were the same dimensions as 
the gel to be blotted. The gel was then placed on top followed by nylon, 3MM paper 
and paper towels. Filters were then baked at 80°C for at least 2 hours.
2.23 Phylogenetic analysis:
Nucleotide multiple aligments were obtained using PILEUP (Program Manual for the 
Wisconsin Package, Version 8, September 1994, Genetics Computer Group, 575 
Science Drive, Madison, Wisconsin, USA 53711); trout (S72665), mousel 
(M58567), mouse2 (M77015), mouse3 (M75886), mouse4 (L16919), mouse5 
(L41519), rati (M38179), rat2 (M38178), rat3 (L17138), rat4 (M67465), macaque 
(M67467), human type I (M35493), human type II (M77144) and bovine (X17614).
If necessary manual adjustments were made using the LINEUP (Program Manual for 
the Wisconsin Package, Version 8, September 1994, Genetics Computer Group, 575 
Science Drive, Madison, Wisconsin, USA 53711). Phylogenetic relationship of the 
new human 36-HSD sequences relative to other mammalian cDNA sequences was 
determined using the maximum parsimony method of the PAUP 3.1.1 programme 
(Swofford 1993).
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Chapter 3
Cloning and expression of the cDNA clone B3 (P10), and it's identification as 315- 
hydroxysteroid A5/ A4 isomerase type I (315-HSD type I).
3.1 Introduction
The mouse monoclonal antibody designated FDO 161G reacts with a 43kDa protein 
found in human placental tissues, non-villous trophoblast and villous syncytiotrophoblast 
(Mueller et al 1987). It has also been shown to react immunohistochemically with cells 
of the adrenal cortex, sebaceous glands in skin, interstitial Ley dig cells of the adult testis 
and ovarian follicle cumulus cells. However, a further mouse monoclonal antibody FDO 
26G raised against the purified human 43kDa protein shows more restrictive staining 
patterns in trophoblast cell populations and gonads. FDO 26G reacted strongly with 
villous syncytiotrophoblast, weakly with some trophoblast cells in the chorion laeve and 
not at all with extravillous trophoblast in cytotrophoblast cell islands. Adult Ley dig cells 
of the testis do not show reactivity with FDO 26G, however, like FDO 161G, FDO 26G 
reacted strongly with cells of the adrenal cortex. The 43 kDa protein expressed in these 
tissues attracted interest because of these discrepencies in monoclonal antibody staining 
(Hawes et al 1994).
Using an affinity-purified sheep anti-161G antibody, a partial cDNA, clone 1/6, had 
previously been isolated from a X gtl 1 placental cDNA expression library (Nickson et al 
1991). The main objective of the experiments presented in this chapter were to isolate a 
cDNA encoding the entire open reading of the 43 kDa protein, and to confirm reactivity 
to FDO 161G and FDO 26G monclonal antibodies in tissue culture cells. The staining 
patterns described above and in section 1.13, could be explained by either the expression 
of two or more closly related gene products or post-translational modification of a single 
protein. Therefore a further objective was to estimate the number of different cDNA 
sequences encoded by postive clones identified in the library screen using DGGE.
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Results
3.2. Isolation ofB3, a 1700bp placental cDNA clone.
Clone 1/6 insert DNA was radioactively labelled and used as a probe to isolate further 
clones from the original placental cDNA Xgtl 1 library (1.5xl06independent clones). 
Forty eight positive clones were identified from 150,000 plaques screened, a frequency of 
3x1 O'4, and partially purified. PCR primers, 695 and 696, were designed to hybridise to 
regions flanking the polycloning sites of lambda gtl 1 to allow simple estimation of insert 
size (Figure 3.1).
^F orw ard  primer 696 EcoR I
________________________________ GAATTC
------------------------------------------------- CTTAAG
Xgt 11 DNA \
Reverse primer 695
Figure 3.1. Placental cDNA inserts were cloned into the EcoR I restriction enzyme site of A,gtl 1. 
Schematic diagram showing PCR primer hybridisation sites of PCR primers 696 and 695 in relation to the 
EcoR I cloning site in A-gtl 1. Extra sequence containing restriction enzyme sites are included in the PCR 
primers 695 (Xba I and Not I) and 696 (Xba I and Hind III) illustrated by the tail at the end of the primer. 
Primers 696 and 695 were used to amplify cDNA inserts from positive clones isolated from the placental 
A,gtl 1 cDNA library, probed with 1/6 (X-32P radiolabelled DNA.
Ten positive clones were randomly selected for further analysis, and purified. Positive 
plaques were picked as BBL-agarose plugs and twice freeze thawed to release 
bacteriophage DNA suitable for PCR amplification. The approximate size of each PCR 
product using primers 695, 696 was estimated (Figure 3.2).
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
15 8 4 b p ■ 
983bp'
Lane 1 - X Hind III/  EcoR I Lane 6- P42 (1.1 kb) Lane 11 - P 4 1 (1 ,6kb)
Lane 2- PI (1.6kb) Lane 7- 1/6 (1.2kb) Lane 12- P10(B 3) (1.7kb)
Lane 3- P4 (1.2kb) Lane 8- 1/6 (1.2kb) Lane 13- P44 (1.6kb)
Lane 4- P6 (1.2kb) Lane 9- PI 1 (1.6kb) Lane 14- N egative control
Lane 5- P33 (1.4kb) Lane 1 0 -P12 (1.6kb) Lane 15- X Hind III/ EcoR I
Figure 3.2. Estimation o f  clone insert size by PCR analysis using primers 696 and 695 from ten cD N A  
clones isolated from the placental cD N A  2cgt 11; P I, P4, P6, P10(B3), PI 1, P I2, P33, P41, P42 and P44 
library (approximate sizes are indicated in brackets. Lanes 7 and 8 show the insert size o f  clone 1/6. P10 
(B 3) Lane 12 was selected for further analysis. Clone 33 in Lane 5, is not purified to hom ogeneity. Lane 
14 is a negative control for the PCR reaction (no template DNA).
Clone B3 (P10) PCR product (Figure 3.2, Lane 12 ) was estimated to contain a 1700bp 
insert and was cloned into pUC18 and sequenced by Debra Nickson (Figure 3.3) 
(Nickson et al 1991).
N o t I 695
EcoR I Kpn I Hind III Bam HI Pst I 
I I I I
57bp 348bp 164bp 151 bp 93bp 564bp
I 1------------------------1----------1---------- 1----1-------------------
Fsp I Sac I Eco RI
_l l_  ‘
696 Hind  III 
| 146bp|103bq 47bp^
Figure 3.3. Partial restriction map and sizes in base pairs o f PCR clone B3 (P10) amplified with primers 
695 and 696 (1673 bp). Open boxes are untranslated regions, filled boxes are coding sequence. EcoR I 
sites are maintained from A.gt 11.
This sequence was used to search Genbank data base and the clone B3 was identified as 
3B-hydroxysteroid A5/ A4 isomerase type I (3B-HSD type I).
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3.3 B3 (3J3-HSD type I) PCR cloning into the eukaryotic expression vector pcDNAI/Neo
The purpose of this experiment was to confirm reactivity of FDO 161G to the B3 open 
reading (ORF) frame isolated from the placental cDNA library. B3 open reading frame 
was amplified using primer pairs 35/696 introducing a Bel I restriction enzyme digestion 
site (Figure 3.4 a). B3 PCR product could then be cloned into the BamH  1/ EcoR  V 
restriction sites of pcDNAI/Neo (Figure 3.4 b). 
a)
Qligo-35
cctggtgagtgattcctgctactttggatggcc ATG ACG GGC TGG
Kpn I Hind III BamH  I Pst I Fsp I Sac I EcoR  I
6 9 6  Hind III
b)
I T7 promoter 1  jp
K h * *< >
•—* . ry . *  HH _
so Ocq tq o, cq
. s j; ^  « a r
I f l $ ^L Sp6 promoter
CMV promoter
R SV/ N eo/ PolyA
pcDNAI/Neo
7100 bp
Sup F 
selection
SV 40
Col E l
M13
Figure 3.4. Schematic representation o f PCR amplification o f B3 utilising primers 35/ 696 and subsequent 
cloning into pcD NA I/N eo. a) The upstream 5' untranslated and the initial 12 nucleotides encoding the first 
4 amino acids o f pUCB3 cD N A . Untranslated sequence is presented in lower case. The arrow indicates 
hybridisation between oligo 35 and upstream sequence, whereas the 'tail' represents extra sequence at the 5' 
end o f  the oligo including a Bel I restriction enzyme site. PCR amplification using oligo 35 and 696 with  
pUCB3 as template, amplified B3 (3B-HSD type I) open reading frame, b) pcD N A I/N eo is a 7.1 kb 
eukaryotic expression vector, containing the Neom ycin gene. This provides a marker for stable selection in 
eukaryotic transfections. The N eom ycin gene confers Kanamycin resistance in bacteria. Unique polylinker 
sites are shown in bold. * indicates restriction enzym e sites lost during the cloning o f B3 ORF.
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Using pUCB3 as template, B3 open reading frame was PCR amplified using primers 
35/696 (Figure 3.5 a). pcDNAI/Neo vector was prepared by restriction with enzymes 
BamH  I and EcoR V (Figure 3.5 b).
WMtt
a)
Lane 1 - X Pstl
Lane2- 7 - B3 PCR using primers 35/696
b)
L anel- X Pstl
Lane2- pcD N A I/N eo BamH 1/ EcoRV 
Lane3- pcD N A I/N eo BamH 1/ EcoRV
Figure 3.5. a) B3 open reading frame was amplified was amplified using PCR primers pair 35 and 696. 
b) Expression vector pcD N A I/N eo restricted with Bam HI and EcoR V.
B3 ORF cloned into pCDNAI/Neo yields the construct pcDNeoB3. To confirm B3 had 
been successfully cloned into pcDNAI/Neo, restriction enzyme digestions were compared 
between pcDNAI/Neo vector DNA and the pcDNeoB3 clone (Figure 3.6).
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
4200bp
2000bp
Lane 1- \E coR H  HindlU 
Lane 2- Uncut pcD N A I/N eo  
Lane 3- Uncut pcD N eoB3  
Lane 5- pcD N A I/N eo (EcoRl) 
Lane 6- pcD N eoB 3 (EcoRl)
Lane 8- pcD N A I/N eo (EcoRV) 
Lane 9- pcD N eoB3 (EcoRW) 
Lane 11- pcD N A I/N eo (BamHI) 
Lane 12- pcD N eoB 3 (BamHI)
Lane 14- pcD N A I/N eo (Pstl) 
Lane 15- pcD N eoB 3 (Pstl) 
Lane 17-XEcoRV Hindlll
Figure 3.6. Comparison o f restriction digests o f pcD N A I/N eo and construct pcD N eoB 3. EcoR I and Pst I 
digests (Lanes 5and 6, and 14 and 15) suggest P10 (B3) cD N A  has been inserted in the correct orientation.
A number of restriction enzyme site were lost when the B3 open reading frame was 
cloned into pcDNAI/Neo (Figure 3.4 b). The restriction enzyme digestions in figure 3.6 
are diagnostic of B3 open reading frame successfully cloned into pcDNAI/Neo, including 
the loss of an EcoR I (lanes 5and 6) and EcoR V (lanes 8 and 9) restriction sites, and the 
altered restriction digest pattern with BamH  I (lanes 11 and 12) and Pst I (lanes 15 and 
16).
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3.4 Transient expression o f  pCDNeo/B3 in COS-7 cells and immunostaining with FDO  
161G monoclonal antibody.
Transfected COS-7 cells were prepared for analysis using immunostaining and 
fluorescence microscopy. The integrity of COS-7 cells was determined by 
immunostaining with anti-HLA class I primary monoclonal antibody W6/32 (Barnstable 
et al 1978), followed by detection with an FITC conjugated second antibody (Figure 3.7). 
Propidium iodide stains the nuclei red.
Figure 3.7. Positive control, COS cells immunostained with W 6/32 antibody (1 /50  dilution).
The construct pcDNeo/B3 was transiently transfected into in COS-7 cells using CaP0 4 . 
After two days, COS-7 transfected cells were fixed and immunostained with FDO 161G, 
followed by detection with an FITC conjugated second antibody (Figure 3.8)
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a)
1
Figure 3.8. (a) N egative control, COS cells transfected with pcD N A I/N eo vector were im m unostained  
with FDO 161G (1 /10  dilutiuon). (b) COS cells transfected with p cD N eo /B 3 (lO ug), im m unostained with 
FDO  161G (1 /10  dilution).
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3.5 FDO 26G staining o f CHO cells stably transfected with pcDNeo/B3.
pcDNAI/B3 was transfected into Chinese hamster ovary (CHO) cells. Several stable cell 
lines were selected using resistance to G 418 conferred by expression of neomycin (Figure
3.4 b). Immunoreactivity of FD 026G  was confirmed by western immunoblot analysis 
(Figure 3.9)
1 2 3 4 5 6 7 8 9  10
Bovine albumin 
(45,000 Da)
Figure 3.9. W estern im m unoblot analysis o f  FDO 26G antibody on several independent pcD N eo/B 3 stable 
CHO cell lines.
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3.6 Evidence fo r  Bgl II polymorphism from  clones isolated in the placental library 
screen.
As indicated previously, B3 (P10) sequence was used to search Genbank and identified as 
36-hydroxysteroid dehydrogenase A5/ A4 isomerase type I (313-HSD type I). B3 sequence 
diverged from the published cDNA sequence encoding amino acid residue 338, removing 
a Bgl II restriction enzyme site. PCR product from B3 and the other clones amplified in 
figure 3.1, were restricted with Bgl II to determine if the placental library was 
heterozygous for this restriction enzyme site (Figure 3.10).
1584bp
983bp
Lane 1- 
Lane 2- 
Lane 3- 
Lane 4- 
Lane 5- 
Lane 6- 
Lane 7- 
Lane 8- 
Lane 9-
Figure 3.10. Bgl II analysis o f  PCR products amplified using primers 696 and 695 from positive clones P I, 
P4, P6, P10 (B 3), PI 1, P12, P33, P41 and 1/6, clone 44 was not included in this analysis. Six clones 
contained the B gtll restriction enzym e site, P I, P4, P6 PI 1, P12, P41. Four clones did not contain the Bgl 
II restriction site, 1/6, B3 (P10), P33 and P42.
These clones, including 1/6, represent two sequence variants of codon 338 of the open 
reading frame. There is evidence that this synonomous mutation encoding residue 338 is 
a common polymorphism (Russell et al 1994). Further sequence analysis by Alan 
Russell revealed a second base pair missense mutation encoding residue 367, N367T 
(Russell et al 1994).
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
XH ind  III/ EcoR  I 
P10 (B 3)
P10 (B 3) Bgtll 
1/6
1/6 Bgtll 
PI
PI Bgtll 
P4
P4 B gtll
Lane 10- P6
Lane 11- P6 Bgtll
Lane 12- PI 1
Lane 13- PI 1 Bgtll
Lane 14- X H indlll/ EcoRl
Lane 15-P 12
Lane \ 6 - ?  12 Bgtll
Lane 17- P33 
Lane 18- P33 Bgtll 
Lane 19- P41 
Lane 20- P41 Bglll 
Lane 21- P42  
Lane 22- P42 Bgtll
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3.7 DGGE analysis o f positive clones isolated from the placental library.
To investigate the remaining clones and confirm they contained 36-HSD type I sequence, 
PCR amplification using primers (G, H) was attempted from each of the remaining 
partially purified clones. PCR primer pair G, H would amplify 480 bp at the 3' end of B3 
coding region (Figure 3.11).
1 34bp
I I
c c t g g t g a g t g a t t c c t g c t a c t t t g g a t g g c c  ATG ACG GGC TGG AGC
M e t T h r  G l y  T r p  S e r
1153bp 
TGA FspI Sacl1562bpKpnl Hindlll BamHI Pstl
Bgl i f "  N367T
ex 4B
480bp PCR product
Figure 3.11. Stucture of the placental cDNA clone B3 (1562bp). The dark box represents coding DNA 
sequence, the open boxes are 5' and 3' untranslated sequence. Translational start and stop codons are 
shown along with 33bp of up stream sequence, including the inframe stop and start codons highlighted in 
bold. Primer pair G and H hybridisation sites are illustrated in relation to two polymorphic sites at the 3' 
end of the coding sequence. Primer G contained a GC clamp for DGGE analysis.
46 out of 48 clones gave an amplification product of the expected size and these PCR 
products were analysed using denaturing gradient gel electrophoresis (D.G.G.E.) (Figure 
3.12). Haplotype controls (BglII +, Thr and BglII Asn) had already been identified 
from the placental cDNA library by restriction digestion analysis (Figure 3.10).
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1 2 3 4 5 6 7 8 9 10 11 12
/ -: ;'Vv;; '^•■'•V>;:-.,':,
■'■■ v • £ . I:, ’■■'■:■'•••’ ■.. :;^ . v . ' .
:
- 1 L  : 
i-Wyi-
|S |iM P i NjB 3 B Eg
m . ,  ,v,j p f
mm28 ISsl S
Lane 1- C lone 2 
Lane 2- C lone 3 
Lane 3- C lone 7
Lane 4- Clone 10 (B3) 
Lane 5- Clone 15 
Lane 6- Clone 42 (Asn,-)
Lane 7- Clone 1 (Thr,+) 
Lane 8- Clone 16 
Lane 9- Clone 17
Lane 10- Clone 24  
Lane 11- Clone 27 
Lane 12- Clone 28
10 11 12
WMK
Lane 1- C lone 18 
Lane 2- C lone 21 
Lane 3- C lone 22
Lane 4- Clone 23 
Lane 5- Clone 42 (Asn,-) 
Lane 6- Clone 6 (Thr,+)
Lane 7- Clone 25 
Lane 8- Clone 26 
Lane 9- Clone 30
Lane 10- Clone 32 
Lane 11- Clone 34 
Lane 12- Clone 35
10 11 12
Lane 1- C lone 29 Lane 4- Clone 40 Lane 7- Clone 4 (Thr,+) Lane 10- Clone 9
Lane 2 - C lone 31 Lane 5 - Clone 41 Lane 8 - Clone 43 Lane 1 1 -Clone 13
Lane 3- C lone 39 Lane 6- Clone 42 (A sn,-) Lane 9- Clone 47 Lane 12- Clone 14
Asn - 
Thr +
Lane 1 - C lone 5 Lane 5 - Clone 37 Lane 8- Blank
Lane 2- C lone 19 Lane 6- Clone 42 (A sn,-) Lane 9- Clone 38
Lane 3- C lone 23 Lane 7- Clone 6 (Thr,+) Lane 10- Clone 44
Lane 4- Blank
Figure 3.12. Denaturing gradient gel electrophoresis (DGGE) analysis o f  placental clones amplified with 
placental 3B-HSD exon 4B primers (G, H). Haplotype controls (Asn - and Thr +) are indicated on the 
DGGE gels.
Clone 36 did not amplify with primers G, H. Further PCR amplification was attempted 
with primers 695 and 696, the PCR product was cloned, sequenced and identified as a 38- 
HSD type I clone foreshortened at the 3’ end. Clone 38 failed to support amplification 
with PCR primer pairs (G, H) and (695, 696). An attempt was made to recover this 
bacteriophage clone by rehybridisation with 1/6 probe, but was unsuccessful. The 38- 
HSD type I haplotypes from the positive clones identified in this screen from the 
placental library are summarised in Table 3.1.
Lane 11- C lone 45 
Lane 12- C lone 46  
Lane 13- Clone 48
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Table 3.1. Summary haplotypes of 3B-HSD type I clones from the placental library amplified with PCR
Placental
clone
Approximate size 
primers 695/696
367 allele Bgl II 
+ or
1/6 1.2 kbp Asn -
1 1.6 kbp Thr +
2 Asn -
3 Thr +
4 1.2 kbp Thr +
5 Asn -
6 1.2 kbp Thr +
7 Asn -
8 Asn -
9 Thr +
10 (B3) 1.7 kbp Asn -
11 1.6 kbp +
12 1.6 kbp +
13 Thr +
14 Asn -
15 Asn -
16 1.2kbp Asn -
17 Asn -
18 Asn -
19 Asn -
20 Thr +
21 Thr +
22 Asn -
23 Thr +
24 Thr +
25 Thr +
26 Thr +
27 Thr +
28 Asn -
29 Thr +
30 Asn -
31 Asn -
32 Thr +
33 1.4 kbp -
34 Thr +
35 Thr +
36 Asn -
37 Asn -
38 ND ND
39 Asn -
40 Asn -
41 1.6 kbp +
42 1.1 kbp Asn -
43 Asn -
44 Thr +
45 Thr +
46 Thr +
47 Asn -
48 Asn -
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Chapter 4
Mapping the monoclonal antibody FDO 26G epitope to the carboxy-terminus of B3
(38-HSD type I). 
4.1 Introduction.
Immunocytochemically FDO 161G reacts with 38-HSD in trophoblast cells of the 
placenta, sebaceous glands in skin, cells of the adrenal cortex and gonadal tissue (Mueller 
et al 1987). However, a further mouse monoclonal antibody FDO 26G raised against 
purified human placental 38-HSD shows more restrictive staining patterns in trophoblast 
cell populations and gonads. FDO 26G reacted strongly with villous syncytiotrophoblast, 
weakly with some trophoblast cells in the chorion laeve and not at all with extravillous 
trophoblast in cytotrophoblast cell islands. Leydig cells of the testis do not show 
reactivity with FDO 26G, however, like FDO 161G, FDO 26G reacted strongly with cells 
of the adrenal cortex. The monoclonal antibodies FDO 161G and FDO 26G have been 
shown to react to B3 (38-HSD type I) protein expressed in COS-7 cells and CHO cells 
respectively (Figures 3.8 and 3.9).
The differences in staining patterns suggests the expression of a further 38-HSD isozyme 
in certain placental trophoblast populations and gonads. RNase protection assays and 
RT-PCR experiments have shown that 38-HSD type I transcripts are found in trophoblast 
cells and 38-HSD type II is the principal 38-HSD transcript found in gonads and the 
adrenal cortex. It seems likely therefore that either a post-translational modification of
38-HSD type I and type II or the expression of a new gene in the appropriate tissue 
results in the extinction of FDO 26G reactivity . The main objective in this results 
chapter is to map the FDO 26G epitope. This would allow either the potential post- 
translational modifications to be tested, or identify the sequence of amino acids that 
would be altered in the unreactive tissue, complementing the search for new 38-HSD 
genes (results chapters 5 and 6).
Results
4.2 Mapping the FDO 26G epitope using bacterial lacZfusion genes.
Plasmids pUR290, pUR291 and pUR292 (Ruther U & Mueller-Hill 1983) can be used for 
expression of genes without their own translational initiation region as fusion proteins 
with 8-galactosidase (lac Z). DNA sequence can be subcloned, inframe, into the carboxy 
terminus of the lacZ gene using unique restriction sites. The restriction enzyme digestion 
sites are in different reading frames in different plasmids (Figure 4.1).
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a)
Hind III Pst I Sal I BamH I
Amp
pUR290
5200 bp
B-gal
P/dic UV5
promoter
b)
p U R 2  9  0 5 'C A A A A A GG G^G AT CCG TCG ACC TGC ! g c  c I a  g c t T A T
BamH  I c , T Sal I Pst I 
1
Hind  III
1
p U R 2  9 1 5 'T G T CGG
f
GGA TCC GTC GAC
*
C TG CAG
♦
C CA  AGC T T A 3 '
BamH  I S a il P s tl Hind  III
p U R 2  9 2 5 'T G T CAG
♦
GGG A TC CGT CGA
*
C C T  GCA
*
GCC AAG C T T A TC
BamH  I Sal I Pst I Hind III
Figure 4.1. a) Schem atic diagram o f pUR290 vector, showing the full length B-glactosidase gene with  
unique restriction enzym e sites at the 3' terminal region o f lacZ. The lacZ sequence is preceded by the 
lacUV5 promoter allow ing regulation o f expression o f the fusion protein with the lac repressor and IPTG. 
The am picillin gene is the selectable marker, b) The unique cloning restriction enzym e sites for the 
plasmids pU R 290, pU R 291, pU R292 are shown. The triplet codons represent lacZ reading frame.
Restriction fragments were subcloned from pUCB3 into the bacterial expression vectors, 
however, suitable restriction sites were not always available and were introduced into the 
cDNA sequence of B3 by PCR amplification or by site selected PCR mutagenesis.
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4.3 Constructs pURMMl and pURMM2 (Residues 1-241 and 210-373).
B3 was divided into two convenient overlapping 5' and 3' restriction fragments. The 5' 
fragment is derived from PCR amplification using pUCB3 and 35/696 primers followed 
by restriction with Bel I/Pst I enzymes(Figure 4.2 a). The 3' fragment is derived from 
BamH l/Hind  III restriction of pUCB3 DNA, (Figure 4.2 b). The predicted fusion genes 
are illustarted in (Figure 4.2 c).
a)
Bell 35
Kpnl Hindlll BamHI Pstl 
I I______ I I
5 ’ restriction fragment (746 bp)
B ell- Pstl
TGA FspI Sacl
_ l_
* \
6 9 6  Hindlll
b)
EcoR IATG 
Not I Nj I Kpn I
Hind III
lacl
Ori
Bam H  I
Pst IB3
pUCB3
4400 bp
 TGA
Amp
Fsp 1
lacZ' Sst
-A EcoR 
H ind  III
3 ’ restriction fragment (950 bp)
BamH I Hind III
c)
pURM M l (5' construct)
pUR2 91-TGT CGG Gga tea ctg eta ctt tgg atg gee ATG ACG GGC TGG AGC-B3
pURMM2 (3' construct)
PUR2 92-TGT CAG GGG ATC CTG TCA AGT GTT GGA AAG TTC TCC ACT-B3
Figure 4.2. a) PCR amplification from the placental clone B3, using PCR primers 35 and 696. O ligo 35 
hybridises to sequence upstream of the initiation codon o f  B3 and introduces a Bel I restriction site at the 5' 
end o f  the PCR product. B e ll/ Pst I restriction isolates the 5' fragment, b) Clone B3 subcloned into 
pU C18, BamH l/Hind III restriction isolates the 3' fragment, c) Predicted sequence from the successful 
cloning o f the two restriction fragments pURMM 1 and pURM M 2. The reading frame o f the lacZ gene is 
indicated by triplet codons. Sequence derived from pUR plasmid is shown in plain text, B3 open reading 
frame is highlighted in bold. The sequences in lower case are upstream untranslated nucleotides.
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The 5' fragment was cloned into pUR291 vector restricted with BamH  1/ Pst I restriction 
digestion enzymes. The upstream inframe stop codon is not included (see Figure 4.3). 
The 3' fragment from pUCB3 was cloned into pUR292 restricted with BamH  1/ Hind  III 
restriction digestion enzymes (Figure 4.3)
- ♦ 9 5 0 b p
805bp - ►
746 bp - ►  3 fragment
5’ fragment
L an el- B3 (35 /696) D N A , Bel It Pst I 
Lane2- pU R 291, BamH l/Pst  I 
Lane3- pU R 292, BamH VHind III 
Lane4- pU R 292, BamH VHind III 
Lane5- X Pst  I marker
Lane6- Uncut pUCB3 D N A  
Lane7- pUCB3, BamH VHind III 
Lane8- pUCB3, BamH VHind III
Figure 4.3. Restriction digests o f  D N A  required for pURM M l and pURM M 2 constructs. Lane 1 B3 
(35 /696) PCR am plified D N A , restricted with Bcll/Pstl. Lane2 pLTR291 BamH I/PstI restricted D N A . 
Lanes 7 and 8 pUCB3 D N A  restricted with BamH VHind III. Lanes 3 and 4 pUR292 D N A  restricted with 
BamH VHind III. Lane5 X Pstl marker. Sizes o f the restricted pUCB3 DNA are shown.
pURM M l plasmid transformants that contained the 5' construct were screened using the 
unique Kpn I restriction digestion enzyme (Figure 4.4 a), while pUMM2 clones were 
screened using Sst I restriction enzyme (Figure 4.4 b).
a) b)
12 3 4 5 6 7 8 9 10 11 1213 14 15 16 17 1819 20 21 12 3 4 5 6 7
1700bp- 1700bp
Figure 4.4. pURM M  1 and pURM M 2 transformants, a) pURMM 1 transformants were screened using the 
unique Kpn I restriction digestion site. Lane 14 contains a plasmid that has been linearised, b) pURM M 2  
constructs were screened using the restriction enzyme Sst I, predicted to excise a 1,900 bp fragment. Lane 
2 contains a plasmid that excises a D N A  fragment o f the correct size.
1700bp
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The plasmids in figure 4.4 a) lane 14 and b) lane 2 were selected for further analysis. The 
sequence over the polycloning region of each of the constructs was determined to ensure 
that frame throughout the fusion gene was maintained. The sequence from pUR291 and 
the pURM M l construct is presented in figure 4.5.
a) b)
A
“ t -
T
Hindlll g
A
A
“ C
_C
G 
A 
C 
G 
T 
_C
Sail S
T 
_G
C
B3 coding 
sequence
Pstl
BamHIir Upstream 5’ untranslated 
sequence
pUR291
B3 sequence
pUR 291 sequence
G.
G
G
c
T
G
T
A C G T
pURMMl
Figure 4.5. a) pUR291 sequence over the polylinker region at the 3' end o f the lacZ gene, b) Sequence of 
construct pU R M M l. B3 sequence is highlighted in bold; 5' untranslated D NA  is shown in low er case, 
w hile coding D N A  is presented in capitol letters. The sequence o f pURM M l constructs suggests that the 
D N A  is in frame and will express fusion protein.
The sequence from pUR292 and the pURMM2 construct is shown in figure 4.6. The 
frameshift encountered by the using the wrong translational vector was corrected by the 
insertion of an oligonucleotide (Figure 4.6 c).
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Hindlll
B3 coding 
sequence
B3 coding £ 
sequence g
BamHI T
Linker t
pURMM2p U R 2  9  0
pURMM2+linker
Figure 4.6. a) Sequence analysis indicates pUR290 was used ias vector nstead o f  pUR292. b) The 
pURM M 2 fusion gene contains a frameshift and is one base pair out o f frame, c) An oligonucleotide 
linker D N A  sequence was cloned into the pURM M 2 fusion gene to correct the frameshift introduced by 
using pU R 290 vector.
pURM M l and PURMM2 constructs were expressed in E.coli and protein was recovered 
as inclusion bodies, according to the methods of Ruther & Muller-Hill (1983). pURM M l 
and 2 inclusion body preparations were tested for reactivity to FDO 26G (Figure 4.13). 
FDO 26G reacted positively to pURMM2 localising the epitope to residues 241-373 of 
36-HSD type I.
4.4 Construct pURMM3 (Residues 263-373)
The FDO 26G epitope was localised to the 3' region of B3 (3B-HSD type I). As there 
were few restriction enzyme sites in this region a Pst I restriction enzyme site was 
introduced into the B3 cDNA by site directed mutagenesis by overlap extension using the 
polymerase chain reaction illustrated in figure 4.7 (a)-(d). The resultant mutant product 
m B3(l) is shown in figure 4.7 (d). Initially this product was cloned into pUC 18 before 
being subcloned into pUR292 (Figure4.8 and 4.9).
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a)
Oligo b
A
GAC ACG CCT CTG CAG AGC TAT GAT AAC 
I— P s tI—*
Serine 257 I
3B-HSD type 1 5 ' " TCA GAT GAC ACG CCT CAC CAA AGC TAT GAT A AC  CTT * A T - 3 ‘ 
sequence 3 '- A G T  CTA CTG TGC GGA GTG GTT TCG ATA CTA TTG GAA T T A -5 '
CTG TGC GGA GAC GTC TCG ATA CTA TTG
Oligo c
Not I 695
Kpn I Hind III BamH I P st I,EcoR I Fsp I Sac I EcoR  I
813bp P s t l 860 bp 696 Hind III
b)
PCR amplification using primers 695/oligo c and oligo b/696 yield products 695C and 696B.
695C (892bp)
-KKTSk- 696B (807bp)
 ^481
Products 695C and 696B are band purified from agarose gels, mixed together and reamplified using 
primers 695 and 696. XX represent introduced mutations within oligos b and c.
c)
Not I 695
-XXr
\ X X
696 Hind III
d)
P st I Pst I
Hind HI------------------------------------------------------------------ a * ---------------------------------------------------- ^
1-----------------
813bp . 67bp. 793bp Required mB3(l) fragment.
Introduction of a Pstl restriction enzyme site into the cDNA sequence of 36-HSD type I, mB3(l).
Figure 4.7. Site directed mutagenesis by overlap extension using the polymerase chain reaction, a) PCR 
primers b and c hybridise to 36-HSD type I cDNA, but are synthesised with base mutations encoding amino 
acid residues 262 and 263, that introduce a Pst I restriction enzyme site, b) PCR products 695B and 696C 
overlap and contain the introduced Pst I restriction site, c) These PCR products are band purified from 
agarose gels, mixed and reamplified using primers 695 and 696. d) The resultant full length PCR product, 
m B3(l), contains the introduced Pst I site. Incorporation of the mutant nucleotides was confirmed by 
restriction digest. The sizes of Pst I restriction digests are indicated in (a) and (d).
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Figure 4.8 (a) and (b) show the products of the PCR reaction 695C and 696B, and 
confirmation of the incorporation of the mutant nucleotides by Pst I restriction digestion 
(Figure 4.8 (b) lanes 5 and 6). The Pst VHind III m B3(l) fragment (Figure 4.8 c) was
cloned into pUC18 to give the construct pUCmB3(l) (Figure 4.8 d). 
a) b) c)
2000bp
lOOObp
L an el- lkb  ladder 
Lane2- pU C B3 PCR (695/696) 
Lane3- pU C B3 PCR (695C ) 
Lane4- pU C B3 PCR (696B )
d)
L an el- lkb ladder 
Lane2- pUCB3 (695/696) 
Lane3- mB3 (695/696)
Lane4-
Lane5- pUCB3 (695/696) Pst I 
Lane6- mB3 (695/696) Pst I
1 2  3 4 5 6 7
L anel- lkb ladder 
Lane2- X Hind III ligation 
control
Lane3- pUC18 Pst VHind III 
Lane4- m B 3 (l) Pst 1/ Hind III 
insert
L anel- lkb ladder Lane5- D igest 4 Pst VHind III
Lane2- D igest 1 Pst VHind III Lane6- D igest 5 Pst VHind III
Lane3- D igest 2 Pst VHind III Lane7- D igest 6 Pst VHind III
Lane4- D igest 3 Pst VHind III
Figure 4.8. C loning m B 3 (l) Pst VHind III fragment into pUC 18. a) PCR amplification o f pUCB3 using 
primers 695/696 , 695/oligo c and oligob/696. b) PCR amplification o f wild type and mutant B3. Pst I 
restriction digests confirms the incorporation o f mutant nucleotides, c) Ligation control, pUC 18 Pst 
VHind III vector and mB3 Pst VHind III insert DNA. d) Transformants were screened for insert by Pst 
VHind III restriction digests.
Digestion 6 (Figure 4.8 d) lane 7) exicised the required fragment from pUC 18 and was 
designated pUCmB3(l). This Pst VHind III fragment was then cloned into pUR 292 
restricted with Pst VHind III restriction enzymes to make the construct pURMM3 (Figure
4.9).
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2000bp
2000bp
lOOObp
500bp
lOOObp
L an el- lkb ladder 
Lane2- X Hind III D NA  
Lane3- X ligation control 
Lane4- X ligation controls 
Lane5- X ligation controls
L anel- lkb ladder 
Lane2- mB3 (1) Pst l/Hind III 
Lane3- pU R 292 Pst VHind III 
Lane4- pUR292 Pst VHind III
L anel- lkb ladder 
Lane2- D igest 1 Pst VHind III 
Lane3- D igest 2 Pst VHind III 
Lane4- D igest 3 Pst VHind III 
Lane5- D igest 4 Pst VHind III
Figure 4.9. Cloning m B 3 (l) into the translational vector pUR 292. a) X Hind III restricted D N A  was used 
as controls in ligation reactions, b) mB3 (1) Pst VHind III insert was band purified and subcloned into 
pU R 292. c) pUR292 transformants were screened for inserts by Pst VHind III restriction digestion. Lanes 
2 and 5 excise the required 793 bp fragment from pUR292.
pURMM3 constructs were identified by Pst VHind III restriction enzyme digestion. 
(Figure 4.9 c, lanes 2 and 5). The pURMM3 construct was expressed in E.coli and 
inclusion body preparations (Ruther & Muller-Hill 1983) were tested for reactivity to 
FDO 26G (Figure 4.13). FDO 26G reacted positively to pURMM3 localising the epitope 
to residues 263-373 of 3B-HSD type I.
4.5 pURMM4 and 5 constructs. (3J3-HSD type I residues 241-285, and 289-373)
Site directed mutagenesis by overlap extension using the polymerase chain reaction was 
also utilised to construct tha translational fusion genes pURMM4 and pURMM5. A 
premature stop codon (TGA) and a BamH  I restriction enzyme site was introduced into 
the cDNA sequence of B3 (38-HSD type I) to yield the PCR product mB3(2) (Figure
4.10).
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a)
Oligo b
A
9 0 1  AGA TGG AGC TGA CCT GGA TCC CTG ATG
Residue 281 ,- stop* \-B am H  H
38-HSD type 1 5 ' -G A T TCC AGA TGG AGC TTT CCT TTA TCC CTG ATG TAT T G G - 3 '
seq u en ce  3 ' -C T A  AGG TCT ACC TCG AAA GGA AAT AGG GAC TAC ATA A C C -5 '
TCT CCA TCG ACT GGA CCT AGG GAC TAC
Oligo c
Not I 695
.EcoR I Kpn I Hind III BamH ] Pst I FspI Sac I EcoR I
720 bp
BamHI
953 bp
b)
PCR amplification using primers 695/oligo c and oligo b/696 yield products 695C and 696B.
695C (953bp) 
696B (720bp)
696 h i
-NMr
Products 695C and 696B are band purified from agarose gels, mixed together and reamplified using 
primers 695 and 696. XX represent introduced mutations within oligos b and c.
c)
N o tl  695
d)
BamH I Pst I BamHI
696 Hind III
1----------- 720 bp , 233 bp , ____________ l
Hind m
\Hind III
720 bp BamH VHind III required mB(2) fragment
-------------------------------------- 1 Hind m
860 bp Pst VHind III required mB(2) fragment
Introduction of a premature stop codon and a BamH I restriction enzyme site into the cDNA sequence of 
3B-HSD type I., mB3(2).
Figure 4.10. Site directed mutagenesis by overlap extension using the polymerase chain reaction, a) PCR 
primers b and c hybridise to 36-HSD type I cDNA, but are synthesised with base mutations encoding amnio 
acid residues 286 and 288, that introduce a premature stop codon and a BamH I restriction enzyme site, b) 
PCR products 695B and 696C overlap and contain the introduced mutation sites, c) These PCR products 
are band purified from agarose gels, mixed and reamplified using primers 695 and 696. d) The resultant 
full length PCR product, mB3(2) contains the introduced stop and Bam HI restriction site. Incorporation of 
the mutant nucleotides was confirmed by restriction digest. The sizes of BamH I restriction digests are 
indicated in (a) and (d).
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Figure 4.11 (a) and (b) illustrate the incorporation of mutations into the PCR product to 
form mB3(2). Restriction enzyme digestion confirms that mB3(2) is cloned into T-vector 
to make the construct Tvec mB3(2) (Figure 4.11 c).
a) b)
1 2  3 4 5
2000bp
L anel- X Hind III ligation control 
Lane2- X Hind III ligation control 
Lane3- pUCB3 PCR (696B ) 
Lane4- pUCB3 PCR (695C) 
Lane5- 1 kb ladder
L anel- lkb ladder 
Lane2- pUCB3 (695/696)
Lane3- m B3(2) (695/696)
Lane4- pUCB3 (695/696) BamH I 
Lane5- m B3(2) (695/696) BamH I
c)
2000bp-^»-
lOOObp-^-
500bp- -^
L an el- lkb ladder Lane7- Tvec m B3(2) B/H Lane 12- Tvec m B3(2) BamH I
L ane2-T vecm B 3(2) P/H L ane8-T vec m B3(2) B/H L anel3-T vec m B 3(2) BamH I
Lane3- T vecm B 3(2) P/H Lane9- Tvec m B3(2) B/H
Lane4- T vecm B 3(2) P/H LanelO- Tvec m B3(2) B/H L anel5- Tvec m B3(2) Hind III
Lane5- T vecm B 3(2) P/H Lane 16- Tvec m B3(2) Hind III
Figure 4.11. Cloning m B3(2) PCR fragment into T-vector. a) PCR amplification o f pUCB3 using primers 
695/696 , 695/o ligo  c and oligob/696. b) PCR amplification o f wild type and mutant B3. BamH I 
restriction digests confirms the incorporation o f mutant nucleotides, d) The T-vector clone containing 
m B 3(2) was restricted to isolate the Pstl/Hind III and BamH l/Hind III restriction fragments and cloned into 
pU R 292, pURM M 4 and pURM M 5 respectively.
The T-vector clone containg the mB3(2) fragment was restricted with Pst VHind III. The 
860 bp band (Figure 4.11 c, lanes 2-5) was purified and cloned into pUR292 to give the 
construct pURMM4. Tvec mB3(2) was also restricted with BamH VHind III (Figure 4.11 
c, lanes 7-10). The 720 bp BamH VHind III fragment was purified and cloned into
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pUR292 to make the construt pURMM5. Transformants were screened using single 
colony gels (Figure 4.12 a and b). Restriction enzyme digestion confirmed the insert size 
in pURMM4 and 5 (Figure 4.12 c).
a) b)
1 2 3 4 5 6 7 8 9  10* 11*12 13 14 15 16 17 12 3 4 5 6 7 8* 9*10 11 12 1314 15 16 17 18 19 20
Lane 1 - 1 kb ladder 
Lane2- Tvector only
Lanes- 3-17 Transformants from pURMM4 
cloning experiment.
L anel- lkb ladder 
Lane2- Tvector only
Lane3- 20 Transformants from pURM M 5 
cloning experiment.
c)
2 3 4 5
2000bp■
lOOObp-
500bp
pURMM4 
»  860 bp 
fragment
pURMM5 
720 bp 
fragment
L anel- lkb ladder Lane4- 8* BamH l/Hind III (figure (b) above)
Lane2- 10* Pstl/Hind III (figure (a) above) Lane5- 9* BamH l/Hind III (figure (b) above)
Lane3- 11 * Pstl/Hind III (figure (a) above)
Figure 4.12. Isolation o f pURM M 4 and pURMM5 constructs, a) Single colony gel o f  pUR292 plasmid 
and transformants from the pURM M 4 cloning experiment. Lanes 10 and 11 contain plasmids that have 
different m obilities from the control Tvector plasmid in lane 2. b) Single colony gel o f  pU R292 plasmid 
and transformants from the pURMM5 cloning experiment. Lanes 8 and 9 contain plasmids that have 
different m obilities from the control plasmid in lane 2. c) Restriction digestion o f  plasmids identified in (a) 
and (b). The plasmid in lane 2 is identified as pURM M 4 and the plasmid in lane 4 is identified as 
pURM M 5.
pURMM4 (Figure 4.12 c, lane 2) and pURMM5 (Figure 4.12 c lane 4) plasmid constructs 
were expressed in E.coli and protein was recovered as inclusion bodies according to the
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methods of Ruther & Muller-Hill (1983). pURMM4 and 5 inclusion body preparations 
were tested for reactivity to FDO 26G (Figure 4.13).
4.6 Western immunoblot analysis o f inclusion body preparations from  constructs 
pU R M M l-5.
1 2 3 4 5 6
B-galactosidase 
(116,000 Da)-1
Lanel - Protein marker Lane4- pURMM 3 inclusion body preparation
Lane2- pURMM 1 inclusion body preparation Lane5- pURMM 4 inclusion body preparation
Lane3- pURM M  2 inclusion body preparation Lane6- pURMM 5 inclusion body preparation
Figure 4.13. Western immunoblot analysis o f pURMM 1-5 inclusion body preparations, tested for 
reactivity to FDO 26G monoclonal antibody.
pURMM2, 3 and 5 inclusion body preparations reacted positively with FDO 26G 
monoclonal antibody, localising the monoclonal antibody FDO 26G epitope to residues 
289 and 373 of B3 (3B-HSD type I) protein.
4.7 Peptide mapping experiments.
To further localise the FDO 26G epitope, a series of overlapping synthetic peptides were 
synthesised that spanned the C-terminal region (Table 4.1). Each peptide included an 
amino-terminal cysteine for possible conjugation to carrier proteins, and a amino-terminal 
amide group to minimise charge differences when compared to native protein.
Table 4.1
Peptide Residues Amino acid sequence of oligopeptides (single letter code)
C5 341-352 n h 2- c - k -p -l -y -s -w -e -e -a - k -q -k
C6 346-357 N H 2- C-W -E-E-A-K-Q-K -T-V-F-W -V
B6 354-366 N H 2- C -V -E -W -V -G -S-L -V -D -R -H -K -E
C8 356-364 N H 2- C -W -V -G -S-L -V -D -R -H
62
Western immunoblot analysis showed reactivity of FDO 26G antibody with pURMM2 
fusion protein at antibody dilution 1:100 and 1:500. Blots containing the same 
concentration of fusion protein were probed with 1:200 FDO 26G antibody after 
preabsorption with the test peptides at concentrations of 10 mM. Peptide B6, residues 
354-366, absorbed the FDO 26G antibody and resulted in loss of antibody reactivity 
(Figure 4.14 a).
Peptides were coupled to keyhole limpet haemocyanin (KLH) and tested for reactivity on 
dot blots. The 354-366 peptide showed significant reactivity, although the shorter 
internal peptide, 356-364, had very slight reactivity (Figure 4.14 b).
p(JRMM2 on western blots
1/100  26G 1/500 26G
adsorption ^  1 /200  26G --------------------- ►
with peptide: 341-352 346-357 354-366 356-364
KLH-341-352 
KLH-354-366 
KLH-356-364
Figure 4 .14. R eactivity o f  FDO 26G  with fusion proteins and peptides o f  3B-HSD type I. (a) W estern 
m em branes each bearing tw o lanes o f  313-HSD fusion inclusion body protein from pU RM M 2. The low er  
four panels show  the pattern o f  staining when antibody at 1:200 was preabsorbed with each o f  the peptides 
(10m M ).(b) R eactivity o f  FDO 26G  with three peptides conjugated to keyhole lim pet haem ocyanin (KLH), 
at 10, 100 and lOOOng.
A summary of lacZ  gene fusion and oligopeptide mapping data, localising the FDO 26G 
epitope to residues 354-366 of the B3 (36-HSD type I) protein is presented in Table 4.2.
KLH - peptides on dot blots
1000 ng 100 ng 10 ng
s> *
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4.8. Summary o f lacZ gene fusion and oligopeptide mapping data, localising the FDO
26G epitope to residues 354-366 o f the B3 (3J3-HSD type I) protein.
Table 4.2. Summary of reactivities of FDO 26G with full length 38-HSD type I, lac Z  fusion genes 
(constructs pURM M l-5), and with synthetic oligopeptides corresponding to the C-terminal region o f B3 
protein. pU RM M l-5 are subclones of B3 cDNA cloned into pUR series of bacterial expression vectors. 
For each polypeptide/ peptide the residue numbers correspond to the amino acid sequence of 38-HSD type
I. The reactivity of each with FDO 26 G is shown as + or -.
Construct/peptide 1 
residues
100 200
38-HSD type I
pURM M l (1-241) -  
pURMM2 (210-373) 
pURMM3 (263-373) 
pURMM4 (241-285) 
pURMM5 (289-373)
peptide 341-352 
peptide 346-357 
peptide 354-366 
peptide356-364
300 
_L_
FDO 26G 
epitope
+ve
-ve
+ve
+ve
-ve
+ve
-ve
-ve
+ve
+/-ve
Residues 359-362 (S-L-V-D) of the FDO 26G immunoreactive peptide, B6, contain the 
casein kinase n  phosphorylation consensus sequence, (S,T)-X-X-(D,E) with serine 359 
the target for phosphorylation. Peptide 354-366 was resynthesised with a phosphoserine 
at residue 359. The phosphopeptide conjugated to BSA reacted strongly with FDO 26G 
over a range of dilutions, in an similar way to unphosphorylated peptide. To determine 
the relative affinities of phosphopeptide and unphosphorylated peptide for FDO 26G, 
their abilities to preabsorb FDO 26G antibody and extinguish reactivity of 26G was 
compared to aliquots of non-phosphorylated peptide conjugated to BSA (Figure 4.15).
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4.9 Effect o f phosphorylation on the binding o f FDO 26G to peptide 354-366.
COMPETITOR PEPTIDE nM
phosphopeptide peptide
0
— — 1
— — 1 0 0
_ 2 5 0
5 0 0
7 5 0
1 5 0 0
1 0 0 0 0
Figure 4 .15 . Peptide 354-366  (unphosphorylated, conjugated to B SA ) w as im m unoblotted onto Hybond  
mem brane. The resulting sixteen p ieces o f  membrane were stained with aliquots o f  FD O  26G  w hich had 
been preabsorbed w ith 0-10,000nM  o f  either phosphopeptide (left hand colum n) or unphosphorylated (right 
hand colum n).
A reduction o f antibody binding was evident at concentrations of approximately 250nM 
free peptide and end points were estimated as 10pM for the unphosphorylated peptide 
and 1.5 pM  for the phosphopeptide (three determinations).
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Chapter 5
Characterisation of clone 24-4, a new member of the human 313-HSD gene family 
and its identification as a presumptive unprocessed pseudogene (3B-HSD\j/l).
5.1 Introduction
Inherited defects of 3B-HSD can result in congenital adrenal hyperplasia (CAH) 
(Bongiovanni 1962; New and Levine 1984; see section 1.8) and nonsense and frameshift 
mutations in HSD3B2, the gene encoding 3G-HSD type II, have been described in 
classical cases of severe CAH affected with salt losing crises, deficiencies in 
glucocorticoid metabolism and incomplete masculinization (Rheaume et al 1992). A 
range of less severe phenotypes have also been ascribed to 3B-HSD, including 
hypospadias, male pseudohemahproditism, late onset virilisation and clitoral enlargement 
in women (Pang et al 1985; Mendonca et al 1987; Fisher et al 1987; Frank-Raue et al 
1989; New eta l 1989).
Four hirsute females from a family exhibiting idiopathic dominant hirsutism were 
examined. Basal blood levels of A5 and A4 steroids were within normal limits, but ACTH 
stimulation led to increases in 17-hydroxypregnenolone and DHEA. Kindred Phe is 
shown in figure 5.1.
3B-HSD types I and II genes from affected family members were screened for mutations 
using PCR amplification and DGGE analysis (Russell 1993). A single base pair 
substitution, C->A, of base 1426 in the untranslated exon 1 of 3B-HSD type I was 
identified. No other mutations were detected when the remaining exons were screened, 
furthermore the haplotype of 3B-HSD types I and II did not segregate with hirsutism in 
this family (Figure 5.1). However, during mutational analysis by Alan Russell, novel 
exon 3 and exon 4 fragments were isolated. In particular exon 3 PCR amplification using 
the intron primer pair (A,B) (Figure 5.2) produced an additional band, (<|>), in the three 
members of the Phe family availible (Russell 1993).
The $ fragment was cloned and sequenced and found to contain an open reading frame, 
with similar, but not identical sequence to the third exons of the type I and type II genes 
(Russell 1993). Due to the number of base pair changes it is unlikely that <|> sequence 
originated by Taq polymerase errors and is therefore most likely to have come from a 
distinct gene with similar exon sequence to 3B-HSD types I and n. Furthermore, PCR 
primers (P,Q) designed to specifically amplify a 124 bp internal fragment of <|> was 
present in the genome of unaffected individuals. The appearence of <|) only in the Phe 
family with PCR primer pair (A,B) may be explained by point mutations within one of
6 6
the intron hybridisation primer sites. It is therefore possible that either mutations or 
specific rearrangements involving this novel gene may be responsible for the clinical 
symptoms in the Phe family.
To test this hypothesis it was necessary to isolate and sequence the <j) gene from one of the 
patients, and the corresponding gene sequence from an unrelated control individual. PCR 
primers (P, Q) would allow simple identification of clones containing the <j> fragment.
Family Phe: dominant idiopathic hirsutism
II
m  , Q
IV
1 1
D
+  
c 
3 4
*
w 2 <5
+
+
A  A  
1 1
Haplotype key
3B-HSD type I +
3B-HSD type II 1
-  exon 1 mutation C > A 
+ Bgl II 
A  codon 367 
1  intron C microsattelite
6
Figure 5.1. Family Phe. The haplotypes of type I and type II do not segregate with hirsutism in the Phe 
family.
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Figure 5.2. PCR amplification and DGGE analysis of HSD3B1 and HSD3B2. Intron/ exon organization of 
HSD3B1 and HSD3B2 and positions of hybridisation sites for PCR and sequencing primers. Primers P, Q 
hybridise specifically to clone <J>. S, T were designed to amplify 36-HSD type II sequences, while the 
remaining primers hybridise to 36-HSD type I (see also figure 6.1 a and b).
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Results.
5.2 Isolation o f the clone 24-4 from  a Phe genomic fam ily library and its identification 
as the (p gene.
In order to isolate the (j) gene, a genomic library was constructed from family member IV- 
2 (Figure 5.1) and hybridised with radioactively labelled B3 (3B-HSD type I cDNA). 14 
bacteriophage lambda positive clones were isolated from the Phe library. After a second 
round of purification, positive plaques were picked as BBL-agarose plugs, and screened 
by PCR using <p specific primers (P,Q). Clone 24-3 and 24-4 were isolated from the Phe 
genomic library and supported PCR with (P,Q) (124bp) primers and other PCR primer 
pairs designed to amplify 3B-HSD type I and II genes (Figure 5.3 a and b).
a)
1 2  3 4 5 6 7 8 9 10 11 12 13 14 15 16
1000bp-^».
154bp-B^ -
L an el- lkb  ladder 
Lane2- Genom ic D N A  (L, J) 
Lane3- Genom ic D N A  (T, S) 
Lane4- Genom ic D N A  (A, B) 
Lane5- Genom ic D NA  (P, Q) 
Lane6- Genom ic D N A  (G, R)
Lane7- Clone 24-3 (L, J) 
Lane8- Clone 24-3 (T, S) 
Lane9- Clone 24-3 (A ,B) 
Lane 10- Clone 24-3 (P, Q) 
Lanel 1 -Clone 24-3 (G, R)
Lane 12- Clone 24-4 (L, J) 
Lane 13- Clone 24-4 (T, S) 
Lane 14- Clone 24-4 (A, B) 
Lane 15- Clone 24-4 (P, Q) 
Lane 16- Clone 24-4 (G, R)
b)
1 2 3 4 5
lOOObp- 
500bp -
L anel- lkb ladder 
Lane2- Clone 24-3 (M, K) 
Lane 3- Clone 24-4 (M, K)
Lane4- Clone 24-3(L, K) 
Lane5- Clone 24-4 (L, K)
Figure 5.3. Hom ologous exon 1/ 2 , exon 3 and exon 4 PCR amplification o f clones 24-3 and 24-4 isolated  
from the Phe genom ic library, a) Clones 24-3 and 24-4 support PCR amplification suggesting that they 
contain the 4> fragment (Lanes 10 and 15). Clone 24-4 is also shown to contain the 3' end o f  exon 4 (Lane 
16). b) Both clones contain hom ologous exon 1 and 2 sequences (lanes 2-5).
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Based upon PCR analysis clone 24-4 contains sequences similar to 3B-HSD exons 1-4, 
whereas 24-3 does not contain the 3'end of exon 4 (Figure 5.3). Exon 1/2 (PCR primers 
(M,K)-expected size 437 bp), exon 3 (PCR primers (A,B)-expected size 226 bp) and exon 
4 (PCR primers (G,R)- expected size 522bp) PCR products were cloned into T-vector. 
Transformants were screened using PCR amplification (Figure 5.4 a-c).
b)
a)
lOOObp-
154bp-
L an el- lkb  ladder
Lane2- C lone24-4 (M, K) (+ve)
Lane3- C lone24-4 (L, K) (+ve)
12 3 4 5 6 7 8 9 10 11 12
12 3 4 5 6 7 8 9 10 11 12 13
Lane4- 8 exon 1/2 T-vector transformants (M, K) 
Lane9- 13 exon 2 T-vector transformants (L, K)
c)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
lOOObp-
I54bp-
L anel, 13- lkb ladder
Lane2- 11 exon 3 T-vector transformants (A, B)
L anel, 17- lkb ladder
Lane2- 16 exon 4 T-vector transformants (G, R)
Figure 5.4. Clone 24-4 exon hom ologue PCR products were cloned into T-vector. a) Exon 1/2 
transformants were screened using PCR, primers M, K and L, K. b) Exon 3 transformants were screened  
using PCR primers A, B. c) Exon 4 transformants were screened using PCR, primers G, R.
T-vector clones were identified that contained 24-4 exon homologues; exon 1/2 (Figure 
5.4 (a), lanes 4-8), exon 3 (Figure 5.4 (b), lanes 4, 7-9, 11) and exon 4 (Figure 5.4 (c), 
lanes 4, 5, 7 and 11).
Sequence was determined from T-vector clones containing the 24-4 exon 3 homologue. 
The sequence, presented in figure 5.13, matched the previously identified (j) fragment 
(Russell 1993), and clone 24-4 was assigned as its corresponding genomic clone.
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5. 3 Isolation of clone 1-1 from a control genomic library.
A control genomic library was also screened with the 3B-HSD type I cDNA. 43 positive 
clones reproducibly hybridised through to the secondary stages of purification. Clone 1-1 
was identified from this control genomic library and supported amplification with primers 
(P, Q). Clone 1-1 was also shown to contain exon homologues of a similar size as 
HSD3B1, HSD3B2 and clone 24-4 (Figure 5.5).
lOOObp ^  
15-% m
-ve controls ■ Clone 24-4  | C lone 1 -1
4 5 6 7 8 9 10 11 12 13 14 15 16
Lane 1 - 1 kb ladder Lane 11 - Clone 1 -1 (M, K)
Lane2- Lane7- Clone 24-4 (M, K) Lane 12- Clone 1-1 (A , B)
Lane3- N egative control (M, K) Lane8- Clone 24-4 (A, B) Lane 13- Clone 1-1 (P, Q)
Lane4- N egative control (A , B) Lane9- Clone 24-4 (P, Q) Lane 14- Clone 1-1 (G, R)
L an e5-N egative control (P, Q) Lane 1 0 -Clone 24-4 (G, R) Lane 15-
Lane6- N egative control (G, R) Lane 16- lkb  ladder
Figure 5.5. PCR amplification o f hom ologous exons 1/2, exon 3 and exon 4 from clones 24-4 and 1-1. 
C lone 24-4  was identified from the Phe genomic library, while clone 1-1 was identified from a control 
human genom ic library.
Homologous exon 1/2, exon 3 and exon 4 PCR products from clone 1-1 were cloned into 
T-vector. Transformants were selected by PCR (Figure 5.6).
1 2  3 4 5 6 7 8 9  1 0 1 1 1 2 1 3 1 4  15 1 6 1 7 1 8 1 9  2 0 2 1 2 2 2 3 2 4 2 5 2 6  27 2 8 2 9 3 0
500bp
31 3 2 3 3  3 4 3 5  3 6 3 7  38 394041  4 2 4 3 4 4  4 5 4 6 4 7 4 8 4 9  5 0 5 1 5 2 5 3 5 4 5 5  56 57 5 8 5 9 6 0
500bp
L an el- 20 exon 1/2 T-vector transformants (M, K) Lane30- lkb ladder
Lane21- 48 exon 3 T-vector transformants (A, B) Lane60- lkb ladder
Lane49- 59 exon 4 T-vector transformants (G, R)
Figure 5.6. Hom ologous clone 1-1 exon 1/2, exon 3 and exon 4 PCR fragments were cloned into T-vector. 
Transformants were screened by PCR; exon 1/2 transformants were screened using PCR, primers (M ,K), 
exon 3 transformants were screened using PCR, primers (A ,B ), and exon 4 transformants were screened 
using PCR, primers (G,R).
M
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T-vector clones were identified that contained 1-1 homologous exons; exon 1/2 (Figure 
5.6, lanes 1, 3-5, 8-11,13, 15-20), exon 3 (Figure 5.6, lanes 21-23, 25-27, 29, 33, 35, 37,
39-41) and exon 4 (Figure 5.6, lanes 43, 49-51, 54 and 57).
PCR amplification using primer pairs (I,B) and (P,R) (Figure 5.7) yielded products of 
approximately 4.5kb and 3.5kb respectively. These values were similar with the 
predicted corresponding amplification products from HSD3B1 and HSD3B2, 4.3kb and 
3.9kb (Figure 5.7).
1 2 3 4 5
3000bp m  
lOOObp ^
L anel- lkb ladder Lane4- Clone 24-4 (A, R)
Lane 2- Clone 24-4 (I, B) Lane5- Clone 1-1 (A, R)
Lane 3- Clone 1-1 (I, B)
Figure 5.7. PCR amplifications from clones 24-4 and 1-1 showing they contain introns similar in size to 
HSD3B1 and H SD 3B2. Clones 24-4 and 1-1 (I, B) and (A, R) PCR product estimated size approximately 
4.5kb and 3.5kb respectively. HSD3B 1 and H SD 3B2 correspondibg PCR products w ould be predicted as 
4.3kb and 3.9kb respectively.
Sequence obtained from 24-4 T-vector clones corresponded exactly with sequence 
obtained from the 1-1 T-vector clones and had significant similarity with HSD3B1 and 
HSD3B2 (Figure 5.13). PCR amplification and sequencing was useful for quickly 
identifying the (J) fragment contained within the genomic bacteriophage clones 24-4 and 
1-1 and that these clones contained similar sequences to exons 1-4 of 36-HSD types 1 and
II. However, to complete the sequencing of putative exon material and adjacent potential 
intron/ exon boundaries, it was necessary to subclone the appropriate fragments from 
both clones for sequence analysis.
A further objective was to sequence over the (A,B) primer hybridisation sites, to address 
why the (}) fragment was only amplified from the Phe family. It was assumed that 
subcloning putative exon fragments would allow sequence determination of adjacent 
intron DNA.
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5.4 Southern analysis o f of bacteriophage clones 24-4 and 1-1.
To identify restriction digestion enzymes useful for subcloning, Southern blots of cloies 
24-4 and 1-1 lambda DNA were prepared and hybridised with HSD3B1 exon specific 
probes (Figures 5.8 and 5.9).
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a ) Clone 24-4 Clone 1-1I I I
1 2 3 4 5  6 7  8 9  10 II
5000bp-^-
looobp m
b)
L anel- lkb ladder 
Lane2- 24-4 BamHI 
Lane3- 24-4  EcoRI 
Lane4- 24-4 H indlll
Clone 24-4
Lane5- 24-4 SstI 
Lane6- 24-4 Xbal 
Lane7- 1-1 BamHI 
Lane8- 1-1 EcoRI
Clone 1-1
I 2 3 4  5 6 7  8 9 10 II
c)
Lane9- 1-1 H indlll 
Lane 10- 1-1 SstI 
Lanel 1- 1-1 Xbal
Clone 24-4 Clone 1-1
I I I
1 2 3 4 5 6 7  8 9 10 11
5000bi
1000b
«(•
Figure 5.8. (a)Southern blot analysis o f genom ic clones 24-4 and 1-1, isolated from the IV-2 patient and 
control libraries, and probed with 36-H SD  type I (b) exon 2 and (c) exon 3.
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Clone 24-4 I I
1 2 3 4 5 6 7
Clone 1-1 
8 9 10 n
5000bi
lOOObp
L anel- lkb ladder 
Lane2- 24-4 BamHI 
Lane3- 24-4 EcoRI 
Lane4- 24-4 H indlll
Lane5- 24-4 SstI 
Lane6- 24-4 Xbal 
Lane7- 1-1 BamHI 
Lane8- 1-1 EcoRI
Lane9- 1-1 H indlll 
Lane 10- 1-1 SstI 
Lanel 1-1-1 Xbal
Clone 24-4 Clone
9 10 11
5000bi
1000b
Figure 5.9- Southern blot analysis o f genomic clones 24-4 and 1-1, isolated from the IV -2 patient and 
control libraries, and probed with H S D 3B 1 exon 4.
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5.5 Subcloning clone 24-4 putative exons into pUC18.
The 7kb EcoR I fragment of clone 24-4 containing exon 1/2 and exon 3 and the Sst I 
fragment containing exon 4 were subcloned into pUC18 (Figure 5.10 a and b). 
a) b)
1 2 3 4 5 6 7 8 9  10 11
6 7 8 9 10 11
298bi
517 bp
L anel- lkb ladder
Lane2- C lone 24-4 PCR (A, B)
Lane3- N egative control (A , B)
Lanes4- 4-11 exon 3 transformants (A, B)
Lane 1- lkb ladder
Lane2- Clone 24-4 PCR (G, R)
Lane3- N egative control (G, R) 
L anes4-11 exon 4 transformants (G, R)
Figure 5.10. PCR screening o f putaitve exon 3 and exon 4 subclones from clone 24-4. a) Transformants 
containing exons 1-3 were screened with PCR primers (A,B) (262 bp), b) Exon 4 transformants were 
screened using PCR primers (G,R) (520bp).
Subclones that contained 24-4 homologous exons 1-3 (Figure 5.10 a, lanes 4-8 and 10- 
11) and 24-4 exon 4 (Figure 5.10 b, lanes 10 and 11) were isolated and sequenced 
(Figures 5.12 and 5.13).
5.6 Subcloning clone 1-1 putative exons into pUC18.
Clone 1-1 putative exon 1/2, exon 3 and exon 4 separate into distinct Sst I fragments 
(Figures 5.8 and 5.9). These fragments were subcloned into pUC18 (Figure 5.11).
Exon 4 
Exon 3
Exon 1/2
5000bp
Lanel - C lone 1-1 bacteriophage D N A  restricted with Sst I Lane 11- lkb ladder
Lane2- 8 C lone 1-1 transformants restricted with Sst I.
Figure 5.11.  Transformants containing putative exons 1/2, 3 and 4 were selected by restriction enzym e 
digestion with Sst I and size comparison with 1-1 Sst I restricted DNA. Sst I fragments containing 1-1 
exons had already been identified from Southern analysis, (Figure 5.8).
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1-1 subclones that contained similar sequences to HSD3B1 and HSD3B2 were isolated 
and sequenced (Figure 5.12); exon 1 and exon 2 (Figure 5.11 lane 6), exon 3 (Figure 5.11 
lane 7) and exon 4 (Figure 5.11 lane 8). The lineup between 24-4, 1-1, HSD3B1 and 
HSD3B2 is presented in figure 5.13.
5.7 Sequencing 24-4 and 1-1 subclones.
(4)
V
..........X ' ............. ..........\ __ V✓1/
(1)
v N.
' ..........X \ ..........X __ X
....... \ \ '
Figure 5.12. Sequencing extent for clones 24-4 and 1-1. The dotted lines show the sequence obtained from 
PCR amplified fragments of clones 24-4 and 1-1 after being subcloned into T-vector. The solid lines show 
the sequence obtained from subclones of the original bacteriophage clones, without the use of PCR. (b) 
Location of PCR primers in relation to the structure of the 24-4 gene and the restriction enzyme digestion 
sites Sst I and EcoR I used in the subcloning of clone 24-4 and 1-1.
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Figure 5.13. Sequence obtained from clones 24-4 and 1-1, aligned with homologous sequences from 36- 
HSD type I and II (exons 1-4). The position of PCR primer hybridisation sites are shown (I,K), (A,B), 
(P,Q) and (G,R). The triplet bases underlined in types I, II and 24-4 are the potential translational start and 
stop codons. In clone 24-4, exon 3, the underlined sequence is that obtained from sequencing the original <|) 
PCR band. Dashes indicate gaps introduced to optimse the alignmnent. Bases corresponding to intron 
sequence in 36-HSD types I and II are shown in lower case.
82
5.8 Clone 24-4 and clone 1-1 identification as 3fi-HSD\i/l.
The codon sequence of the 24-4 and 1-1 genes contained frameshift mutations and 
premature stop codons mutations within the clone 24-4 and 1-1 putative exon 4 causing 
premature termination of the predicted polypeptide at amino acid position 173. No other 
significant open reading frames were found within the sequenced fragments. The first 
framshift mutation, deletion of a G residue, was confirmed by sequencing over this region 
on both strands in clones 24-4 and 1-1 (Figure 5.14).
a) b)
A C G T
A C G T
24-4 sense
c) d)
A C  G T
1-1 sense
A C G T
24-4 reverse 1-1 reverse
Figure 5.14. DNA sequence from clones 24-4 and 1-1 highlighting the first frameshift mutation, a) Clone 
24-4 sense strand sequence. This sequence does not contain a H in d  III restriction enzyme recognition site 
because a guanine nucleotide is missing, b) Clone 24-4 reverse strand sequence. c)& d) Clone 1-1 
sequence confirms the loss of the Hindlll restriction site.
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Chapter 6
Characterisation of further novel members of the human 3B-HSD gene family.
6.1 Introduction
Multigene families for 36-HSD have been described in rodents. To date, five mouse 
cDNAs (Bain et al 1991; Clarke et al 1993a; Clarke et al 1993b; Abbaszade et al 1995) 
and four rat cDNAs have been isolated. These isoforms are products of distinct genes, 
are expressed in a sex- and tissue- specific manner (see section 1.9), and include two 
functionally distinct groups of proteins. 36-HSD type I-in in mouse and I, HI and IV in 
rat have dehydrogenase/ isomerase activities and utilise NAD+ as cofactor (Bain et al 
1991;Zhao HF et al 1991; Keeney et al 1993; Simard et al 1993a). 36-HSD types IV and 
V in mouse (Clarke et al 1993b; Abbaszade et al 1995) and type III in rat (DeLaunoit et 
al 1992) have an exclusive keto-steroid reductase (KSR) activity, which is NADP- 
dependent and is most likely associated with the inactivation of reduced hormone 
derivitives such as 5a-dihydrotestosterone. Furthermore the genes encoding the five 
different isoforms in mouse are closely linked on mouse chromosome 3 syntenic with the 
human chromosomal region lpl3.
Two forms of 36-HSD have been described in humans (Luu-The et al 1989; Rheaume et 
al 1991), encoded by genes that are closely linked on chromosome lpl3.1 (Russell et al 
1994; Morissette et al 1995; see section 1.9). However, when Southern blots of human 
genomic DNA are probed with 36-HSD type I exon 4 DNA, several bands of 
hybridisation are detected from 0.7kb to 30kb (Russell 1993). Intense bands were 
observed which corresponded to the sizes predicted by the restriction maps of HSD3B1 
and HSD3B2, but other bands of varying size and intensity were also present. It was 
therefore not surprising that primers designed to amplify fragments of 36-HSD type I and 
II genes were found, on occasion, to amplify DNA products of the appropriate length but 
which resolved as distinct sequence by DGGE analysis (Russell 1993). When exon 3 was 
amplified using PCR intron primer pair (A,B), two bands were usually detected by 
DGGE (a and p); in one case a third band (<(>; see section 5.1) was detected. When exon 
4 was amplified with primer pair (G,H) three additional bands (T, X and p) were observed 
on DGGE gels.
Given the multigene family in rodents, Southern data on human genomic DNA and the 
identification of novel gene segments, it seems likely that the human 36-HSD gene 
family mapping to human chromosomal region lpl3 had yet to be fully defined. Some of 
these gene family members may be unprocessed pseudogenes (Results Chapter 5),
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however there is good evidence for 36-HSD activity in peripheral tissues (Labrie 1991) 
and for keto-steroid reductase activity in human prostate (Abalain et al 1989).
57 positive lambda clones had previously been isolated from two human genomic 
libraries that hybridised with 38-HSD type I cDNA under non-stringent conditions 
(Results Chapter 5). These clones were screened for novel members of the gene family 
by PCR amplification followed by DGGE analysis. Various combinations of PCR 
primers, particularly those that previously amplified novel PCR products from genomic 
DNA (A,B) and (G,H) (Russell 1993) were utilised (Figure 6.1). It was hoped that 
genomic clones could be identified that included these fragments as well as other 38-HSD 
genes. Also exon 4B PCR amplification would allow rapid analysis of the putative amino 
acid sequence over the FDO 26G epitope (results chapter 4).
a)
Exon 4B (480bp)I------------------ 1
Bgl n + /N367T
I II III IV
b)
I II III IV
Figure 6.1. Schematic diagram showing the intron/ exon structural organization of (a) HSD3B1 and (b) 
HSD3B2 (exons I-IV) and positions of hybridisation sites for PCR/ sequencing primers (Not to scale). The 
position of the the genetic polymorphisms of HSD3B1 in exon 4 and the size of the PCR exon 4B product 
are indicated, but do not include the GC clamp at one end of the PCR product, required for DGGE analysis. 
This accounts for an extra 36 base pairs in the exon 4B PCR product.
Initially, the relevant PCR amplification products were cloned into T-vector to allow 
sequencing. If the clone was confirmed to have novel 38-HSD sequence, the putative 
exons were subcloned into pUC18 to allow more extensive sequence analysis.
85
Results
6.2 Analysis o f genomic clones by exon 4B (G, H) PCR amplification and DGGE 
analysis.
36-HSD type I gene has two polymorphisms 88bp apart in the coding sequence of exon 4; 
Bgl II RFLP and the missense (non-synonomous) substitution Asn367Thr. My first piece 
of analysis is dependent on the exon 4B region (G,H PCR amplification product), 
therefore the different haplotypes of HSD3B1 must be distinguishable from potential new 
sequence. Figure 6.2 shows the mobilities of the three most common type I haplotypes; 
Asn,+, Thr,+ and Asn,- in DGGE gels. Also indicated in figure 6.2 are the mobilities of 
three similar putative exon 4 fragments (T, X and p) identified during mutation screening 
by Alan Russell (Russell 1993).
1 2 3 4 5 6
L an el-T yp e I (A sn ,+) L ane3-T ype I (A sn ,-) L ane5-E  fragment
Lane2- Type I (Thr, +) Lane4- T fragment Lane6- p fragment
Figure 6.2. DGGE analysis o f G, H PCR amplification products from 36-H SD  type I haplotypes and three 
hom ologous exon 4 sequence fragments (p, E and T) identified from different fam ilies (Russell 1993).
Bacteriophage clones were picked as BBL-agarose plugs into lOOfil H2O, freeze thawed 
twice to release bacteriophage DNA suitable for PCR amplification. Primers (G,H) were 
used for test amplifications from the 57 positive genomic plaques. Primer H was initially 
designed to hybridise to HSD3B1 as opposed to type II. 35 lambda plaques yielded PCR 
products of the expected 480bp (Figure 6.1). DGGE was used to distinguish type I 
haplotypes from novel sequences (Figure 6.3 (a)-(f) and Fgure 6.4).
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Figure 6.3. Exon 4B DGGE gels o f  clones isolated from the Phe and control libraries, (a)-(f). PCR 
amplification o f  exon 4 using primer pair (G,H). Primer G contains a GC clamp at the 5' end o f the primer 
to improve sesitivity o f  detection o f base pair substitutions within the amplified region. In one gel (d), 
primer H contains the GC clamp. DGGE classification is indicated in brackets (). (see table 6.1).
L an el- Clone 19-1 (a )  
Lane2- C lone 19-2 (typel) 
Lane3- C lone 19-3 (a )  
Lane4- Clone 19-4 (a )
Lane5- Asn + (control) 
Lane6- Thr + (control) 
Lane7- Asn - (control)
Lane8- Clone 24-2 (typel) 
Lane9- Clone 23-1 (a )  
Lane 10- Clone 24-1 (a )
Lanel - C lone 25-1 (x) 
Lane2- Clone 19-1 (a )  
Lane3- C lone 4-5 (a )  
Lane4- C lone 2-2 (Asn +) 
Lane5- C lone 6-2 (%)
Lane6- Asn + (control) 
Lane7- gap 
Lane8- gap
Lane9- Thr + (control) 
Lane 10- Asn - (control)
Lanel 1- Clone 4-6 (Asn -) 
Lane 12- Clone 4-7 (Asn -) 
Lane 13- Clone 7-1 (Asn -)
c)
1 2  3 4 5 6 7 8 9 10 11 12 13 14
A sn - 
Asn +
~~^^m—  a  
— " —  X
L anel - Clone 1-3 (Asn -) 
Lane2- Clone 1-4 (a )  
Lane3- Clone 24-2 (a )  
Lane4- Clone 2-3 (Asn +) 
Lane5- Clone 2-4 (Asn -)
Lane6- 2-6 (%)
Lane7- Asn +(control) 
Lane8- 3-1 (Asn +) 
Lane9- 3-2 (x)
Lane 10- 3-3 (%)
Lane 11 - C lone 4-1 (x) 
Lane 12- C lone 4-2 (A sn +) 
Lane 13- gap 
Lane 14- Clone 4-5 (a )
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d)
Lanel - C lone 6-3 (Asn +) 
Lane2- Clone 6-5 (y) 
Lane3- C lone 6-6 (a) 
Lane4- C lone 6-9 (?) 
Lane5- C lone 6-10 (a)
Lane6- 7-1 (Asn, -) 
Lane7- Asn - (control) 
Lane8- Asn + (control) 
Lane9- 19-1 (a )
Lane 10- 19-3 (a )
Lane 1 1 -Clone 19-4 (a) 
Lane 12- Clone 23-1 (a) 
Lane 13- Clone 24-1 (a)
e)
1 2 3 4  5 6 7 8 9
Asn i —ii
y—
H i
L anel - Clone 6-1 (Asn +) Lane4- Clone 5-3 (y) Lane7- Clone 4-7 (Asn -)
Lane2- Clone 5-5 (y) Lane5- Asn - (control) Lane8- Clone 4-6 (Asn -)
Lane3- C lone 5-4 (Asn -) Lane6- Asn + (control) Lane9- Clone 1-5 (y)
L anel - Clone 6-5 (y) 
Lane2- gap
Lane3- Clone 19-1 (a) 
Lane4- Asn + (control)
Lane5- 6-10 (a )  
Lane6- Asn - (control) 
Lane7- 6-6 (a )
Lane8- 3-3 (a )
Lane9- gap 
Lane 10- Clone 2-6 (a) 
Lanel 1- Clone 6-2 (a) 
Lane 12- Clone 25-1 (a)
Although the haplotype controls have not separated well in some cases, there is clear 
indications that distinct sequences exist in clones identified from the genomic libraries 
(Figure 6.4).
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6.3 Summary DGGE gel of exon 4B analysis.
L an el- T fragment Lane5- Asn + (control) Lane9- C lone 2-1 (T) fragment
Lane2- L fragment Lane6-Thr + (control) Lane 10- C lone 3-3 (a  and
Lane3- p fragment Lane7- 19-4 (a )  Lanel 1- C lone 6-5 (y)
Lane4- Asn - (control) Lane8- 1-2 (p) fragment
Figure 6.4. Summary o f  exon 4B DGGE analysis. Lanes 1-3 contain the exon 4B fragments identified  
during mutation screening. Lanes 4-6 are type I haplotype controls. The remaining lanes, 7-11, contain 
exon 4B PCR amplification products from clones isolated from the Phe and control genom ic libraries.
GH amplification products were resolved by DGGE into at least 4 novel groups; 19-4 (a), 
6-5 (y), 1-2 (p), and 2-1 (T) (Figure 6.3 (a-f) and Figure 6.4). When the genomic clones
1-2 and 2-1 were amplified with PCR primers GH, the PCR product had a similar 
mobility on DGGE gels as the p and T fragments (Figure 6.4). To confirm these clones 
contained novel 3B-HSD sequences, further analysis is presented in sections 6.4.1-6.4.4.
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6.4 Characterisation of novel clones identified by exon 4B DGGE, from two human 
genomic libraries.
6.4.1 Clone 19-4. DGGE classification a  (Figure 6.4).
Clone 19-4 (G,H) amplification product was cloned into T-vector (Figure 6.5c) and 
sequenced, confirming that this clone contained novel 36-HSD sequence. Interestingly, 
the DNA sequence over the FDO 26G (Results chapter 4), if expressed, would encode a 
different sequence of amino acids than 36-HSD type I and II (see Figure 6.13).
Clone 19-4 was shown to have similar structural organization as HSD3B1 and HSD3B2 
by PCR (Figure 6.5 a and b). The remaining (M,K) (437bp) and (A,B) (226bp) PCR 
products were cloned into T-vector (Figure 6.5 c) and sequenced (Figure 6.7 and Figure 
6.13) and were also shown to contain novel sequence similar to HSD3B1 and HSD3B2. 
To allow more extensive sequence analysis of clone 19-4, exon specific Southern blots 
were used to identify potential restriction enzymes useful for subcloning 19-4 putative 
exons into pUC 18.
Clone 19-4 putative exons seperate into distinct Sst I restriction fragments (Figure 6.6), 
suitable for subcloning (Figure 6.7).
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a)
1 2  3 4 5 6
b)
1 2 3 4  5 6 7
lO O O bp-^.
154bp-^ -
L a n e l - lk b  ladder L a n e 4 -19-4 (A ,B) L a n e l - 1 kb ladder L a n e 5 - 19-4 (A ,H )
Lane2- 19-4 (M ,K ) Lane6- 19-4 (G ,H ) Lane2- 19-4 (I,B) Lane6- -ve (I, B)
Lane3- 19-4 (I,B) Lane7- -ve (A ,H )
Lane4- 19-4 (A ,H )
C)
lOOObp ^  
154bp m
L a n e l-  lk b  ladder
Lane2- 1-6 transform ants (I,B) Lane4- 8-12 transform ants (A,B ) Lane 14- 19 transform ants (V ,H )
Lane6- PC R  (-ve) control (I,B) Lane5- PCR (-ve) control (A ,B) Lane20- PC R  (-ve) control (V ,H )
Figure 6.5. H om ologous exon PCR am plifications from clone 19-4 (See F igure 5.2(a) for schem atic PCR 
prim ert hybrid isation  sites), (a) 19-4 exon hom ologuePC R  am plifications (1/2,3 and 4). (b) 19-4 long 
range PC R  using 19-4 phage D N A  as tem plate; exons 2- 3 across intron B and exons 3-4 across intron C. 
(c) 19-4 hom ologous exons 1/2, 3 and 4 cloned into T-vector. C loning w as confirm ed by PCR.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
lOOObp-^-
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a)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
looobp m
154bp—
L an el- lkb ladder 
Lane2- 19-4 BamH I 
Lane3- 19-4 EcoR 1 
Lane4- 19-4 Hind III 
Lane5- 19-4 Sst I
b)
2
looobp m
V.
Exon 2 Exon 3
2 3 4  5 6 7 8
IQOObp m
mmm
Lane6- 19-4 Xba I 
Lane7- 19-4 Kpn I 
Lane8- 19-4 Sal I 
Lane9- blank
Lane 10- lkb ladder 
Lanel 1- 19-4 BamH I 
Lane 12- 19-4 EcoR I 
Lane 13- 19-4 Hind III
Lane 14- 19-4 Sst I 
Lane 15- 19-4 Xba I 
Lane16- 19-4 Kpn I 
Lane 17- 19-4 5a /1
12 13 14 15 16 17
Exon 4
Figure 6.6. (a) Restriction analysis o f clone 19-4 (a )  b) Southern blots o f 19-4 D N A  hybridised with 
exon specific probes.
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19-4 Sst I retriction products were cloned into pUC18. Clones were shown to contain 19- 
4 exons by PCR analysis; exon 1/2 (I,K), exon 4 (G,H). The extent of sequencing from 
T-vector clones and pUC18 subclones is illustrated in figure 6.7.
x. X
........ - \ ..........\ X
K........ \
Figure 6.8. Sequencing extent for clone 19-4. The dotted lines show the sequence obtained from PCR 
amplified fragments of clonel9-4 after being subcloned into T-vector. The solid lines show the sequence 
obtained from subclones of the original bacteriophage clones, without the use of PCR. Location of PCR 
primers in relation to the structure of Clone 19-4 and the Sst I restriction enzyme digestion sites used in the 
cloning strategy.
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6.4.2 Clone 6-5- DGGE classification y  (Figure 6.4).
Clone 6-5 (G,H) PCR amplification product was cloned into T-vector (Figure 6.8).
1 2 3 4 5 6 7 8 9 10 11 12
y.IH
L anel- lkb ladder Lane 3- 12 6-5 transformants (G, H)
Lane2- PCR (-ve) control (G, H)
Figure 4.8. Selection o f T-vector clones that contained clone 6-5 G, H amplification product.
A number of transformants were identified that contained exon 4 B amplification from 
clone 6-5. Two transformants (track 5 and 7) were sequenced on both strands. This 
sequence was identical to the published 3B-HSD type II cDNA sequence (Figure 6.15).
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6.4.3 Clone 1-2. DGGE exon 4B classification p (Figure 6.4).
Clone 1-2 had a similar mobility on DGGE gels as the previously identified p fragment 
(Russell 1993). To confirm this result clone 1-2 (G,H) PCR amplification product was 
cloned into T-vector and sequenced (Figure 6.9).
1 2  3 4 5 6 7  8 9  10 11
L anel- lkb ladder Lane 3- 11 Clone 1-2 transformants (G, H)
Lane2- PCR (-ve) control (G, H)
Figure 6.9. Selection o f T-vector clones containing clone 1-2 (G,H) exon 4B amplification product.
A number of transformants were identified that contained clone 1-2 putative exon 4B 
DNA. Two transformants (lanes 3 and 4) were sequenced on both strands to eliminate 
the possibility of PCR mutation. The sequence, presented in figure 6.13, matched the p 
fragment and was assigned as its corresponding genomic clone.
Clone 1-2 was also shown to contain an identical sequence as clone 2-7 within the 
putative exon 4 region. 2-7 had been identified as a clone containing in the exon 3 
DGGE analysis (see section 6.5). A colleague in the laboratoy, Alison McVie, under my 
supervision, was already cloning and sequencing the putative exons of this clone. Clone
2-7 was also identified as the p gene (see Figure 6.10). Therefore no more sequence 
analysis was performed on clone 1-2. Interestingly the reason clone 2-7 was not 
identified in the PCR/ DGGE analysis using primer pair (G,H) because clone 2-7 was 
foreshortened at the 3' end, so it did not contain exon4B sequences. Clone 2-7 sequence, 
except for the exon 4B region, presented in figure 6.13 was determined by Alison McVie.
6.4.4 Clone 2-1. DGGE exon 4B classification Tfragment (Figure 6.4).
Clone 2-1 exon 4B DNA sequence was determined by direct sequencing of the PCR 
product. It was established that this clone had been misclassified and was shown to 
contain 3B-HSD type I exon 4B sequence.
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6.5 Analysis of genomic clones by exon 3 (A, C) PCR amplification and DGGE analysis.
Of the initial 57 clones, 22 did not amplify with primers GH. 3B-HSD type II exon 3 
DGGE PCR primers (A, C) were used to amplify homologous exon 3 fragments from 7 
of the 22 clones and were analysed on DGGE gels (Figure 6.10).
1 2  3 4 5  6 7  8 9
T yp e II —
L anel - Clone 8-1 (Type II) Lane4- type II control Lane7- Clone 6-9 (Type II)
Lane2- Clone 7-3 (p) Lane5- Clone 2-8 (p) Lane8- Clone 7-2 (p)
Lane3- Clone 2-10 (Type II) Lane6- Clone 2-7 (p) Lane9- Clone type II control
Figure 6.5. DGGE analysis o f hom ologous exon 3 PCR products and DGGE classification. Lanes 1, 3 and 
7 comigrate with 36-H SD type II exon 3 controls, lanes 4 and 9. Lanes 2, 5, 6 and 8 contain exon 3 
fragments that have a distinct mobility and may represent a novel hom ologous exon 3 sequence. Extra 
bands were apparent in the type II control amplified from human genomic D N A  .
The clones amplified using DGGE/ PCR primer pair (A,C) were separated into two 
distinct groups. One group co-migrated with the HSD3B2 exon 3 control, while the other 
group co-migrated with clone 2-7. As has been previously mentioned in section 6.4.3, 
clone 2-7 had already been assigned as the p gene. Sequence from clone 2-7, except for 
the exon 4B region, was determined by Alsion McVie (Figure 6.13).
R esolved
fragments
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6.6 Identification of further members of the human 3JI-HSD gene family by PCR 
amplification followed by direct sequencing of subsequent PCR products.
Exon 3 and exon 4B PCR and DGGE analysis proved very useful in efficiently grouping 
42 of the 57 bacteriophage clones. The remaining 15 clones were classified by PCR 
amplification using PCR primers hybridising to exons 2, exon 3 and exon 4 of the genes 
encoding 36-HSD types I and n, followed by direct sequence analysis. All 15 clones 
supported PCR amplification with one or more PCR primer pairs. Two further distinct 
gene sequences were identified (sections 6.6.1 and 6.6.2).
6.6.1 Clone 4-3
Clone 4-3 was amplified using HSD3B2 exon 3 PCR primer pair (D,C) and sequenced 
(Figure 6.13). This new exon 3 sequence was classified as ( j l l ) (Table 6.1). Further 
subcloning and sequence analysis of the putative exon2 region was carried out by Nicola 
Craig (Figure 6.13).
6.6.2 Clone 8-3
Clone 8-3 was initially identified using primers (D,B), sequenced and classified (e)
(Table 6.1). Clone 8-3 was shown to contain novel homologous 36-HSD exons by PCR 
amplification and direct sequence determination of PCR fragments (Figure 6.11).
Limited putative exon sequence was obtained directly from these PCR products in lanes 4 
(expected size 280bp), 7 (expected size 235bp) and 9 (expected size 435bp) (Figure 6.13). 
It was necessary to subclone the putative exon fragments into pUC18 for more extensive 
sequence analysis. 8-3 bacteriophage DNA was synthesised and analysed on Southern 
blots (Figure 6.14).
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a)
1 2  3 4 5 6 7 9 10 11 12 13
L anel- lkb ladder Lane6-
Lane2- 8-3 (I,K) Lane7-
Lane3- 8-3 (Y,J) Lane8-
Lane4- 8-3 (I,J) Lane9-
Lane5- 8-3 (Y ,S)
8-3 (V,W )
Lane 10- 8-3 (V,Z) 
Lanel 1 - 8- 3  (E,W ) 
Lane 12- 8-3 (F,W) 
Lane 13- lkb  ladder
b )
__________ \ _ _ _  v ______________ V
\ \ \
Figure 6.11.  a) Clone 8-3 was shown to contain novel sequence by direct sequencing o f the exon 3 PCR 
product (lane 7). Further test PCR amplifications using a varitety o f primers amplified fragments o f  each 
exon (See Figure 6.1 a and b). Exon 3 (lane 7) and exon 4 (lane9) products were also sequenced, b) 
Sequencing extent for clone 8-3, The dotted lines show the sequence obtained from PCR amplified  
fragments o f  clone8-3 after being subcloned into T-vector. Location o f PCR primers in relation to the 
structure o f  clone 8-3 and the Sst I restriction enzym e digestion sites that would prove useful in the cloning  
strategy (Figure 6.12).
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a)
4 0 0 0 b p -
L a n el- lkb  ladder 
Lanc2- 8-3 BamH I 
Lane3- 8-3 EcoR I 
Lane4- 8-3 Hind III 
Lane5- 8-3 Ss11
Lane6- 8-3 Xba I 
Lane7- 8-3 Kpn I 
Lane8- 8-3 Sal I 
Lane9- blank
Lane 10- lkb ladder 
Lanel 1- 19-4 BamH 1 
Lane 12- 19-4 EcoR I 
Lane 13- 19-4 Hind III
Lane 14- 19-4 Sst I 
Lane 15- 19-4 Xba I 
Lane 16- 19-4 Kpn I 
Lane 17- 19-4 Sal I
lOOObp
Exon 2 Exon 3 Exon 4
Figure 6.14. Restriction and Southern analysis o f clone 8-3. a) Restriction digestion anlysis o f  clone 8-3. 
b) Southern analysis o f clone 8-3 using exon specific probes.
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6.7 Summary table o f clones and classifications.
Table 6.1. 57 positive clones from two human genomic libraries were separated into distinct gene sequence 
classifications according to their mobility on DGGE gels and direct sequence analysis of PCR products. 
Clones 18-1 - 25-2 were isolated from the Phe family library and clones 1-1- 8-3 were isolated from a 
control human library. Single letter codes refer to PCR/ sequencing primers (Figure 6.1 a and b).
DGGE analysis Direct sequencing analysis
Clone
Number
Classification
(Haplotypes of 
HSD3B1 are 
indicated where 
possible)
Exon 3 
PCR 
primers
Exon 4 
PCR 
primers
Exon 2 
PCR 
primers
Exon 3 
PCR 
primers
Exon 4 
PCR 
primers
18-1 d> Y,K
18-2 n Y,K
19-1 a G,H
19-2 Type I G,H
19-3 a G,H
19-4 a G,H
19-5 a Y,K
23-1 a G,H
24-1 a G,H
24-2 Type I G,H
24-3 ♦ A,Band P,Q
3b-HSDyl <t> A,B and P,Q
25-1 a G,H
25-2 <D A,B and P ,0
1-1 4> A,B and P ,0
1-2 P G,H V,H
1-3 Type I G,H
1-4 a G,H
1-5 Type II (y) G,H
1-6 e Y,K
2-1 Type I G,H
2-2 Type I (Asn +) G,H
2-3 Type I (Asn -) G,H
2-4 Type I (Asn +) G,H
2-5 e Y,K
2-6 a G,H
2-7 P A,C v,x
2-8 P A,C
2-10 Type II A,C
3-1 Type I (Asn +) G,H
3-2 a G,H
3-3 a G,H
4-1 a G,H
4-2 Type I (Asn +) G,H
4-3 V D,C
4-4 a v,w
4-5 a G,H
4-6 Type I (Asn -) G,H
4-7 Type I (Asn -) G,H
5-2 Type II Y,K
5-3 Type II (y) G,H
5-4 Type I (Asn -) G,H
5-5 Type II (Y) G,H
6-1 Type I (Asn +) G,H
100
6-2 a G,H
6-3 Type I (Asn +) G,H
6-4 P D,C
6-5 Type II (y) G,H
6-6 a G,H
6-9 Type II A,C
6-10 a G,H
7-1 Type I (Asn -) G,H
7-2 P D,C
7-3 P A,C
8-1 Type II A,C
8-2 a V,W
8-3 e I J D,B V ,x
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6.8 Sequence alignment
Figure 6.15. Sequences obtained from clones isolated from two human genomic libraries, aligned with 
homologous sequences from 36-HSD type I and type II (exons 1-4). Triplet nucleotides in bold and 
underlined are translational start and stop codons. 36-HSD type II missense and nonsense mutations are 
shown above the aligned sequences in brackets. Corresponding single nucleotides in the clones 19-4, 4-3, 
36-HSD\j/l and 8-3 are highlighted in bold and underlined. The seventeen nucleotides underlined in each 
sequence are gene specific PCR primers that could potentially be used to map each of the genes to YACs or 
BACs. Dashes indicate gaps introduced for alignment. Bases corresponding to intron sequence in 36-HSD 
types I and II are shown in lower case. Unknown sequence is represented by the character N.
a) Exons 1 and 2
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*
T y p e  2 GAGGCAGTAA GGACTTGGAC TCT-CTGTCC AGCTTTTAAC AATCTAAGTT
T y p e l . . . . TGAG. . . T . . G . C C . . . . . T .............. . C . A
C l o n e l 9 - 4 . . A . TGACC. . C . . . C T . . . . .NNNNNNNN NNNNNNNNNN NNNNN . TAA
C l o n e 4 - 3 . . ATGGAC. . . C . . CCT. . . . . . T T ........... .C A -
C l o n e 2 - 7 . . . . TGACC. . C . . C C T . . . . A . T .............. . . . . A . . . . T . C . A
3&-HSD1J/1 . . A. T G. CC . . C . . - C T . . . . . . T .............. . . . C .............. C T . . T . A
C l o n e 8 - 3 NNNNNNNNNN NNNNNNNNNN NNNNNNNNN. . c .................... G. . . . .CAA
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*
100
T y p e  2 A C G g tta g a g c t t t c t c c t t t t c t t t c a a c t a ----- c t c c t g g c a g t t g t g
T y p e l . T .................... .................g . . . ....... ............. g .  . .
C l o n e l 9 - 4 T .T a c a g t g a g . . - . . t a . . .............. - . g . . . ----- . . . -  . g . . .
C l o n e 4 - 3 ----- . . a . . . . ....................g . . . ....... ............. g .  . .
C l o n e 2 - 7 . T .................... . . a . t . . g .  . ....................g- . . - - a . . t . . g .  . .
3 £ -H S D \|/l . T . . . g . a . . . . . . t . . a . . .................. e g . . ----- . . . t . . g .  . .
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6.9 Sequence divergence and phylogenetic analysis of the human 3B-HSD gene 
family.
The relationship between the nucleotide sequences was determined by a weighted 
parsimony analysis of the alignment between the mammalian 36-HSD exon sequences 
and the similar novel sequences of clone 24-4 (\|/1), 8-3 (\|/2), 2-7 (i|/3), 19-4 (\|/4)and 4-3 
(\j/5) (Figure 6.16). In figure 6.14, branch lengths represent the number of informative 
nucleotide substitutions in the data set. The sequence similarity between HSD3B1 and 
HSD3B2 exon and exon homologues of the new sequences are presented in table 6.2.
Table 6.2. Estimated nucleotide sequence similarity of clone fragments to HSD3B1 and HSD3B2 exons.
Type II Type I 19-4
(3B-HSD\|/4)
4-3
(3B-HSD\j/5)
2-7
(3B-HSD\|/3)
24-4
(3B-HSD\|/1)
8-3
(3B-HSD\|/2)
Type II “ 93.5% 90.5% 89.4% 91.5% 88.24% 85.4%
Type I “ 91.6% 91.6% 91.5% 88.8% 87.0%
19-4
(3B-HSD\j/4)
“ 94.5% 91.3% 87.3% 85.4%
4-3
(3B-HSD\j/5)
89.4% 90.3% 88.3%
2-7
(3B-HSD\|/3)
“ 88.3% 84.4%
24-4
(3B-HSD\j/l)
88.7%
8-3
(3B-HSD\|/2)
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Figure 6.14. Weighted parsimony analysis of an alignment between expressed mammalian cDNAs and 
human exon homologue DNA sequences (\yl-y5). Branch lengths represent the number of informative 
nucleotide substitutions in the data set. Bootstrapping percentages greater than 50% are shown on internal 
nodes (based on 1000 replications with the input order shuffled randomly on each replication).
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The phylogenetic tree in figure 6.14 proved useful in further analysis of the human gene 
family. Hypothetical ancestors were constructed from the extant genes, which allowed 
the number of transitions and tranversion to be characterised throughout the evolution of 
the macaque and human gene family (Table 6.3 and Table 6.4).
Table 6.3. Numbers of transitions and tranversions within the primate lineage from known sequences; 1st, 
2nd and 3rd nucleotides of the codon are indicated. Hypothetical ancestors are highlighted in BOLD. 
Ancestor 6 is included in both tables, because from this hypothetical gene sequence arose both the active 
and three of the unprocessed pseudogenes.
a)___________________________________________________________
Transitions r "ransversions
1st 2nd 3rd Total 1st 2nd 3rd Total
Macaque 3 1 12 16 2 1 2 5
Anc-II 2 2 7 11 1 0 2 3
Type II 3 5 17 25 1 1 7 9
Anc-Primates 1 1 2 4 0 0 0 0
Type I 8 3 16 27 1 3 6 10
Anc-6 3 1 7 11 1 2 1 4
94 31
Transitions r "ransversions
1st 2nd 3rd Total 1st 2nd 3rd Total
Anc-6 3 1 7 11 1 2 1 4
19-4 12 8 11 31 5 6 8 19
Anc 19-4/4-3 4 0 3 5 1 1 1 3
4-3 6 0 3 9 1 1 1 3
Ancl9-4/4-3/2-7 3 0 4 7 1 1 1 3
2-7 9 10 13 32 6 6 6 18
24-4 18 9 15 42 16 8 6 30
Anc-24-4/8-3 2 1 3 6 0 0 1 1
8-3 10 10 12 32 7 4 10 21
175 102
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Table 6.4. Types of nucleotide substitutions, within the exons of functional primate genes and similar 
sequences in the pseudogenes, a) The active genes include human 36-HSD type I and II and macaque, b) 
The unprocessed pseudogenes are the novel human sequences identified in results chapters 5 and 6. c) 
Final nucleotide ratios in the exons of the functional genes and similar sequences in the pseudogenes.
a) Functional genes.
To
From A C G T
A - 5 15 5
C 4 - 5 31
G 26 7 - 2
T 2 22 1 -
Transitions - 94 (75.2%) 
Transversions - 31 (24.8%)
b) Pseudogenes.
To
From A C G T
A _ 12 24 10
C 19 - 11 65
G 56 19 - 16
T 11 28 6 -
Transitions - 175 (63.2%) 
Transversions - 102 (36.8%)
c)
A+T ratios C+G ratios CpG dinucleotiude 
frequencies
Macaque 47.9% 52.1% 19
TypeD 49.0% 51.0% 22
Type I 48.9% 51.1% 28
19-4 (\|/4) 48.8% 51.2% 19
4-3 (\|/5) N.D N.D N.D
2-7 (vj/3) 49.7% 50.3% 16
24-4 (\[/l) 51.0% 49.2% 12
8-3 (\|/2) 53.8% 46.2% 8
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Chapter 7 
General discussion
7.1 Mapping the monoclonal antibody FDO 26G epitope.
36-HSD enzyme activity is present in the microsomes of chorion laeve at levels similar to 
those in villous syncytiotrophoblast (Gibb et al1978, Gibb et al1985), and chorion laeve 
can synthesise progesterone from labelled pregnenolone (Mitchell et a/1982). This is 
consistent with monoclonal antibody FDO 161G reactivity in these placental tissue 
(Mueller 1987). The expression of 36-HSD in intrauterine trophoblast indicates a 
capacity to synthesise A4- steroids from circulating precursors. Androstenedione can then 
be converted to oestrogens by placental aromatase (Kilgore et al1992). Thus, intrauterine 
trophoblast is likely to contribute to the hormonal maintenance of the uterine decidua in 
early pregnancy. FDO 161G reacts in a tissue specific manner to 36-HSD protein in 
syncytiotrophoblast, nonvillous trophoblast, sebaceous glands in skin, cells of the adrenal 
cortex and the gonads. This is a similar pattern of reactivity to that described by others 
using polyclonal antisera (Pelletier et al1992; Riley et al1992). Since expression of 36- 
HSD type I and II are almost mutually exclusive in placenta and adrenals, it seems likely 
that FDO 161G binds a common epitope in the two forms. This epitope is probably 
conformational, being undetectable in western blots. Monclonal antibody FDO 26G was 
raised against 36-HSD type I which had been purified from villous syncytiotrophoblast, 
the sequence of which had been confirmed by sequencing an N-terminal and an internal 
peptide (Nickson et a/1991). This antibody showed a more restrictive staining pattern; 
reacting strongly with villous syncytiotrophoblast and adrenal cortex, but their was 
greatly reduced reactivity with trophoblast from the chorion laeve and no reactivity with 
intrauterine trophoblast and cytotrophoblast cell islands. These staining patterns were 
unaffected by varying dilutions of the monoclonal antibodies over a wide range, and we 
infer that the lack of FDO 26G reactivity with non-villous trophoblast is due to the 
expression of a different isoform of the enzyme. When sheep polyclonal anti-36-HSD 
was used to stain western blots, protein bands of the same mobility were detected in 
villous trophoblast and chorion laeve (Hawes et al1994) and it may have been that same 
fraction that was detected in western blots.
To identify the cDNA encoding FDO 161G reactive protein, a previously identified, 
partial cDNA fragment, 1/6, was used to screen a X gtl 1 cDNA expression library, in 
which 48 positive clones were identified. Ten positive clones were selected randomly for 
purification and further analysis. cDNA insert size was determined by PCR amplification 
using primers hybridising to the Xgtl 1 bacteriophage arms. B3 (P10) was shown to 
contain an insert of approximately 1.7 kb (Figure 3.2), was sequenced and identified as 
36-HSD type I (Nickson et al 1991). It was been demonstrated, by immunofluorescent
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(FITC) staining, that clone B3 contains an open reading frame encoding a polypeptide 
that transiently expressed in COS-7 cells reacts with the monoclonal antibody FDO 161G 
(Figure 3.8). B3 was also stably transfected into Chinese hamster ovary (CHO) cells and 
reactivity was confirmed to the monoclonal antibody FDO 26G by western immunoblot 
analysis (Figure 3.9). Given the immunostaining patterns described in section 1.13 from 
our colleagues in Australia, it seemed likely that both monoclonal antibodies react with 
the same protein in vivo and that the discrepancies in staining patterns may either be 
explained by post-translational modification or by the presence of an unidentified 
member of the 36-HSD gene family, that may cross react with FDO 161G but not FDO 
26G. Analysis of the remaining clones isolated from the placental library using 
denaturing gradient gel electrophoresis (DGGE) confirmed that all clones identified in the 
screen, which reproducibly hybridised with 1/6 DNA, were haplotypes of 36-HSD type I 
(Figure 3.12, summarised in Table 3.1). This suggests that 36-HSD type I is the major 
transcript expressed in the placenta. However, the amplification of the cDNA library 
may favour one form of 36-HSD over another, therefore we cannot exclude the 
possibility of expression of other 36-HSD isoforms in the placenta based on this data 
alone.
The next line of investigation was to locate and identify the FDO 26G epitope. Lac Z 
fusion genes and oligopeptide mapping located the FDO 26G epitope to the amino acid 
sequence VEWVGSLVDRHKE, residues 354-366 of 36-HSD type I (Figure 4.14). The 
same sequence exists in 36-HSD type II (residues 353-365) consistent with FDO 26G 
reactivity in the adrenal cortex. The epitope contains a consensus for casein kinase II 
(CK-II) phosphorylation site (S,T X X D,E). The glutamic acid residues at -4 and +4 
from the consensus are associated with CK-II activation, as is the choice of S-359 and D- 
362 at the consensus residue (Pinna 1990). Nevertheless, the peptide competition data 
(Figure 4.15) shows that phosphorylation of S-359 has only a marginal effect on the 
binding of peptide to antibody, with evidence of the phosphopeptide having an higher 
affinity. This data would suggest that differential phosphorylation of S-359 could not 
account for the extinction of FDO 26G reactivity on extravillous trophoblast. There were 
no other identifiable post translational modification consensus sequences within the FDO 
26G epitope (residues 354-366), therefore no other putative modifications were tested. 
More recently, the staining data from adult Ley dig cells, which reacts with FDO 161G 
but not FDO 26G, supports the post-translational modification hypothesis. At present the 
staining pattern of these antibodies in fetal Leydig cells is unknown, but it would be 
interesting to investigate the role of post-translational modification of 36-HSD during 
human development.
Figure 7.1 shows an alignment of amino acid sequences homologous to the human 36- 
HSD type I peptide, over the FDO 26G epitope (residues 354-366). The human type I is
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represented in its two allelic forms. All mammalian 36-HSD enzymes have diverged 
over the FDO 26G epitope except for the human type I, II and macaque 36-HSD. The 
four sequences for rat 36-HSD have diverged from the type I human peptide sequence 
and no reaction was observed of FDO 26G with frozen sections of rat steroidogenic 
tissues (U. M. Mueller personnel communication). Despite this divergence it is notable 
that the potential casein kinase II phosphorylation site (CK-II) is widespread amongst 
mammalian 36-HSD. A further CK-II consensus site is located 14 residues upstream in 
all these species (human type I, residues 344-347: SWEE). A protein kinase C (PKC) 
consensus site is located seven residues from the carboxy terminus of 36-HSD from 
bovine, human and macaque but not rodents. The basic lysine residues at -2 and +2 from 
the consensus site are associated with the enhancement of functional PKC sites (Woodget 
et a /1986). A genetic polymorphism exists at residue 367 (Russell et a/1991, 1994). 
Since clinically normal individuals can readily be identified who are homozygous for 
367N/N allele, the putative PKC site in the type I protein cannot fulfil a vital function. No 
such polymorphism exists in the human type II isoform, which is expressed in the adrenal 
cortex and gonads, and may be subject to different regulatory circuits.
FDO 26G epitope
CK-II PK-C
Human type 1367 V E W V G S L V D R H K E N L K S K T Q *
Human type 1 367 V E W V G S L V D R H K E T L K S K T Q *
Human type II V E W V G S L V D R H K E T L K S K T Q *
Macaque V E W V G S L V D R H K E T L K S K T Q *
Rat I-IV s E W I G T L V E Q H R E T L D T K S Q *
Mouse I s E W I G T I V E Q H R E I L D T K S Q *
Mouse II and HI s E W I G T L V E Q H R E T L D T K S Q *
Bovine K E W I G _S L V K Q H K E ^ | l [k | t K I H *
Mouse IV S E W I G T L V M Q H R E I G N K K S Q *
Mouse V S E W I G T L V K Q H R E T L H K K s Q ★
t
367
Figure 7.1. The C-terminal 20 amino acid residues from various forms of mammalian 36-HSD, showing 
the position of the FDO 26G epitope in the human enzyme and the consensus site of phosphorylation by the 
protein kinases, casein kinase II (CK-II) and protein kinase C (PK-C). The arrow marks the position of 
amino acid residue 367 in the human 36-HSD type I enzyme. * represents the stop codon.
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Protein kinase A (PK-A) is the major signal regulating transcription of 36-HSD in 
response to the action of trophic hormones at the cell surface, via cyclic AMP (cAMP). 
There is also evidence for the interactive effects of PKA and PKC stimulation on the 
levels of 36-HSD mRNA in choriocarcinoma cells (Tremblay & Beaudoin 1993). In 
cultured human adrenocortical cells, such interactions lead to increases in 36-HSD 
activity, elevation of non-17a-hydroxylated steroids and reduction of adrenal androgen 
synthesis (McAllister & Horsby 1988). CK-II phosphorylation is observed in many 
classes of protein, though the functional consequences of this remain to be established 
(Pinna 1990). CK-II acts synergistically with glycogen synthase kinase-3 stimulating the 
phosphorylation of phosphoprotein phosphatase (DePaoli-Roach 1984), and with PK-A 
on dopamine- and cAMP-regulated phosphoprotein (Girault et <3/1989). Consensus sites 
for CK-II, PK-A and PK-C have been found clustered at the N-terminus of the cAMP 
response element-binding protein from PC 12 cells (Gonzalez et a/1989). It is therefore 
possible that the CK-II and PK-C consensus sites at the C terminus of the 36-HSD 
polypepitde are involved in either the post-transcriptional regulation of 36-HSD activity 
or substrate specificity, potentially modifying or amplifying the effect of transcriptional 
regulation.
7.2 Investigation into the extent o f the human 3fi-HSD gene family.
The association between P450c21 deficiency and hirsutism led to interest in the possible 
role of mutations in 36-HSD in the pathogenesis of hirsutism. However, deficiency of 
36-HSD type I has yet to be reported and proven deficiency of 36-HSD II is rare. Only a 
small number of females have been reported with type II deficiency, some show clinical 
phenotypes, including amenorrhoea, virilization, and premature pubarche (Mendonca et 
al. 1994, Sanchez et al. 1994b, Paula et al. 1995). In others the mutation has no clinical 
effect despite markedly abnormal blood steroid levels (Mendonca et al. 1994) and 
heterozygotes for partial 36-HSD deficiency are not affected with hirsutism (Russell et 
al. 1994). Mathieson et al. (1992) failed to find evidence of 36-HSD deficiency in a 
large series of patients affected with primary hirsutism, but others have claimed that a 
non-classical form of 36-HSD deficiency existed in hirsutism (Pang et al. 1985, Zerah et 
al. 1991). This deduction was based on serum ratios of A5/A4 steroids, and the effect of 
ACTH stimulation, the results of which exceeded the normal range, but were less 
extreme than was found in cases now proven to be affected with partial 36-HSD type II 
deficiency. Recently, these biochemical signs were re-investigated in a group of patients 
previously classed as having non-classical 36-HSD mutations (Zerah et al. 1994). The 
biochemical signs were found to be inconsistent over time and no mutation were detected 
in the genes for 36-HSD type I and II.
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In the Phe family, hirsutism was found in seven out of eleven family members over four 
generations, with a pattern of sex-limited dominant inheritance (Figure 5.1). Kindred Phe 
was not suggestive of classical or non-classical 36-HSD deficiency and was included in 
an ongoing screen for mutations in 36-HSD because of the intriguing dominant mode of 
inheritance and the evidence of increased responsiveness of 17-hydroxypregnenolone and 
DHEA to synacthen. There was no basal elevation of A5 steroids, nor a general 
secondary rise in A4 steroids due to peripheral steroid metabolism. The haplotypes of 36- 
HSD types I (Asn-; Asn+) and II (intron C microsatellite) did not cosegregate with 
hirsutism in case IV-5, indicating that, unless IV-5 was a sporadic case (unlikely since 
EH-5, the mother of IV-5 was also affected) of unrelated aetiology, hirsutism in this 
family was not closely linked to the genes for 36-HSD types I and II (HSD3B1 and 
HSD3B2 respectively), which map to lpl3.
During the routine screening for mutations in the genes for 36-HSD types I and n, a 
novel homologous exon 3 fragment (<J)) containing an open reading frame was identified 
from a patient IV-2 (Figure 5.1) suggesting that, in some families, the expression of other 
human 36-HSD genes may be responsible for 36-HSD deficiency . Corresponding genes 
were isolated from patient IV-2 and control human genomic libraries, clones 24-4 and 1- 
1 respectively (sections 5.2 and 5.3). The order of the putative exons for clones 24-4 and 
1-1 were confirmed by PCR (Figure 5.7) and Southern blot evidence (Figures 5.8 and 
5.9) also confirms that clones 24-4 and 1-1 are very similar at the structural level. 
Therefore it is unlikely there is any gross rearrangement within clone 24-4, that could 
account for the phenotype in the Phe family. The sequence of the putative exons and 
adjacent intron fragments of the genomic clones 24-4 and 1-1 were determined, and 
found to be identical, including the sequences that flanked exon 3 from which band <() was 
amplified (PCR primer hybridisation sites (A,B)(Figure 5.13). It is difficult to explain 
why the <J> fragment was initially only amplified in the Phe family using PCR primer pair 
(A,B). The presence of nonsense and frameshift mutations in clones 24-4 argues that it is 
not expressed as a functional 36-HSD enzyme, and is probably an intron containing 
unprocessed pseudogene which has been identified as 36-HSD\|/l (McBride et al 1995a).
Using rat- human somatic cell hybrids, (P,Q) PCR primer pair were used to map the 
novel exon 3 fragment to chromosome 1. Using the 36-HSD\|/l genomic clone, the map 
position was further refined by fluorescent in situ hybridisation (FISH) to the human 
chromosomal region lp l3  (McBride et a/1995). The location of 36-HSD \|/1 at a similar 
chromosome location as genes encoding the enzymes 36-HSD type I and II enzymes, 
also argues against the involvment of 36-HSD\|/l in the Phe family phenotype, though 
the linkage between the genes for types I and II and 36-HSD\|/l, at this time, had yet to 
be established. Interestingly, a cluster of functional 36-HSD genes, including 36-HSD
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keto-steroid reductase genes, has been reported on mouse chromosome 3 (Bain et 
<3/1993), syntenic with the human chromosomal region lpl3. This suggests that other 
3B-HSD gene sequences in addition to 36-HSD \j/l may exist at this location in the 
human. The size of the cluster has yet to be fully defined, though it may not include the 
gene for 36-hydroxy-A5-C27-steroid dehydrogenase (Russell et al. 1995b).
The findings from Southern blots hybridised with 36-HSD type I exon 4 provides 
evidence of the existence of further members of the human 36-HSD gene family, but it 
was not possible to deduce how many different members of the family existed. In an 
attempt to define the extent of the 36-HSD family in humans, 57 clones were isolated 
from two genomic DNA libraries by homology probing with 36-HSD type I cDNA. 
Analysis of these clones by non-stringent PCR amplification, DGGE, and PCR 
sequencing led to the identification of five novel gene sequences similar to HSD3B1 and 
HSD3B2 (Figure 6.13 ). The groups identified were; HSD3B1 (15 clones, roughly equal 
proportions of the HSD3B1 haplotypes Asn- and Asn+), HSD3B2 (8 clones), 19-4 clones 
(18 clones), 4-3 (2 clones), 2-7 (6 clones), 36-HSD\|/l(5 clones) and 8-3 (3 clones)(Table 
6 .1). The difference in representation of clones may not be significant. The numbers will 
reflect efficiencies of cloning different sequences, and a proportion of sibling clones are 
likely to have been isolated since the libraries had been amplified before this study. All 
novel genomic clones were mapped initially using FISH, to the human chromosomal 
region lpl3. With the identification of gene specific PCR primer pairs (Figure 6.13), it 
was possible to undertake a more detailed mapping strategy, to localise and order the 
known 36-HSD sequences to yeast artificial chromosomes (YACs) and bacterial artificial 
chromosomes (BACs) (McBride et al 1997).
It is difficult to predict whether there are as yet unidentified 36-HSD functional genes 
present in the human genome. Two inconsistencies were noted during the DGGE 
analysis that may suggest the presence of further genes. Clones initially designated %; 
Figure 6.3 (b) lane 1 (clone 25-1), lane 5 (clone 6-2) and Figure 6.3 (c) lane 6 (clone 2-6), 
lane 9 (clone 3-2), lane 10 (clone 3-3) and lane 11 (clone 4-1), were subsequently shown 
to have the same mobility as groups of clones designated a; Figure 6.3 (f) lane 8 (clone
3-3), lane 10 (clone 2-6), lane 11 (clone 6-2), lane 12 (clone 25-1) and Figure 6.4 lane 10 
(clone 3-3). Mutation introduced by the PCR amplification reaction cannot explain this 
inconsistency because independent PCR products are unlikely to contain the same PCR 
mutations (see Figure 6.3 b and c). It is possible that initially the DGGE gels detected a 
nucleotide substitution within these fragments that was not seperated in subsequent 
DGGE gels. Further DGGE analysis could have been undertaken using a 3' GC clamp 
primer or sequence of the exon 4B PCR product from these inconsistent clones could 
have been determined. Due to other priorities these experiments were not undertaken. .In
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the HSD3B2 exon 3 DGGE analysis (Figure 6.10) extra putative exon 3 fragments were 
observed, however, as a full exon 3 DGGE analysis was not carried out on the genomic 
clones, it is uncertain whether these extra bands represent unidentified exon 3 sequences 
or exon homologues in the other newly identified members of the 36-HSD gene family.
An alignment of 36-HSD types I and II with exon homologues identified from each of the 
novel genes is presented in figure 6.13. It is of interest that a number of these sequences, 
if expressed would encode different amino acid sequences over the FDO 26G epitope. 
However, although 36-HSD\|/l, and the four new sequences; 8-3, 2-7, 19-4 and 4-3 
(Figure 6.13) all have ATG codons in equivalent position to the start codon of the type I 
gene, all have stop codons that occur well before the stop codons of the type I and II 
genes (clone 24-4 has a stop at residue 173; clone 8-3 a stop at residue 143; 2-7 has a stop 
at residue 42; and clones 19-4 and 4-3 have a stop at residue 16) as well as other missense 
and frameshift mutations. It is clear that the deletion of any major portion of 36-HSD I or 
II would lead to an inactive enzyme. Exon 2 of 3-HSDI and II contains a nucleotide 
binding (Wierenga et a/1986) consensus sequence, and substrate protection studies show 
the substrate binding site of 36-HSD type I is located in exon 4 (between residues 175 
and 274) (Thomas et a/1993). Further, type II mutations have been detected between 
residues 15-318, and all either abolish or greatly reduce enzyme activity (see Table 1.1). 
Since the integrity of all three exons is required, these stop codons would disrupt enzyme 
activity. RNA products from 19-4 and 4-3 were detected by reverse transcription with 
oligo (dT) and therefore had been processed with poly (A) tails (S. Burridge personnel 
communication). However, these products showed forms of alternate splicing that 
created frame shifts from exon 3 to 4 and/or inserted intron sequence. This suggests that 
these sequences do not encode functional 36-HSD enzymes and therefore should 
classified as unprocessed pseudogenes, which we name 8-3 (\|/2), 2-7 (\|/3), 19-4 (\j/4) and
4-3 (vj/5). 36-HSD\|/l was identified in results chapter 5. Presumably these sequences 
have been generated by gene duplication events.
Gene duplication is a critical process in the evolution of higher organisms. It recruits pre­
existing genetic material as a substrate for the formation of novel functional units. Extra 
gene copies created through duplications may ultimately diverge to perform related 
specialised developmental and biochemical function. This process is exemplified by the 
globin family which has evolved a highly co-ordinated process of tissue- and stage- 
specific expression of developmentally specialised genes from a single ancestral gene 
(Goodman 1987). The apparent necessity for the differential gene expression during 
development presumably has provided selective pressure to maintain expression of 
multiple copies. Genes can duplicate by a variety of mechanisms (Maeda & Smithies 
1986). How much of the pattern of duplication that can be unravelled in any given gene
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family generally depends on the age and complexity of the family. Initial duplication 
events of a single copy gene are rare, but may be catalysed by repetitive elements such as 
Alu or LI (Cross and Renawitz 1990). Depending on the number of genes and the 
location of the cross-over events, duplication by this mechanism can drastically affect the 
gene copy number of a family. After the gene has duplicated, the two copies start begin 
to diverge by accumulating mutations. If there is no selective advantage for multiple 
copies, one of the genes could either develop different regulation from the original copy, 
become a non-functional pseudogene, or fortuitously gain a new function. Presumably, 
because of the similarity between the genes, recombination may be frequent.
In the alignment of human 36-HSD in figure 6.13, the new pseudogene sequences diverge 
at a number of positions including missense substitutions that correspond to 36-HSD type 
II mutations. This raises the question of whether certain DNA mutations associated with 
36-HSD type II deficiency may have arisen from gene conversion events similar to those 
suggested in the molecular genetics of P450c21 deficiency, encoded by CYP21 (see 
section 1.8). Although mechanism of apparent gene conversion in higher eukaryotes is 
not well understood, there are strong reasons for suspecting it occurs. In P450c21 
deficiency apparent gene conversion events generate CYP21 mutations when short 
sequences from the highly homologous (98% over exon homologues) CYP21 
pseudogene are transferred to the active gene. Collier 1993 suggests that a gene 
conversion involving the exchange of up to 390 nucleotides arose by a microconversion 
event between CYP21 and CYP21P. Intergenic recombination has also been shown to be 
responsible for glucocorticoid-remediable aldosteronism and human hypertension (Lifton 
et al\992). The tandem arrangement of the closely related CYP11B1 and CYP11B2 
genes results in an unequal crossing over, leading to a chimeric gene expressing 
aldosterone synthesising properties under the regulatory control of ACTH (Figure 1.6). 
Although more recent investigations into detection of mutations within the CYP11B1 
gene suggest that replication based mutagenesis is more likely to account for CYP11B1 
deficiency than either gene conversion or recombination events (Skinner et a /1996). 
Turning to the present data (Figure 6.13), above the type II exon sequence are shown 
positions of 22 mutations in the type II gene that have been observed in cases of 
congenital adrenal hyperplasia, pseudohemaphroditism and premature pubarche 
published to date. In 17 (77%) of these mutations the type II mutations is not present in 
36-HSD \j/l-\|f5, and cannot be the source of these mutations. The remaining 5 (23%) 
mutations are present in 36-HSD pseudogene sequence, highlighted in bold and 
underlined (Figure 6.13). However, type II mutations in 36-HSD deficiency mainly have 
single nucleotide substitutions. If gene conversion did occur we would expect to see a 
number of nucleotide substitutions reflecting the nucleotide difference between 36-HSD 
type II and the donar pseudogene sequence. Such multiple mutations would be expected
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to have severe effects on type II enzyme function as in cases of classical salt wasting 
congenital adrenal hyperplasia. To date no such mutations have been described. It is 
probable that the divergence between the members of the 36-HSD gene cluster is 
sufficient to reduce the occurrence of conversion and recombination, as well seperated 
point mutations efficiently inhibit homologous recombination (Leach 1996).
The relationship between the nucleotide sequences was determined by a weighted 
parsimony analysis (Figure 6.14) of the alignment between the mammalian 36-HSD exon 
sequence and the homologous sequences of 36-HSD\j/l-5. In figure 6.14, branch lengths 
represent the number of informative nucleotide substitutions in the data set. The human 
sequences for type I, n, and pseudogenes are more closely related to each other than to rat 
or mouse. As previously noted (Abbaszade et al 1995), this indicates that the human gene 
family expanded since the divergence from the common ancestor with rodents. Human 
pseudogenes 36-HSD\|/l-5 have ATG in the homologous position to the initiator ATG 
codon of the type I gene, which is placed one codon earlier than the type II gene. This 
suggests that they are more closely related to the type I gene, a view supported by the 
analysis in figure 6.14. Pseudogenes \|/4 and \p-5 are both expressed as RNA in several 
tissues (S. Burridge personnel communication) and show the closest homology to the type 
I and II genes (Table 6.2). This suggests that they either arose more recently than the 
other pseudogenes, or have been more recently released from the selective pressure 
associated with the expression of functional enzymes. There is insufficient evidence to 
determine whether i|/-4 and VJ/-5 represent extinct enzymatic functions distinct from type I 
and II, although it is possible to date the duplication event that gave rise to these genes, 
because they contain the same inactivation mutation (Figure 6.13). Assuming that 
noncoding regions of human DNA accumulate at the rate of approximately 0.3%/ million 
years (Maeda et a/1996) and given the percentage divergence of \|/-4 and \|/-5 (Table 6.2), 
this dates the duplication event to approximately 18 million years ago.
Further analysis suggests there was rapid amplification of the human gene family, because 
of the low number of transitions and tranversions in the hypothetical ancestors calculated 
from the extant gene sequences (Table 6.3). The non-random pattern of nucleotiude 
substitutions within the 36-HSD unprocessed pseudgene family are characteristic of 
pseudogene sequences (Li et a/1984). Nucleotide substitutions occur more frequently in 
the first and second positions of the 'codon' within pseudogenes (Table 6.3). Transitions 
are more likely to occur, because transversions require two rare tautomeric and rotameric 
states of the bases to form a purine-purine mispair that avoids detection by the repair 
systems, whereas transitions require only one (Topal & Fresco 1976). The rates of both 
transitions and transversions collectivley lead to a gradual decrease in the (G+C) content 
(Table 6.4). The reason for this gradual change is not because of inherent liability in the 
CpG dinucleotide, but because cytosine residues 5' to neighbouring guanines are prone to
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be methylated. 5-methyl-cytosine is more susceptible to spontaneous deamination, which 
leads to the formation of thymine, a normal residue in DNA. Generally, the CG 
dinucleotide occurs in low frequencies in metazoan DNAs (Ehrlich et al 1990), whereas 
we do not see this in E.Coli DNA, which is not subject to the same pattern of methylation.
In rodents, ketosteroid reductase and dehydrogenase/isomerase activites are due to distinct 
members of the 36-HSD gene family, which had probably diverged in a common ancestor 
to rat and mouse (Abbaszade et a/1995). In human, both activities can been detected 
when either the type I or the type II enzyme are expressed in transfected tissue culture 
cells (Rheaume et a/1991; Lorence et al1990). This apparent dual function of the human 
enzyme may account for the presence of ketosteroid reductase activity in human prostate, 
since that tissue contains detectable levels of 36-HSD type IIRNA (S. Burridge personnel 
communication). The dual function of the two human 36-HSD enyzmes may explain why 
the human genome apparently has a small number of functional 36-HSD genes, compared 
with rodents. However, the lack of a specific ketosteroid reductase gene in man has not 
been specifically proven in this study; such a gene may have been underrepresented in the 
library, or be sufficiently diverged in sequence to be undetected when the library was 
screened.
Surprisingly the present work suggests independent expansion of the human 36-HSD 
gene family since the divergence from the common ancestor with rodents and bovine.
The expectation was that expansion of the 36-HSD gene family occurred in a common 
ancestor of primates and rodents. However, in the macaque (old world monkey), it seems 
likely that the gene family is also expanded (Figure 6.14) raising the question whether 
more than two functional genes are expressed in this lineage, as there is clear evidence for 
expression of 36-HSD enzymes in peripheral tissues such as liver and kidney. Further 
investigations into the 36-HSD gene families within primate lineages may yield important 
clues into the timing of expansion of the 36-HSD gene family.
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